

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 August 2004 (26.08.2004)

PCT

(10) International Publication Number
WO 2004/072231 A2

- (51) International Patent Classification⁷: **C12N**
- (21) International Application Number:
PCT/US2004/002013
- (22) International Filing Date: 10 February 2004 (10.02.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
10/361,002 10 February 2003 (10.02.2003) US
- (71) Applicant (for all designated States except US): **CLEAR-ANT, INC.** [US/US]; Suite 650, 11111 Santa Monica Boulevard, Los Angeles, CA 90025 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **MCKENNEY, Keith** [US/US]; 11918 Glen Mill Road, Potomac, MD 20854 (US). **GILLMEISTER, Lidja** [US/US]; 9419 Lee Highway, Fairfax, VA 22031 (US). **MARLOWE, Kristina** [US/US]; 9419 Lee Highway, Fairfax, VA 22031 (US). **ARMISTEAD, David** [US/US]; 1810 North Wayne Street, Arlington, VA 22201 (US).
- (74) Agents: **MCPHAIL, Donald, R.** et al.; Fleshner & Kim, LLP, P.O. Box 221200, Chantilly, VA 20153-1200 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PATHOGEN INACTIVATION ASSAY

(57) Abstract: The present invention relates to methods for determining the level of potentially active biological pathogens, such as viruses, bacteria (including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia, rickettsias), fungi (including yeasts) and single cell parasites, which may be found in a biological material. The present invention particularly relates to methods of determining the level of potentially active biological pathogens in a biological material using quantitative PCR.

WO 2004/072231 A2

PATHOGEN INACTIVATION ASSAY

BACKGROUND OF THE INVENTION

5 1. Field of the Invention

The present invention relates to methods for determining the level of potentially active biological pathogens, such as viruses, bacteria (including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia, rickettsias), fungi (including yeasts), and single- and multi-cell parasites, which may be found in a biological material. The present invention particularly relates to methods of determining the level of potentially active biological pathogens in a biological material using quantitative PCR, and so may be particularly useful for determining the effectiveness of a sterilization process that has been applied to the biological material.

15 2. Background of the Related Art

Many biological materials that are prepared for human, veterinary, diagnostic and/or experimental use may contain unwanted and potentially dangerous biological pathogens, such as viruses, bacteria, in both vegetative and spore states, (including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia, rickettsias), fungi (including yeasts), and single- and multi-cell parasites. This may also be true of biological materials that are produced in or exported from locations where certain biological pathogens may exist to locations where those biological pathogens are not endemic. Consequently, it is of utmost importance that any biological pathogen in the

biological material be inactivated before the material is used. This is especially critical when the biological material is to be administered directly to a patient, for example in tissue implants, blood transfusions, blood factor replacement therapy, organ transplants, and other forms of human and/or other animal therapy corrected or treated by surgical implantation, intravenous, intramuscular or other forms of injection or introduction. This is also critical for the various biological materials that are prepared in media or via the culture of cells, or recombinant cells which contain various types of plasma and/or plasma derivatives or other biological materials and which may be subject to mycoplasmal, prion, ureaplasma, bacterial, viral and/or other biological pathogens.

10 All living cells and multi-cellular organisms can be infected with viruses and other pathogens. Thus, the products of unicellular natural or recombinant organisms or tissues virtually always carry a risk of pathogen contamination. In addition to the risk that the producing cells or cell cultures may be infected, the processing of these and other biological materials also creates opportunities for environmental contamination. The risks of infection are more apparent for multi-cellular natural and recombinant organisms, such as transgenic animals.

Interestingly, even products from species as different from humans as transgenic plants carry risks, both due to processing contamination as described above, and from environmental contamination in the growing facilities, which may be contaminated by pathogens from the environment or infected organisms that co-inhabit the facility along with the desired plants. For example, a crop of transgenic corn grown in a field could be expected to be exposed to rodents such as mice during the growing season. Mice can harbor

serious human pathogens such as the frequently fatal Hanta virus. Since these animals would be undetectable in the growing crop, viruses shed by the animals could be carried into the transgenic material at harvest. Indeed, such rodents are notoriously difficult to control, and may gain access to a crop during sowing, growth, harvest or storage. Likewise, 5 contamination from overflying or perching birds has the potential to transmit such serious pathogens as the causative agent for psittacosis. Thus, any biological material, regardless of its source, may harbor serious pathogens that must be removed or inactivated prior to administration of the material to a recipient human or other animal.

Accordingly, many procedures for producing human compatible biological materials 10 have involved methods that screen or test the biological materials for one or more particular biological pathogens rather than removal or inactivation of the pathogen(s) from the biological material. The typical protocol for disposition of materials that test positive for a biological pathogen simply is non-use/discarding of that material.

Examples of screening procedures for contaminants include testing for a particular 15 virus in human blood and tissues from donors. Such procedures, however, are not always reliable and are not able to detect the presence of certain viruses, and prions, particularly those present in very low numbers. This reduces the value, certainty, and safety of such tests in view of the consequences associated with a false negative result, which can be life threatening in certain cases, for example in the case of Acquired Immune Deficiency 20 Syndrome (AIDS). Furthermore, in some instances it can take weeks, if not months, to determine whether or not the material is contaminated. Moreover, to date, there is no commercially available, reliable test or assay for identifying ureaplasmas, mycoplasmas, and

chlamydia within a biological material that is fully suitable for screening out potential donors or infected material (*Advances in Contraception* 10(4):309-315(1994)). This serves to heighten the need for an effective means of destroying ureaplasmas, mycoplasmas, chlamydia, etc., within a biological material, while still retaining the desired activity of that material.

5 Therefore, it is highly desirable to apply techniques that kill or inactivate biological pathogens during and/or after manufacturing and/or harvesting the biological material.

More recent efforts have focussed on methods to remove or inactivate contaminants in products intended for use in humans and other animals. Particularly useful methods are those that alter the genetic material of a biological pathogen, such as the addition of

10 chemical inactivants or sensitizers to a biological material or irradiation of a biological material.

The use of chemical inactivants or sensitizers involves the addition of noxious agents which bind to the DNA/RNA of the virus, and which are activated either by UV or other radiation. This radiation produces reactive intermediates and/or free radicals which bind to

15 the DNA/RNA of the virus, break the chemical bonds in the backbone of the DNA/RNA, and/or cross-link or complex it in such a way that the virus can no longer replicate.

Irradiating a biological material with ionizing radiation, such as gamma, UV or e-beam radiation, is another method of sterilizing a product. The direct effects of gamma radiation are particularly useful for destroying the genetic material within viruses and

20 bacteria, particularly when given in total doses of at least 25 kGy (*See* Keathly, *et al.*, "Is There Life After Irradiation? Part 2," *BioPharm* July-August, 1993, and Leitman, "Use of Blood Cell Irradiation in the Prevention of Post Transfusion Graft-vs-Host Disease,"

Transfusion Science 10:219-239(1989)).

The use of such sterilization methods does not, however, remove any biological pathogens from the sterilized biological material. Rather, these methods render inactive any biological pathogens that may be present in the biological material by altering the genetic material within the pathogen, including cleaving, deleting, oxidizing, reducing, covalently bonding, cross-linking and/or complexing that genetic material or a component thereof.

For many potentially active biological pathogens, a single modification in their genome may be sufficient to render them inactive. Significantly, most presently available tests for the detection or quantification of biological pathogens, such as ELISA tests for surface antigens, will not indicate that the biological pathogen has been rendered inactive. Moreover, conventional genetic detection tests, such as the PCR reaction described below, examine only a small portion of the genome and may fail to detect sites of alteration that render the biological pathogen inactive, irrespective of whether there are several such sites or only one. In practice, these tests may frequently report a high level of false positive results, leading to inappropriate product quarantine or destruction

Accordingly, there is a need for methods to examine the genomes of potentially active biological pathogens in biological materials that have been subjected to sterilization in order to differentiate between biological pathogens that have been rendered inactive and those that are still potentially active. By doing so, such a method permits the determination of how effective a particular sterilization technique may be with respect to a particular biological pathogen. No presently available test provides such information.

PCR (polymerase chain reaction) is a method for increasing the concentration of a segment of a target sequence in a mixture of nucleic acid sequences without cloning or purification. (See K. B. Mullis *et al.*, U.S. Pat. Nos. 4,683,195 and 4,683,202). This process for amplifying the target sequence consists of introducing two oligonucleotide primers to the sample containing the desired target nucleic acid sequence, followed by thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the target sequence. To effect amplification, the genetic material within the sample is first denatured and then the primers are annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, annealing and extension can be repeated many times (*i.e.*, denaturation, annealing and extension constitute one "cycle"; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be "PCR amplified". The segment of genetic material that has been amplified is generally referred to as an "amplicon". The conditions employed for PCR reactions, including aspects of the timing, temperature(s) and particular polymerase selection are typically optimized for examining relatively short segments of nucleic acids, generally in the range of 50-200 nucleic acid residues. With PCR, it is possible to amplify a single copy of a specific target sequence in

genomic DNA to a level detectable by several different methodologies (*e.g.*, hybridization with a labelled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; incorporation of ^{32}P -labelled deoxynucleotide triphosphates, *e.g.*, dCTP or dATP, into the amplified segment). In addition to genomic DNA, any oligonucleotide
5 sequence can be amplified with the appropriate set of primer molecules.

End-point PCR is a polynucleotide amplification protocol. The amplification factor that is observed is related to the number (n) of cycles that have occurred and the efficiency of replication at each cycle (E), which, in turn, is a function of the priming and extension efficiencies during each cycle. Amplification has been observed to follow the form E^n , until
10 high concentrations of the PCR product have been made.

At these high product concentrations, the efficiency of replication tends to drop significantly. It has been suggested that this is probably due to the displacement of the primers by the longer complementary strands of the PCR product. At concentrations in excess of 10^{-8} M, the rate of the two complementary PCR amplified product strands finding
15 each other during the priming reactions becomes sufficiently fast that it may occur before or concomitantly with the extension step of the PCR process. This ultimately leads to a reduced priming efficiency, and, consequently, a reduced cycle efficiency. Continued cycles of PCR lead to declining increases of PCR product molecules, until the PCR product eventually reaches a plateau concentration (the "end-point"), usually a concentration of
20 approximately 10^{-8} M. As a typical reaction volume is about 100 microliters, this corresponds to a yield of about 6×10^{11} double stranded product molecules.

Real-time PCR is also a polynucleotide amplification protocol, but PCR product

analysis occurs simultaneously with amplification of the target sequence. Detecting agents, such as DNA dyes or fluorescent probes, can be added to the PCR mixture before amplification and used to analyze PCR products during amplification. Sample analysis occurs concurrently with amplification in the same tube within the same instrument. This
5 combined approach decreases sample handling, saves time, and greatly reduces the risk of product contamination, as there is no need to remove the samples from their closed containers for further analysis. The concept of combining amplification with product analysis has become known as "real time" or "quantitative" PCR. (*See, e.g.*, WO/9746707A2, WO/9746712A2 and WO/9746714A1).

10 Originally, monitoring fluorescence each cycle of PCR involved the use of ethidium bromide. *See* Higuchi *et al.*, "Simultaneous amplification and detection of specific DNA sequences," *Bio/Technology* 10:413-417 (1992); Higuchi *et al.*, "Kinetic PCR analysis: real time monitoring of DNA amplification reactions," *Bio/Technology* 11:1026-1030 (1993). In that system, fluorescence was measured once per cycle as a relative measure of product
15 concentration. Ethidium bromide detects double stranded DNA; thus, if the desired target nucleic acid sequence is present, fluorescence intensity increases with temperature cycling (otherwise no fluorescence). Furthermore, the cycle number where an increase in fluorescence is first detected increases inversely proportionally to the log of the initial target sequence concentration. Other fluorescent systems have since been developed that are
20 capable of providing additional data concerning the nucleic acid concentration.

In view of the difficulties and problems discussed above, there remains a need for a simple, yet accurate method of determining the efficiency of methods of sterilizing biological

materials that act upon the genetic material of potentially active biological pathogens.

Each of the above references is incorporated by reference herein where appropriate for teachings of additional or alternative details, features and/or technical background.

5

SUMMARY OF THE INVENTION

An object of the invention is to solve at least the problems and/or disadvantages of the relevant art, and to provide at least the advantages described hereinafter.

Accordingly, it is an object of the present invention to provide methods of determining the level of potentially active biological pathogens in a biological material.

10 Other objects, features and advantages of the present invention will be set forth in the detailed description of preferred embodiments that follows, and in part will be apparent from the description or may be learned by practice of the invention. These objects and advantages of the invention will be realized and attained by the compositions and methods particularly pointed out in the written description and claims hereof.

15 In accordance with these and other objects, a first embodiment of the present invention is directed to a method for determining the level of potentially active biological pathogens in a biological material, which comprises: (i) adding to a biological material an effective amount of at least two nucleic acid primer pairs, wherein a first nucleic acid primer pair hybridizes under stringent conditions to a first target nucleic acid sequence found in the
20 biological pathogen and a second nucleic acid primer pair hybridizes under stringent conditions to a second target nucleic acid sequence found in the biological pathogen, and

further wherein first and second target nucleic acid sequences are not identical and the second target nucleic acid sequence contains more nucleic acid residues than the first; (ii) amplifying the target nucleic acid sequences by polymerase chain reaction, which comprises adding at least one polymerase to the biological material containing the primer pairs to form
5 an amplification mixture and thermally cycling this amplification mixture between at least one denaturation temperature and at least one elongation temperature for a period of time sufficient to amplify the target nucleic acid sequences; and (iii) detecting and quantifying the target nucleic acid sequences, wherein the quantity of the first target nucleic acid sequence is proportional to the number of biological pathogens in the biological material and the
10 quantity of the second target nucleic acid sequence is proportional to the number of potentially active biological pathogens in the biological material.

Additional advantages, objects, and features of the invention will be set forth in part in the description which follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from practice of the
15 invention. The objects and advantages of the invention may be realized and attained as particularly pointed out in the appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the complete genomic nucleic acid sequence of human Parvovirus
20 B19 (SEQ ID NO. 1), and indicates exemplary sequences for preparing suitable forward and reverse primers and probes.

Figure 2 shows the complete genomic nucleic acid sequence of hepatitis B virus (SEQ ID NO. 2), and indicates exemplary sequences for preparing suitable forward and reverse primers and probes.

Figure 3 shows the complete genomic nucleic acid sequence of porcine Parvovirus (SEQ ID NO. 3), and indicates exemplary sequences for preparing suitable forward and reverse primers and probes.

Figure 4 shows the complete genomic nucleic acid sequence of Sindbis virus (SEQ ID NO. 4), and indicates exemplary sequences for preparing suitable forward and reverse primers and probes.

Figure 5 shows the complete genomic nucleic acid sequence of West Nile virus (SEQ ID NO. 5), and indicates exemplary sequences for preparing suitable forward and reverse primers and probes.

Figures 6A and 6B show the genomic nucleic acid sequence of the 16S ribosomal RNA gene (SEQ ID NO. 6) and the 23S ribosomal RNA gene of *Escherichia coli* (SEQ ID NO. 7), and indicate exemplary sequences for preparing suitable forward and reverse primers and probes.

Figures 7A and 7B show the genomic nucleic acid sequence of the 18S ribosomal RNA gene (SEQ ID NO. 8) and the 25S ribosomal RNA gene of yeast (*S. cerevisiae*) (SEQ ID NO. 9), and indicate exemplary sequences for preparing suitable forward and reverse primers and probes.

Figure 8 shows the complete nucleic acid sequence of human mitochondrial DNA

(SEQ ID NO. 10), and indicates exemplary sequences for preparing suitable forward and reverse primers and probes.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

5 A. *Definitions*

Unless defined otherwise, all technical and scientific terms used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the relevant art.

As used herein, the singular forms "a," "an," and "the" include the plural reference
10 unless the context clearly dictates otherwise.

As used herein, the term "biological material" is intended to mean any substance derived or obtained from a living organism. Illustrative examples of biological materials include, but are not limited to, the following: cells; tissues; blood or blood components; proteins, including recombinant and transgenic proteins, and proetinaceous materials;
15 enzymes, including digestive enzymes, such as trypsin, chymotrypsin, alpha-galactosidase and iduronodate-2-sulfatase; immunoglobulins, including mono and polyimmunoglobulins; botanicals; food and the like. Preferred examples of biological materials include, but are not limited to, the following: ligaments; tendons; nerves; bone, including demineralized bone matrix, grafts, joints, femurs, femoral heads, etc.; teeth; skin grafts; bone marrow, including
20 bone marrow cell suspensions, whole or processed; heart valves; cartilage; corneas; arteries and veins; organs, including organs for transplantation, such as hearts, livers, lungs, kidneys, intestines, pancreas, limbs and digits; lipids; carbohydrates; collagen, including native,

afibrillar, atelomeric, soluble and insoluble, recombinant and transgenic, both native sequence and modified; chitin and its derivatives, including NO-carboxy chitosan (NOCC); stem cells, islet of Langerhans cells and other cells for transplantation, including genetically altered cells; red blood cells; white blood cells, including monocytes; and platelets.

- 5 Additional examples of biological materials include forensic samples, human or animal remains, stomach contents, mummified remains of a once-living organism, fossilized remains, a product of manufacture containing or previously in contact with a biological material, and fomites.

As used herein, the term "biological pathogen" is intended to mean a biological
10 pathogen that, upon direct or indirect contact with a biological material, may have a deleterious effect on the biological material or upon a recipient thereof. Such biological pathogens include, but are not limited to, the various viruses, bacteria (whether in the vegetative or spore state, including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia, rickettsias), fungi (including yeasts) and/or single- or
15 multi-cell parasites and pests known to those of skill in the art to generally be found in or infect biological materials.

Illustrative examples of some biological pathogens include, but are not limited to, the following: viruses, such as human immunodeficiency viruses and other retroviruses, herpes viruses, filoviruses, circoviruses, paramyxoviruses, cytomegaloviruses, hepatitis viruses
20 (including hepatitis A, B, C, and D variants thereof, among others), pox viruses, toga viruses, Epstein-Barr viruses and parvoviruses; bacteria, such as *Escherichia*, *Bacillus*, *Campylobacter*, *Clostridium*, *Streptococcus* and *Staphylococcus*; nanobacteria; single- and multi-cell parasites, such

as *Trypanosoma* and malarial parasites, including *Plasmodium* species; fungi; yeasts; mycoplasmas and ureaplasmas; chlamydia; rickettsias, such as *Coxiella burnetti*; and multi-cell pests and the like.

Additional non-limiting examples of pathogens found in biological materials include

5 the following bacteria: *Escherichia*, *Bacillus*, *Campylobacter*, *Helicobacter*, *Listeria*, *Clostridium*, *Streptococcus*, *Enterococcus*, *Staphylococcus*, *Brucella*, *Haemophilus*, *Salmonella*, *Yersinia*, *Pseudomonas*, *Serratia*, *Enterobacter*, *Klebsiella*, *Proteus*, *Citrobacter*, *Corynebacterium*, *Propionibacterium* and *Coxiella*, such as *Staphylococci* (including, for example, *S. aureus*, *S. epidermidis*, *S. saprophyticus*, among others), *Chlamydia* (including,

10 for example, *C. pneumoniae*, among others), *Streptococci* (including, for example, the viridians group of *Streptococci*: *S. sanguis*, *S. oralis* (mitis), *S. salivarius*, *S. mutans*, and others; and other species of *Streptococci*, such as *S. bovis* and *S. pyogenes*), *Enterococci* (for example, *E. faecalis* and *E. faecium*, among others), various fungi, and the AHACEK group of gram-negative bacilli (*Haemophilus parainfluenzae*, *Haemophilus aphrophilus*,

15 *Actinobacillus actinomycetemcomitans*, *Cardiobacterium hominis*, *Eikenella corrodens*, and *Kingella kingae*), *Neisseria gonorrhoeae*, *Clostridia* sp., *Listeria monocytogenes*, *Salmonella* sp., *Bacteroides fragilis*, *Escherichia coli*, *Proteus* sp, and *Klebsiella-Enterobacter-Serratia* sp., among others.

Still other non-limiting examples of pathogens found in biological materials include

20 the following viruses: Adeno-associated Virus (AAV), California Encephalitis Virus, Coronavirus, Coxsackievirus-A, Coxsackievirus-B, Eastern Equine Encephalitis Virus (EEEV), Echovirus, Hantavirus, Hepatitis A Virus (HAV), Hepatitis C Virus (HCV),

Hepatitis Delta Virus (HDV), Hepatitis E Virus (HEV), Hepatitis G Virus (HGV), Human Immunodeficiency Virus (HIV), Human T-lymphotrophic Virus (HTLV), Influenza Virus (Flu Virus), Measles Virus (Rubeola), Mumps Virus, Norwalk Virus, Parainfluenza Virus, Polio virus, Rabies Virus, Respiratory Syncytial Virus, Rhinovirus, Rubella Virus, Saint Louis
5 Encephalitis Virus, Western Equine Encephalitis Virus (WEEV), Yellow Fever Virus, Adenovirus, Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Hepatitis B Virus (HBV), Herpes Simplex Virus 1 (HHV1), Herpes Simplex Virus 2 (HHV2), Molluscum contagiosum, Papilloma Virus (HPV), Smallpox Virus (Variola), Vaccinia Virus, Venezuelan Equine Encephalitis Virus (VEEV), Ebola Virus, West Nile Virus, Human Parvovirus B19
10 and Rotavirus.

As used herein, the term "potentially active biological pathogen" is intended to mean a biological pathogen that is capable of causing a deleterious effect, either alone or in combination with another factor, such as a second biological contaminant or pathogen or a native protein (wild-type or mutant) or antibody, in the biological material and/or a recipient
15 thereof.

As used herein, the term "wild-type" in reference to a nucleic acid sequence an amino acid sequence is intended to refer to the corresponding sequence found in naturally occurring organisms, such as biological pathogens, including such variants and mutants as are known to those skilled in the art.

20 As used herein, the term "sterilize" is intended to mean a reduction in the level of at least one potentially active biological pathogen found in the biological material being treated.

As used herein, the term "radiation" is intended to mean radiation of sufficient energy to sterilize at least some component of the irradiated biological material. Types of radiation include, but are not limited to, the following: (i) corpuscular (streams of subatomic particles such as neutrons, electrons, and/or protons); (ii) electromagnetic (originating in a varying
5 electromagnetic field, such as radio waves, visible (both mono and polychromatic) and invisible light, infrared, ultraviolet radiation, x-radiation, and gamma rays and mixtures thereof); and (iii) sound and pressure waves. Such radiation is often described as either ionizing (capable of producing ions in irradiated materials) radiation, such as gamma rays, and non-ionizing radiation, such as visible light. The sources of such radiation may vary and,
10 in general, the selection of a specific source of radiation is not critical provided that sufficient radiation is given in an appropriate time and at an appropriate rate to effect sterilization. In practice, gamma radiation is usually produced by isotopes of Cobalt or Cesium, while UV and X-rays are produced by machines that emit UV and X-radiation, respectively, and electrons are often used to sterilize materials in a method known as "E-
15 beam" irradiation that involves their production via a machine. Visible light, both mono- and polychromatic, is produced by machines and may, in practice, be combined with invisible light, such as infrared and UV, that is produced by the same machine or a different machine.

20 B. *Particularly Preferred Embodiments*

A first preferred embodiment of the present invention is directed to a method for determining the level of potentially active biological pathogens in a biological material, which

comprises:

(i) adding to a biological material an effective amount of at least two nucleic acid primer pairs,

wherein a first nucleic acid primer pair hybridizes under stringent conditions to a first target nucleic acid sequence found in the biological pathogen and a second nucleic acid primer pair hybridizes under stringent conditions to a second target nucleic acid sequence found in the biological pathogen, and further wherein first and second target nucleic acid sequences are not identical and the second target nucleic acid sequence contains more nucleic acid residues than the first;

(ii) amplifying the target nucleic acid sequences by polymerase chain reaction, which comprises adding at least one polymerase to the biological material containing the primer pairs to form an amplification mixture and thermally cycling this amplification mixture between at least one denaturation temperature and at least one elongation temperature for a period of time sufficient to amplify the target nucleic acid sequences; and

(iii) detecting and quantifying the target nucleic acid sequences, wherein the quantity of the first target nucleic acid sequence is proportional to the number of biological pathogens in the biological material and the quantity of the second target nucleic acid sequence is proportional to the number of potentially active biological pathogens in the biological material.

The first and second target nucleic acid sequences employed in the methods of the present invention are preferably selected to be specific for a particular biological pathogen of

interest. That is, it is preferred that at least one, and more preferably both, of the first and second nucleic acid sequences is found only in the biological pathogen of interest and not in any other component of the biological material. According to these embodiments of the present invention, such a selection (or selections) for the target nucleic acid sequence(s)
5 allows for the selective determination of the levels of biological pathogen, including the total number of biological pathogens present (potentially active and inactive) as well as the number of potentially active pathogens and the number of inactive pathogens.

One skilled in the art may determine suitable target nucleic acid sequences empirically, based on factors such as the particular biological pathogen(s) of interest, the
10 biological material being tested and the PCR conditions selected.

Preferably, the first target nucleic acid sequence contains between about 50 and about 500 nucleic acid residues. More preferably, the first target nucleic acid sequence contains between about 50 and about 250 nucleic acid residues, and most preferably between about 50 and about 150 nucleic acid residues.

15 The second target nucleic acid sequence preferably contains between about 500 and about 50,000 nucleic acid residues. More preferably, the second target nucleic acid sequence contains between about 1000 and about 10,000 nucleic acid residues, even more preferably between about 2000 and about 5000 nucleic acid residues and most preferably between about 2500 and about 5000 nucleic acid residues.

20 The first and second target nucleic acid sequences may be completely different or they may overlap by some or all of the shorter of the two. According to certain preferred

embodiments of the present invention, the first target nucleic acid sequence and the second nucleic acid sequence contain at least 16 contiguous nucleic acid residues in common.

As noted, the first and second target nucleic acid sequences are preferably selected to be specific for a biological pathogen of interest. According to such embodiments of the present invention, the biological pathogen is preferably selected from the group consisting of
5 bacteria, viruses, mycoplasmas, fungi and single cell parasites.

According to these embodiments of the present invention, at least one of the first and second target nucleic acid sequences, and more preferably both the first and second target nucleic acid sequence, are at least 30% homologous to a wild-type nucleic acid sequence found in the biological pathogen of interest. More preferably, the first and/or
10 second target nucleic acid sequence is at least 50% homologous to a wild-type nucleic acid sequence found in the biological pathogen of interest, and even more preferably at least 70% homologous. Most preferably, the first and/or second target nucleic acid sequence is at least 90% homologous to a wild-type nucleic acid sequence found in the biological pathogen of
15 interest. According to certain preferred embodiments, the first and/or second target nucleic acid sequence is substantially identical to a wild-type nucleic acid sequence found in the biological pathogen of interest.

According to particularly preferred embodiments of the present invention, at least one of the first and second target nucleic acid sequences, and more preferably both, is a
20 nucleic sequence that is highly conserved among different species, different genera or even different families of biological pathogens.

For example, if the biological pathogen of interest is bacteria, then the first and/or second target nucleic acid sequences are preferably sequences that are found in the gene encoding the 16S ribosomal RNA or the gene encoding the 23S ribosomal RNA. According to these preferred embodiments of the present invention, the first target nucleic acid sequence is even more preferably a nucleic acid sequence found in the gene encoding the 16S ribosomal RNA of bacteria. Preferably, such a sequence is conserved among different species and genera of bacteria.

Thus, as shown in Figure 6A, suitable primers and probes were prepared from the gene encoding the 16S ribosomal RNA of bacteria (SEQ ID NO. 6) that were useful for a wide range of bacterial biological pathogens, including *Escherichia coli*, *Bacteroides forsythus*, *Porphyromonas gingivalis*, *Prevotella melaninogenica*, *Cytophaga baltica*, *Campylobacter jejuni*, *Helicobacter pylori*, *Treponema denticola*, *Treponema pallidum*, *Leptothrix mobilis*, *Thiomicrospira dentrificans*, *Neisseria meningitides*, *Actinobacillus actinomycetemcomitans*, *Haemophilus influenzae*, *Salmonella typhi*, *Vibrio cholerae*, *Coxiella burnetii*, *Legionella pneumophila*, *Pseudomonas aeruginosa*, *Caulobacter vibrioides*, *Rhodospirillum rubrum*, *Nitrobacter winogradskyi*, *Wolbachia sp.*, *Myxococcus xanthus*, *Corynebacterium diphtheriae*, *Mycobacterium tuberculosis*, *Streptomyces coelicolor*, *Actinomyces odontolyticus*, *Bacillus subtilis*, *Staphylococcus aureus*, *Listeria monocytogenes*, *Enterococcus faecalis*, *Lactobacillus acidophilus*, *Streptococcus mutans*, *Clostridium botulinum*, *Peptostreptococcus micros*, *Veillonella dispar*, *Fusobacterium nucleatum*, *Clanrdia trachomatis*, *Mycoplasma pneumoniae*.

According to these particularly preferred embodiments of the present invention, i.e. if the biological pathogen of interest is bacteria, then the second target nucleic acid sequence is preferably a nucleic acid sequence found in both the gene encoding the 16S ribosomal RNA

and the gene encoding the 23S ribosomal RNA. According to these embodiments, the second target nucleic acid sequence is even more preferably a nucleic acid sequence found in the gene encoding the 16S ribosomal RNA and at least a portion of the gene encoding the 23S ribosomal RNA, as well as the non-coding nucleic sequence found therebetween in
5 bacterial genomes.

Similarly, if the biological pathogen of interest is fungi, then the first and/or second target nucleic acid sequences are preferably sequences that are found in the gene encoding the 18S ribosomal RNA or the gene encoding the 25S ribosomal RNA. According to these embodiments of the present invention, the first target nucleic acid sequence is even more
10 preferably a nucleic acid sequence found in the gene encoding the 18S ribosomal RNA of fungi. Preferably, such a sequence is conserved among different species and genera of fungi.

According to these particularly preferred embodiments of the present invention, *i.e.* if the biological pathogen of interest is fungi, then the second target nucleic acid sequence is preferably a nucleic acid sequence found in both the gene encoding the 18S ribosomal RNA
15 and the gene encoding the 25S ribosomal RNA. According to these embodiments, the second target nucleic acid sequence is even more preferably a nucleic acid sequence found in the gene encoding the 18S ribosomal RNA and at least a portion of the gene encoding the 25S ribosomal RNA and the non-coding nucleic sequence found therebetween in fungal genomes, and most preferably a nucleic acid sequence found in the gene encoding the 18S
20 ribosomal RNA, at least a portion of the gene encoding the 25S ribosomal RNA and the gene encoding the 5.8S ribosomal RNA, as well as both non-coding nucleic sequences found therebetween in fungal genomes.

The first and second pairs of nucleic acid primers are each selected based on their ability to generate the desired target nucleic acid sequences under the appropriate PCR conditions. Accordingly, each primer must be specific for the desired target nucleic acid sequence. Similarly, each primer must be selected so that they are not self-complementary or
5 complementary to another primer (or probe, if present).

According to certain preferred embodiments of the present invention, at least one member of each pair of nucleic acid primers is substantially identical, *i.e.* one of the first pair of nucleic acid primers and one of the second pair of nucleic acid primers are substantially identical.

10 According to other preferred embodiments of the present invention, the two pairs of nucleic acid primers are completely different, *i.e.*, neither of the first pair of nucleic acid primers is substantially identical to either of the second pair of nucleic acid primers.

According to still other preferred embodiments of the present invention, the two pairs of nucleic acid primers are substantially identical, *i.e.* one of the first pair of nucleic acid
15 primers is substantially identical to one of the second pair of nucleic acid primers and the other one of the first pair is identical to the other one of the second pair. According to such embodiments, two distinct target sequences may still be obtained, for example, in the case where one or both members of each primer pair hybridize to more than one sequence, for example, as in the case where the first and second target sequences are part of a circular
20 nucleic acid sequence, such as a plasmid, where the hybridization location of the primers on the circular nucleic acid sequence is such that transcription in different directions leads to two different amplicons. Similarly, in cases where the first and target sequences are highly

homologous, particularly at their respective 5' and 3' ends, then the primers will hybridize to both, such that transcription leads to two different amplicons.

The polymerize chain reaction employed in the inventive methods is performed according to the methods and techniques known to those skilled in the art, *i.e.*, a nucleic acid
5 primer pair is added to the biological material containing the sequence of interest to form an amplification mixture that is then thermally cycled for a sufficient period of time to amplify the desired sequence. The thermal cycling generally comprises cycling the amplification mixture between at least one denaturation temperature and at least one elongation temperature. Preferably, the thermal cycling comprises cycling the amplification mixture
10 between at least one denaturation temperature, at least one annealing temperature and at least one elongation temperature.

Specific temperatures for use in denaturation, elongation and/or annealing may be determined empirically by one skilled in the art based, for example, on the specific target sequence being amplified and the particular probes employed. Likewise, the specific time(s)
15 that the amplification mixture is maintained at the various denaturation, elongation and/or annealing temperature(s) may be determined empirically by one skilled in the art based on similar considerations.

According to particularly preferred embodiments of the present invention, the elongation temperature selected for use in the PCR of the inventive methods is not more
20 than about 70°C. More preferably, the elongation temperature selected is between about 60°C and about 69°C, and even more preferably between about 65°C and about 69°C. Most

preferably, the elongation temperature employed in the PCR of the inventive methods is about 68°C.

According to additional preferred embodiments of the present invention, the denaturation temperature selected for use in the PCR of the inventive methods is not more
5 than about 95°C. More preferably, the denaturation temperature selected is between about 90°C and about 95°C, and even more preferably between about 92°C and about 95°C. Most preferably, the denaturation temperature employed in the PCR of the inventive methods is about 94°C.

According to other preferred embodiments of the present invention, when the
10 thermal cycling includes an annealing temperature, the annealing temperature selected is about 5-10°C below the melting temperature of the primers being employed. Preferably, the annealing temperature selected is not more than about 65°C. More preferably, the annealing temperature selected is between about 57°C and about 63°C, and even more preferably between about 58°C and about 62°C. Most preferably, the annealing temperature employed
15 in the PCR of the inventive methods is about 60°C.

According to additional preferred embodiments of the present invention, during each thermal cycle, the amplification mixture is maintained at the elongation temperature for a period of not less than about 1 minute. More preferably, during each thermal cycle, the amplification mixture is maintained at the elongation temperature for a period of not less
20 than about 2 minutes, and even more preferably for a period of not less than about 3

minutes.

According to particularly preferred embodiments of the present invention, the amplification mixture is maintained at the elongation temperature for a period of not less than about 2 minutes during the first cycle of the thermal cycling, and then the period during
5 which said amplification mixture is maintained at the elongation temperature is increased by a period of about 5 seconds for each successive thermal cycle. Thus, for example, according to such embodiments of the present invention, if the amplification mixture was maintained at the elongation temperature for a period of 2 minutes during the first cycle of the thermal cycling, it would be maintained at the elongation temperature for a period of 2 minutes, 5
10 seconds for the second cycle, 2 minutes, 10 seconds for the third cycle, 2 minutes, 15 seconds for the fourth cycle, and so on until the thermal cycling is completed.

According to additional preferred embodiments of the present invention, during each thermal cycle, the amplification mixture is maintained at the denaturation temperature for a period of not more than about 1 minute. More preferably, during each thermal cycle, the
15 amplification mixture is maintained at the denaturation temperature for a period of not more than about 45 seconds, and even more preferably for a period of not more than about 30 seconds, and still even more preferably for a period of not more than about 20 seconds. Most preferably, during each thermal cycle, the amplification mixture is maintained at the denaturation temperature for a period of not more than about 15 seconds, such as a period
20 of about 10 seconds.

According to still other preferred embodiments of the present invention, when the thermal cycling includes an annealing temperature, the amplification mixture is maintained at

the annealing temperature for a period of not less than about 30 seconds. More preferably, according to such embodiments, during each thermal cycle, the amplification mixture is maintained at the annealing temperature for a period between 30 seconds and 2 minutes, and even more preferably for a period of not less than about 45 seconds. Most preferably, during each thermal cycle, the amplification mixture is maintained at the annealing temperature for a period of about 1 minute.

The number of thermal cycles employed in the PCR of the inventive methods may be determined empirically by one skilled in the art depending, for example, on the suspected concentration of the target sequence of interest in the biological material being tested. According to preferred embodiments of the present invention, the amplification mixture is subjected to at least about 30 cycles of thermal cycling, and even more preferably at least about 40 cycles. Most preferably, the amplification mixture is subjected to at least about 50 cycles of thermal cycling.

The polymerase employed in the PCR of the inventive methods may be any of the suitable polymerases known to those skilled in the art. Preferably, the polymerase employed is a thermostable polymerase, *i.e.* a polymerase that is not adversely affected by the higher temperatures involved in thermal cycling. More preferably, the polymerase may be a *Taq* polymerase, or a suitable derivative thereof and/or a proof-reading polymerase.

According to particularly preferred embodiments of the present invention, at least two polymerases are employed in the PCR of the inventive methods. Preferably, at least one of the polymerases is a *Taq* polymerase or a suitable derivative thereof, such as TaqMan DNA polymerase (available from Applied BioSystems), and the other polymerase is a proof-

reading polymerase, such as ProofStart DNA polymerase (available from Qiagen).

According to certain preferred embodiments of the present invention, the amplification mixture further contains at least one thermostable inorganic pyrophosphatase. Suitable amounts of thermostable inorganic pyrophosphatase may be determined empirically
5 by one skilled in art. Generally, when present, the ratio of thermostable inorganic pyrophosphatase to *Taq* polymerase is at least about 1:20, more preferably at least about 1:10 and even more preferably at least about 1:5.

The remaining parameters employed in the PCR of the inventive methods, such as the primer concentration (generally about 100-500 nM and preferably about 200 nM)),
10 magnesium concentration (generally 1.5-6 mM and preferably about 1.5 mM of magnesium sulfate and/or magnesium chloride), deoxyribonucleotide triphosphates (dNTP) concentration (generally about 0.2-0.4 mM each and preferably about 0.2 mM each), probe concentration (if present, generally about 50-800 nM, and preferably about 100 nM), may each be determined empirically by one skilled in the art using any of the known methods and
15 techniques.

According to certain particularly preferred embodiments of the present invention, the deoxyribonucleotide triphosphates (dNTP) that are employed in the PCR of the inventive methods are selected from the group consisting of C, T, G and A. Preferably, substantially no dUTP is present in the amplification mixture of the inventive methods. According to still
20 further preferred embodiments, substantially no uracil N-glycosylase is present in the amplification mixture of the inventive methods.

According to certain particularly preferred embodiments of the present invention, the amplification mixture further comprises at least one buffer solution. Suitable buffer solutions are known and available to those skilled in the art. Particularly preferred buffer solutions include pH modifying buffers, such as buffers containing Tris-HCl, and buffers
5 which maintain salt concentration, particular magnesium concentration, such as buffers containing KCl and/or $(\text{NH}_4)_2\text{SO}_4$.

After amplification using PCR, the first and second target nucleic acid sequences are detected and quantified. This detecting and quantifying may be conducted using any of the methods and techniques known to those skilled in the art. For example, detecting and
10 quantifying of the first and second nucleic acid sequences may be conducted by adding a suitable detecting agent, such as an intercalating dye, directly to the amplification mixture or by adding a suitable nucleic acid probe to the mixture, preferably either a suitable nucleic acid probe in combination with a detecting agent or a suitable nucleic acid probe having a detectable label covalently or ionically attached thereto or complexed therewith.

15 Preferably, the first and second target nucleic acid sequences are detected by adding at least one nucleic acid probe to the biological material being tested. If the first and second target nucleic acid sequences were amplified in a single reaction vessel, then it is preferable to use at least two nucleic acid probes, one of which is specific for the first target nucleic acid sequence and the other of which is specific for the second target nucleic acid sequence.
20 Conversely, if the first and second target nucleic acid sequences were amplified in separate reaction vessels, then the same nucleic acid probe may be used for detecting both the first target nucleic acid sequence and the second target nucleic acid sequence.

Any nucleic acid probe employed in the inventive methods should contain sufficient nucleic acid residues to hybridizes selectively under stringent conditions to a specific desired nucleic acid sequence, *i.e.* suitable probes will generally contain at least 16 nucleic acid residues, and preferably hybridizes selectively under stringent conditions to a specific nucleic acid sequence of the first and/or second target nucleic acid sequence that is not the same as the nucleic acid sequence of any of the primers. Suitable nucleic acid probes include, but are not limited to, 5' nuclease probes, hairpin probes, adjacent probes, sunrise probes and scorpion probes.

According to certain preferred embodiments of the present invention, the nucleic acid probe employed in the inventive methods has an endogeneous passive dye, such as Tamra or the like. In other preferred embodiments, such an endogenous passive dye may be replaced by a passive dye that is not covalently bound to the probe, such as Rox or the like.

According to certain particularly preferred embodiments of the present invention, prior to step (i), the biological material being tested has been subjected to a process that alters at least one wild-type nucleic acid sequence in the biological pathogen of interest. Such processes may cause the wild-type nucleic acid sequence to break, cross-link and/or complex. An illustrative, but non-limiting, example of such a process is irradiation of the biological material with ionizing radiation, such as UV or gamma radiation.

Although not limited in application, the inventive methods are particularly useful in determining the effectiveness of processes that alter nucleic acid sequences, such as the inactivation of biological pathogens by gamma irradiation. More specifically, conventional PCR testing methods only determine whether a particular biological pathogen is present in a

biological material, not whether that biological pathogen is active or inactive. The methods of the present invention, however, may be used to determine not only whether a particular biological pathogen is present in a biological material as shown by amplification of the first target sequence, but also whether that biological pathogen is inactive by virtue of an altered
5 wild-type nucleic acid sequence as shown by a relative delay in the amplification of the second target sequence (the greater the delay in amplification, the greater the reduction in the level of potentially active biological pathogens). Thus, the inventive methods are useful for evaluating the effectiveness of sterilization processes because they determine both the original level and the residual level of potentially active biological pathogens.

10

EXAMPLES

The following examples are illustrative, but not limiting, of the present invention. Other suitable modifications and adaptations are of the variety normally encountered by those skilled in the art and are fully within the spirit and scope of the present invention.

15 Example 1

Purpose: To demonstrate linear amplification of B19 DNA.

Materials:

1. B19 virus, titer 7.6×10^{11} iu/ml from Bayer;
2. SNAP whole blood DNA isolation kit;
3. Forward Primer: Prism 5 (Figure 1) (SEQ ID NO. 18);
- 20 4. Reverse Primer: Prism 6 (Figure 1) (SEQ ID NO. 20);
5. Probe 3 (Figure 1) (SEQ ID NO. 19) labeled with FAM at 5'

end and TAMRA at 3' end;

6. TaqMan Universal Master Mix, (ABI; cat. no. 4304437);

7. DNASE, RNASE free water;

8. ABI 96 well plate and adhesive cores;

5

9. ANI 7000.

Procedure:

1. Followed SNAP protocol for extraction of 100 l B19 sample, eluted in 100 l TE;

2. Diluted primers to 18 M with TE;

3. Diluted probe to 5 M with TE;

10

4. Prepared the following master mix:

TaqMan Master Mix: 25 l;

Prism 5 (SEQ ID NO. 18): 2.5 l;

Prism 6 (SEQ ID NO. 20): 2.5 l;

Taqman Probe 2.5 l;

15

Water: 12.54 l;

5. Added 45 l of master mix per well;

6. Serially diluted B19 DNA, adding water to the NTC well;

7. Sealed and centrifuged the plate at 2300 rpm for about 30

seconds;

20

8. Ran PCR program for 50 cycles.

Results: A standard dilution curve was observed for B19 infected plasma, validating primer pair Prism 5 (SEQ ID NO. 18) and Prism 6 (SEQ ID NO. 20) with Probe 3 (SEQ

ID NO. 19).

Example 2

Purpose: To examine irradiated and unirradiated samples containing PPV using a 549
5 bp amplicon.

Materials: 1. PPV (irradiated at 0 kGy, 50 kGy, 65 kGy, 75 kGy or 85
kGy);

2. SNAP Protein Degradar;

3. Cell Lysis Buffer;

10 4. Tris-HCl;

5. Primers: Prism 11 and Prism 12 (Figure 3) (SEQ ID NOS.:
40 and 42, respectively); and

6. Probe 6 (Figure 3) (SEQ ID NO. 41).

Procedure: 1. To 100 µl viral sample, added 50 µl tris-HCl buffer, 60 µl
15 protein degrader, and 200 µl cell lysis buffer;

2. Mixed and incubated for 25 minutes (5 minutes at 70°C);

3. Diluted samples to 1/50, 1/500, 1/5000, 1/25000, 1/50000,
1/250000 and 1/500000;

4. Ran PCR for 55 cycles.

20 Results: Results showed that unirradiated material had regular dilution series curves,
irradiated material (50 kGy) behaved differently, dilute material did not amplify showing a

reduction in the number of copies of the target sequence.

Example 3

Purpose: To determine effects of gamma irradiation (0 kGy sample, 50 kGy sample,
5 mixture of 0+50kGy sample and 75 kGy sample) on samples containing PPV analyzed by
PCR.

Materials:

1. PPV (irradiated at 0 kGy, 50 kGy or 75 kGy);
2. Primers: Prism 11 & Prism 12, Probe 6 (Figure 3) (SEQ ID
NOS.: 40, 42, and 41, respectively);
- 10 3. Primers: Prism 1 & Prism 2, Probe 1 (Figure 3) (SEQ ID
NOS.: 43, 45, and 44, respectively)

Procedure:

1. Diluted samples containing PPV to 1/100, 1/1000, 1-2000,
1/10000, 1/20000, 1/40000 and 1/400000 (0 kGy, 50 kGy, 0+50 kGy and 75 kGy);
2. Ran PCR program for 55 cycles.

15 Results: Irradiation to 50 kGy of PPV material reduced amplification of 549 bp
amplicon.

Example 4

Purpose: To examine the relative effectiveness of Qiagen and Taqman reagents on
20 samples containing PPV.

Materials:

1. PPV DNA (phenol extracted);
2. Taq PCR Core Kit;
3. ProofStart DNA polymerase;
4. Taqman Universal PCR Master Mix;
5. Prism 1, 2, 11 and 17 (Figure 3) (SEQ ID NOS.: 43, 45, 40,
and 47, respectively);
6. Probes 1 and 6 (Figure 3) (SEQ ID NOS.: 44 and 41,
respectively);
7. Agarose;
8. TAE;
9. EtBr.

Procedure:

1. Prepared the following four master mixes:

a. Qiagen:	1	2
10x buffer:	30 μ l	25 μ l
dNTP's:	9 μ l	7.5 μ l
pA:	8.34 μ l	6.95 μ l
pB:	8.34 μ l	6.95 μ l
taq:	6 μ l	5 μ l
H ₂ O:	187.32 μ l	156.1 μ l
probe:	15 μ l	12.5 μ l

- b. Taqman: 3 4

	Master Mix:	150 μ l	125 μ l
	pA:	15 μ l	12.5 μ l
	pB:	15 μ l	12.5 μ l
	probe:	15 μ l	12.5 μ l
5	H ₂ O:	69 μ l	57.5 μ l

2. Pipetted 44 μ l of master mix 1 into row D, wells 1 and 2;
row E, wells 1 and 2; and row H, well 1, of a well plate;

3. Pipetted 44 μ l of master mix 2 into row D, wells 3 and 4;
and row E, wells 3 and 4, of a well plate;

10 4. Pipetted 44 μ l of master mix 3, into row F, wells 1 and 2;
row G, wells 1 and 2; and row H, well 3, of a well plate;

5. Pipetted 44 μ l of master mix 4 into row F, wells 3 and 4; and
row G, wells 3 and 4, of a well plate;

6. Added 1 μ l of ProofStart taq to row D, wells 1-4 and row F,
15 wells 1-4 and added 1 μ l water to remaining wells;

7. Added 5 μ l water to row H, wells 1 and 3 and added 5 μ l
PPV DNA to remaining wells;

8. Ran PCR for 40 cycles.

Results: QiaGen Master with ProofStart taq produced functional large amplicons in
20 realtime PCR with PPV DNA more efficiently than the TaqMan master mix.

Example 5

Purpose: To examine the effects of proofstart in amplifying large amplicons and to examine the effects of 50 kGy irradiation on PPV.

Materials:

1. PPV DNA (irradiated to 0 kGy and 50 kGy);
2. Taq PCR Core Kit;
3. Proofstart DNA polymerase;
4. Prism 11, 16 and 17 (Figure 3) (SEQ ID NOS.: 40, 46, and 47, respectively);
5. Agarose;
6. Ethidium Bromide;
7. TAE buffer.

Procedure:

1. Set up PCR master mix as follows:

10x buffer: 50 l

dNTP's: 15 l

pA: 13.9 l (primer 11 (SEQ ID NO. 40))

taq: 10 l

water: 347.2 l

2. Placed aliquots into PCR tubes;

3. Added either primer 16 or 17 (SEQ ID NOS.: 46 or 47,

respectively) to PCR tubes;

4. Added PPV DNA (diluted to 1:100) to each PCR tube:

5. Added 10 μ l proofstart to half of the samples (2 at 0 kGy and 2 at 50 kGy);

6. Performed PCR (about 55 cycles)

7. Poured a 1% gel and ran at 100 V for 20 minutes.

5 Results: Addition of a proofreading polymerase resulted in improved amplification of longer amplicons. Delay in amplification of target sequence in irradiated samples is proportional to damage done to viral genetic material.

Example 6

10 Purpose: To examine the effect of TSP concentration on amplification of large target amplicons in gamma irradiated and unirradiated PPV.

Materials:

1. TSP (cat. no. M02965);
2. Qiagen Core kit;
3. ProofStart DNA polymerase;
- 15 4. PPV (irradiated to 0 kGy or 50 kGy).

Procedure:

1. Prepared a master mix (standard PCR set-up) for each (TSP: Taq 1:20, 1:10, 1:5);
2. Added 43.61 μ l of each master mix (TSP titration) to PCR tubes;
- 20 3. Added 1.39 μ l of primers 16, 17 or 19 (Figure 3) (SEQ ID NOS.: 46, 47, or 49, respectively) to appropriate PCT tubes;

4. Added 5 l water to the negative control, which contained primer pair 11, 16 (Figure 3) (SEQ ID NOS.: 40 and 46, respectively).

5. Diluted PPV 1:100;

6. Added PPV to PCR tubes;

5 7. Performed PCR;

8. Poured a 1% gel and ran at 100 V for 20 minutes.

Results: Under these conditions, addition of TSP resulted in increased amplification of target amplicons in both irradiated and unirradiated samples, but irradiation of PPV resulted in decreased amplification of target amplicon.

10

Example 7

Purpose: To examine the effects of gamma irradiation on amplification of PPV target amplicons of various sizes.

Materials:

15

1. PPV DNA (irradiated to 0 kGy or 50 kGy);

2. Taq PCR Core Kit;

3. ProofStart DNA Polymerase;

4. Prism 11, 16, 17, 18 and 19 (Figure 3) (SEQ ID NOS.: 40, 46, 47, 48, and 49, respectively);

5. Agarose;

6. TAE;

7. Ethidium Bromide.

Procedure:

1. Prepared PCR Master Mix as follows:

	10x Buffer	5 l
5	dNTPs	1.5 l
	pA	1.39 l
	pB	1.39 l
	taq	1 l
	water	33.72 l
10	PPV	5 l

2. Aliquoted samples into PCR tubes;

3. Ran PCR;

4. Poured a 1% agarose gel and ran at 120 V for about 1.5 hours.

15 Results: Irradiation to 50 kGy resulted in decreased amplification of larger target amplicons.

Example 8

Purpose: To examine PCR sensitivity and determine log reduction of PPV in samples

irradiated to 50 kGy and having a starting concentration of 2.5×10^7 gEq.

Materials:

1. Standard PCR reagents (Qiacen Core Kit, TSP, Proofstart, etc.);
2. Primers 11 and 17 (Figure 3) (SEQ ID NOS.: 40 and 47, respectively);
3. PPV extract.

Procedure:

1. Prepared master mix with primers 11 and 17 (SEQ ID NOS.: 40 and 47, respectively);
2. Performed a 10 fold dilution series from 10^7 to 10^0 of PPV extract;
3. Pipetted 45 μ l of master mix into PCR tubes;
4. Pipetted 5 μ l of each PPV dilution into appropriate PCR tubes;
5. Added 5 μ l water to control;
6. Ran PCR;
7. Ran samples in 1% agarose at 100V for about 47 minutes.

Results: Irradiation of sample to 50 kGy resulted in decreased amplification of target amplicon across all concentration ranges.

20 Example 9

Purpose: To examine PCR sensitivity and determine log reduction of PPV in samples

irradiated to 50 kGy and having a starting concentration of 2.5×10^7 gEq.

Materials:

1. TSP;
2. Standard PCR kit (Qiacen with ProofStart Polymerase);
3. Primers 11 and 19 (Figure 3) (SEQ ID NOS.: 40 and 49,
5 respectively);
4. PPV Extract (Irradiated to 0 kGy and 50 kGy).

Procedure:

1. Prepared master mix with primers 11 and 19 (SEQ ID
NOS.: 40 and 49, respectively);
2. Performed a 10 fold dilution series from 10^7 to 10^0 of PPV
10 extract;
3. Pipetted 45 μ l of master mix into PCR tubes;
4. Pipetted 5 μ l of each PPV dilution into appropriate PCR
tubes;
5. Added 5 μ l water to control;
- 15 6. Ran PCR as follows:
95°C for 2 minutes (1 cycles)
94°C for 10 seconds (40 cycles)
60°C for 1 minute (40 cycles)
68°C for 2 minutes (40 cycles);
7. Cooled to 4°C;
- 20 8. Ran samples on 1% agarose gel in 1x TAE and 5 μ l/100 ml
ethidium bromide at 100 V for 52 minutes (5 μ l on gel).

Results: Irradiation to 50 kGy resulted in decreased amplification of target amplicon across all concentration ranges. For unirradiated samples, relative band strength of observed target amplicon decreased with decreasing concentration.

5 Example 10

Purpose: Primer validation for B19 using probe 7 (SEQ ID NO. 12) and various primers.

Materials:

1. B19 IGIV Paste (irradiated to 0 kGY or 50 kGy);
2. EXB;
- 10 3. Proteinase;
4. yeast tRNA
5. phenol chloroform isoamyl alcohol;
6. 3M NaAc;
7. isopropanol;
- 15 8. 70% EtOH;
9. TE buffer;
10. Prisms 5, 6, 20, 21, 22, 23, 24, 25, 26 (Figure 1) (SEQ ID NOS.: 18, 20, 11, 13, 14, 15, 16, 17, and 21, respectively);
11. Qiagen reagents;
- 20 12. Ampligold Taq;
13. ProofStart Polymerase;

Example 11

Purpose: Use of PCR multiplexing with target amplicons of about 112 bp and about 2.4 kbp for B19 virus in samples irradiated to 0 kGy or 50 kGy.

- 5 Materials:
1. TSP thermostable inorganic pyrophosphatase
 2. Standard PCR reagents;
 3. B19 viral extract (irradiated to 0 kGy and 50 kGy);
 4. Primers 5, 6, 20 and 25 (Figure 1) SEQ ID NOS.: 18, 20, 11, and 17, respectively);

- 10
5. Taq;
 6. ProofStart Polymerase.

- Procedure:
1. Prepared standard PCR set-up with 3x master mixes, for each primer set (primer sets: 5&6 (SEQ ID NOS.: 18 and 20, respectively); 20&25 (SEQ ID NOS.: 11 and 17, respectively); 5&6 (SEQ ID NOS.: 18 and 20, respectively); and 20&25 (SEQ ID NOS.: 11 and 17, respectively));

- 15
2. Prepared appropriate PCR tubes containing the following primer pairs: (5, 6) 0 kGy; (5, 6) 50 kGy; (20, 25) 0 kGy; (20, 25) 50 kGy; (5, 6) & (20, 25), 0 kGy; and (5, 6) and (20, 25), 50 kGy;

- 20
3. Added 5 µl B19 to PCR tubes containing 45 µl of appropriate master mix;

4. Added 5 µl water to control;

5. Ran PCR.

6. Ran samples on 1% agarose gel at 100 V for about 17 minutes.

Results: PCR multiplexing is effective for mixtures containing large target amplicons and small target amplicons. Irradiation to 50 kGy resulted in decreased amplification of the large target amplicon relative to the small target amplicon.

Example 12

Purpose: Irradiated and unirradiated samples containing B19 viral material were examined using real time PCR.

Materials:

1. B19 viral material (irradiated to 0 kGy and 50 kGy);
2. Prism pairs (20, 21) (SEQ ID NOS.: 11 and 13, respectively) and (20, 26) (SEQ ID NOS.: 11 and 21, respectively) (Figure 1)
3. Qiagen PCR reagents;
4. Qiagen ProofStart;
5. Agarose;
6. TAE (1x);
7. sample loading buffer (SLB).

Procedure:

1. Prepared standard samples containing primer pairs with 10^{11} to 10^1 dilution series;
2. Ran PCR (40 cycles);

3. Ran gel on 1% agarose (8 µl PCR product, 1 µl SLB) at 100

V for about 20 minutes.

Results: Unirradiated and irradiated samples amplified in a regular pattern for a dilution series with a small amplicon. As amplicon size increased, unirradiated material
5 maintained a regular dilution pattern while irradiated material did not.

Example 13

Purpose: To investigate the effect of gamma irradiation on samples containing HBV clone and irradiated to 50 kGy.

- 10 Materials:
1. HBV (irradiated to 0 kGy and 50 kGy);
 2. Taq PCR Core Kit;
 3. ProofStart DNA polymerase;
 4. Prisms 34, 9, 10, 15, 29, 30, 31, 36 and 37 (SEQ ID NOS.:
31, 22, 24, 25, 27, 32, 34, 28, and 29, respectively);
 - 15 5. Agarose;
 6. TAE Buffer;
 7. ethidium bromide.

Procedure: 1. Prepared PCR master mix as follows:

	10x PCR buffer	5 µl
20	dNTPs	1.39 µl
	primers	1.39 µl

taq	1 µl
ProofStart	1 µl
water	33.22 µl
TSP	0.5 µl

5 2. Aliquoted 43.61 µl of master mix into PCR tubes.

Appropriate tubes contained the following primer pairs: (3, 4); (9, 10); (9, 15); (9, 29); (9, 30); (9, 31); (36, 37); and (9, 31), for both irradiated and unirradiated samples;

3. Added 5 μ l HBV per tube (irradiated or unirradiated);

4. Ran PCR as follows:

10 50°C for 2 minutes (one cycle)

95°C for 2 minutes (one cycle)

94°C for 10 seconds (40 cycles)

60°C for 1 minute (40 cycles)

68°C for 2 minutes, five seconds (40 cycles);

15 5. Ran 1% agarose gel (9 μ l sample + 1 μ l sample buffer) at
100v for about 20 minutes.

Results: Irradiated samples showed no band, indicating degradation of HBV clone by irradiation to 50 kGy.

20 Example 14

Purpose: To investigate the effect of gamma irradiation on samples containing HBV

DNA and irradiated to 50 kGy.

Materials:

1. HBV DNA material (irradiated to 0 kGy and 50 kGy);
2. Taq PCR Core Kit (Qiagen, cat. no. 201223);
3. ProofStart Taq Polymerase (Qiagen, cat. no. 20);
- 5 4. Prisms 10, 13, 30, 36 and 37 (Figure 2) (SEQ ID NOS.: 24, 26, 32, 28, and 29, respectively);
5. Agarose;
6. TAE Buffer;
7. Ethidium Bromide.

10 Procedure:

1. Prepared the following master mix:

10x buffer	60 µl
dNTP	18 µl
primer 36 (SEQ ID NO. 28)	16.68 µl
Taq	12µl
15 ProofStart	12 µl
water	440.64 µl;

2. Pipetted 46.61 µl of master mix into PCR tubes;

3. Added 1.39 µl of reverse primer (10, 13, 30 or 37) (SEQ ID NOS.: 24, 26, 32, or 29, respectively) and 2 µl HBV DNA (0 kGy and 50 kGy) to
- 20 appropriate tubes;

4. Ran PCR for 50 cycles;

5. Poured a 1% agarose gel (8 µl PCR product + 1 µl sample buffer) at 100 V for about 20 minutes.

Results: Irradiated samples showed no band, indicating degradation of HBV DNA by irradiation to 50 kGy.

5

Example 15

Purpose: HBV amplification of nested primer set (about 80 bp, 400 bp and 697 bp) in samples containing ascorbate, including digestion of 0 kGy and 50 kGy samples with exonuclease I prior to PCR amplification.

- 10 Materials:
1. HBV DNA (irradiated to 0 kGy and 50 kGy, with and without ascorbate);
 2. Primer sets: (9, 10) (SEQ ID NOS.: 22 and 24, respectively); (9, 15) (SEQ ID NOS.: 22 and 25, respectively); and (9, 13) (SEQ ID NOS.: 22 and 26, respectively) (Figure 2);
 - 15 3. Exonuclease I;
 4. Standard PCR reagents.

Procedure:

1. Diluted HBV samples to 1/500, 1/2000 and 1/10000;
2. Digested 1 µl raw HBV extract in 0.25 µl Exonuclease I, 10 µl 10x Exonuclease I buffer and 88.75 µl water at 37°C for 30 minutes, inactivated at 80°C
- 20 for 20 minutes;

3. Dilutes digested HBV to 1/2000 and 1/10000;

4. Ran 55 cycles PCR.

Results: Irradiated and unirradiated samples coamplified with an 80 bp product. Only unirradiated samples amplified with a 697 bp product.

5 Example 16

Purpose: To investigate the amount of bacterial and fungal DNA present in pulverized tendon samples.

Materials: 1. E. Coli samples (tendon) – 0 or 50 kGy + stabilizer
(6.65×10^{10} CFU/ μ l);

10 2. C. Albicans samples (tendon) – 0 or 50 kGy + stabilizer
(3.55×10^9 CFU/ μ l);

3. Staph. Aureus samples;

4. Control tendon;

5. Dneasey tissue kit (Qiagen, cat. no. 69504);

15 6. Taq PCR Core Kit (Qiagen, cat. no. 201223);

7. ProofStart Taq Polymerase (Qiagen, cat. no. 202205);

8. Primers: Ribo 7 and 8, and Ribo 10, 11, 12, 13, 14 (Figures 6A and 6B) (SEQ ID NOS.: 69, 70, 71, 72, and 73, respectively) and Fungi 1, 2, 3, 4, 5, 6, 7, 8 (Figures 7A and 7B) (SEQ ID NOS.: 75, 77, 78, 79, 80, 81, 82 and 83, respectively);

20 9. Probes: FAM-RIBO;

Fungi Probe

(Figure 7A) (SEQ ID NO.: 76) labeled with FAM at 5' end and TAMRA at 3' end;

10. Microcon YM Centrifugal Filter Unit;

Procedure:

1. Using 0.05 tendon samples for *E. coli* and *C. albicans*, followed the Qiagen extraction profile;

5

2. Prepared the following master mixes:

	Mix 1	Mix 2
10x buffer	150 µl	85 µl
dNTPs	45 µl	25.5 µl
Ribo 7 41.7	41.7 µl	---
10 Fungi 1 (SEQ ID NO. 75)	----	23.65 µl
Taq	30 µl	17 µl
ProofStart	30 µl	17 µl
Water	936.6 µl	530.74 µl
FAM-RIBO	75 µl	----
15 Fungi Probe	----	42.5 µl

3. Filtered master mixes using Microcon filter units for 30 minutes at 100x g;

4. Pipetted 43.6 µl of Mix 1 into: rows A-D, columns 1-6; rows A-C, column 9; and row E, column 12;

20

5. Pipetted 43.6 µl of Mix 2 into: rows E-F, columns 1-7 and row H, column 12;

6. Pipetted 1.39 µl of reverse primer into appropriate well;
7. Pipetted 5 µl DNA into appropriate wells;
8. Ran PCR.

Results: Irradiation with 50 kGy resulted in decreased amplification of large target amplicons, indicating degradation of the pathogen genetic material caused by irradiation.

Example 17

Purpose: To show functionality of E. coli primers for RT-PCR using large target amplicons.

- 10 Materials:
1. E. coli prepared from overnight culture;
 2. Dneasy Tissue Kit (Qiagen, cat. no. 96504);
 3. Taq PCR Core Kit (Qiagen, cat. no. 201223)
 4. ProofStart DNA polymerase (Qiagen, cat. no. 202205);
 5. Microcon YM-100 Centrifugal Filter Unit (cat. no. 42413);
 - 15 6. Primers: Ribo 1-9;
 7. Agarose;
 8. TAE Buffer;
 9. Ethidium Bromide.

- Procedure:
1. Pipetted 1 ml of E. coli culture into each of 10 1.5 tubes;
 - 20 2. Centrifuged all 10 tubes for 5 minutes at maximum speed;
 3. Discarded supernatant;

4. Placed 8 tubes in -80°C and used 2 tubes for extraction following the Qiagen protocol;

5. Prepared Master Mix as follows:

	10x Buffer	5 μl
5	dNTPs	1.5 μl
	pA	1.39 μl (Ribo 1 (SEQ ID NO. 62)) or (Ribo 7)
	pB	1.39 μl (Ribo 2, 3, 4, 5, or 6) (SEQ ID NOS.: 64, 65, 66, 67, or 68, respectively) or (Ribo 8 or 9)
10	Taq	1 μl
	ProofStart	1 μl
	Water	33.22 μl
	TSP	0.5 μl

6. Mixed Master Mix by inversion;

15 7. Pipetted Master mix into a Microcon Centrifugal Filter Unit and centrifuged for 30 minutes at 100x g;

8. Pipetted 43.61 μl of Master Mix into PCR tubes;

9. Added appropriate reverse primer and DNA or water to create the following primer pairs: (1, 2) + 5 μl DNA; (1, 2) + 1 μl ; (1, 3) + 5 μl DNA; (1, 3)
20 + 1 μl DNA; (1, 4) + 5 μl DNA; (1, 4) + 1 μl DNA; (1, 5) + 5 μl DNA; (1, 5) + 1 μl DNA;
(1, 6) + 5 μl DNA; (1, 6) + 1 μl DNA; (5, 8) + 5 μl DNA; (7, 8) + 1 μl DNA; (7, 9) + 5 μl

DNA; (7, 9) + 1 µl DNA; and (1, 2) + 5 (1, 4) + 5 µl water;

10. Ran PCR;

11. Ran 1 % Agarose gel at 100 V for about 20 min.

Results: All E. coli primers showed amplification of target sequences, regardless of
5 size.

Example 18

Purpose: To investigate the effects of 50 kGy irradiation on samples containing E. coli.

Materials: 1. E. coli spiked tendon (irradiated to 0 kGy and 50 kGy) +
10 6.65x10¹⁰ CFU/µl;

2. Taq PCR Core Kit (Qiagen, cat. no. 201223);

3. ProofStart Taq Polymerase (Qiagen, cat. no. 202205);

4. Primers: Ribo 7 and 8, and Ribo 13, 14 and 15 (SEQ ID

NOS.: 72, 73, and 74 respectively);

15 5. Agarose;

6. TAE Buffer;

7. Ethidium Bromide;

8. Microcon Centrifugal Filter Unit.

Procedure: 1. Prepared Master Mix as follows:

20 10x Buffer 60 µl
dNTP 18 µl

pA (forward) 16.68 μ l

Taq 12 μ l

ProofStart 12 μ l

Water 452.64 μ l;

2. Placed in Microcon and centrifuged for 30 minutes at 100x g;
3. Pipetted 47-61 μ l master mix into each of 9 PCR tubes;
4. Added 1.39 μ l of reverse primer and 1 μ l DNA into appropriate tubes;
5. Ran PCR.
6. Ran 1% Agarose gel (8 μ l sample + 1 μ l sample buffer) at 100 V for about 20 minutes.

Results: Samples irradiated to 50 kGy showed progressive disappearance of bands with increasing amplicon size, indicating degradation of the *E. coli* genetic material caused by irradiation.

15

Example 19

Purpose: To show functionality of Mt-DNA primers for RT-PCR using large target amplicons.

Materials:

1. Tendon DNA (irradiated to 0 kGy and 50 kGy);
2. ROX 6 (1/10 dilution) molecular probes;
3. Primers: MITO 1, 2, 3, 4, and 5 (Figure 8) (SEQ ID NOS.:

90, 92, 95, 96; and 97, respectively);

4. MITO Probe 1 (Figure 8) (SEQ ID NO.: 91);

5. Human DNA;

6. Qiagen PCR Reagents;

5

7. Qiagen ProofStart.

Procedure:

1. Prepared the following mixtures:

	Buffer	1.5 μ l
	dNTPs	1.5 μ l
	MITO 1	2.5 μ l (SEQ ID NO. 90)
10	reverse primer	2.5 μ l (MITO 2, 3, 4 or 5) (SEQ
	ID NOS.: 92, 95, 96, or 97, respectively)	
	MITO Probe	2.5 μ l
	Taq	1 μ l
	PS	1 μ l
15	1/10 ROX	1 μ l
	water	28 μ l
	DNA	5 μ l

2. Ran 40 PCR;

3. Ran 1% agarose gel (8 μ l product + 1 μ l sample loading
20 buffer) at 100 V for about one hour.

Results: Mt-DNA primers were functional, regardless of amplicon size.

Having now fully described this invention, it will be understood to those of ordinary skill in the art that the methods of the present invention can be carried out with a wide and equivalent range of conditions, formulations and other parameters without departing from the scope of the invention or any embodiments thereof. Moreover, the methods of the present invention may also be applied to situations other than the preferred embodiments described above. For example, instead of determining the level of potentially active pathogens, the methods described above may be used to determine the number of cells having an altered genetic sequence, such as tumour cells or genetically modified cells, in a tissue sample.

10 All patents and publications cited herein are hereby fully incorporated by reference in their entirety. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that such publication is prior art or that the present invention is not entitled to antedate such publication by virtue of prior invention.

WHAT IS CLAIMED IS:

1. A method for determining the level of potentially active biological pathogens in a biological material, said method comprising:

(i) adding to said biological material an effective amount of at least two
5 nucleic acid primer pairs,

wherein a first nucleic acid primer pair hybridizes under stringent conditions to a first target nucleic acid sequence found in said biological pathogen and a second nucleic acid primer pair hybridizes under stringent conditions to a second target nucleic acid sequence found in said biological pathogen, and

10 further wherein said first target nucleic acid sequence and said second target nucleic acid sequence are not identical and said second target nucleic acid sequence contains more nucleic acid residues than said first target nucleic acid sequence;

(ii) amplifying said target nucleic acid sequences by polymerase chain reaction, said polymerase chain reaction comprising adding at least one polymerase to said
15 biological material containing said nucleic acid primer pairs to form an amplification mixture and thermally cycling said amplification mixture between at least one denaturation temperature and at least one elongation temperature for a period of time sufficient to amplify said target nucleic acid sequences; and

(iii) detecting and quantifying said first and second target nucleic acid
20 sequences, wherein the quantity of said first target nucleic acid sequence is proportional to the number of said biological pathogens in said biological material and the quantity of said second target nucleic acid sequence is proportional to the number of potentially active

biological pathogens in said biological material.

2. The method according to claim 1, wherein said first target nucleic acid sequence contains between about 50 and about 500 nucleic acid residues

5

3 The method according to claim 1, wherein said second target nucleic acid sequence contains between about 500 and about 50,000 nucleic acid residues.

4. The method according to claim 1, wherein the nucleic acid sequence of said
10 first target nucleic acid sequence and the nucleic acid sequence of said second target nucleic acid sequence contain at least 16 contiguous nucleic acid residues in common.

5. The method according to claim 1, wherein said step (i) further comprises adding at least one nucleic acid probe to said biological material.

15

6. The method according to claim 5, wherein said nucleic acid probe is selected from the group consisting of 5' nuclease probes, hairpin probes, adjacent probes, sunrise probes and scorpion probes.

20 7. The method according to claim 1, wherein, prior to step (i), said biological material has been subjected to a process that alters at least one wild-type nucleic acid sequence in said biological pathogen.

8. The method according to claim 7, wherein said process comprises irradiating said biological material with gamma radiation.

5 9. The method according to claim 1, wherein one of said first pair of nucleic acid primers and one of said second pair of nucleic acid primers are substantially identical.

10. The method according to claim 1, wherein neither of said first pair of nucleic acid primers is substantially identical to either of said second pair of nucleic acid primers.

10

11. The method according to claim 1, wherein said first pair of nucleic acid primers and said second pair of nucleic acid primers are substantially identical.

12. The method according to claim 5, wherein said nucleic acid probe contains at
15 least 16 nucleic acid residues.

13. The method according to claim 1, wherein said biological pathogen is selected from the group consisting of bacteria, viruses, fungi and single cell parasites.

20 14. The method according to claim 1, wherein said first target nucleic acid sequence is at least 30% homologous to a wild-type nucleic acid sequence found in said biological pathogen.

15. The method according to claim 1, wherein said second target nucleic acid sequence is at least 30% homologous to a wild-type nucleic acid sequence found in said biological pathogen.

5

16. The method according to claim 14 or 15, wherein said biological pathogen is selected from the group consisting of *Aspergillus*, *Candida*, *Histoplasma*, *Saccharomyces*, *Coccidioides* and *Cryptococcus*.

10

17. The method according to claim 14 or 15, wherein said biological pathogen is selected from the group consisting of *Escherichia*, *Bacillus*, *Campylobacter*, *Helicobacter*, *Listeria*, *Clostridium*, *Streptococcus*, *Enterococcus*, *Staphylococcus*, *Brucella*, *Haemophilus*, *Salmonella*, *Yersinia*, *Pseudomonas*, *Serratia*, *Enterobacter*, *Kebsiella*, *Proteus*, *Citrobacter*, *Corynebacterium*, *Propionibacterium* and *Coxiella*.

15

18. The method according to claim 14 or 15, wherein said biological pathogen is selected from the group consisting of Adeno-associated Virus (AAV), California Encephalitis Virus, Coronavirus, Coxsackievirus-A, Coxsackievirus-B, Eastern Equine Encephalitis Virus (EEEV), Echovirus, Hantavirus, Hepatitis A Virus (HAV), Hepatitis C Virus (HCV), Hepatitis Delta Virus (HDV), Hepatitis E Virus (HEV), Hepatitis G Virus (HGV), Human Immunodeficiency Virus (HIV), Human T-lymphotrophic Virus (HTLV), Influenza Virus (Flu Virus), Measles Virus (Rubeola), Mumps Virus, Norwalk Virus,

Parainfluenza Virus, Polio virus, Rabies Virus, Respiratory Syncytial Virus, Rhinovirus, Rubella Virus, Saint Louis Encephalitis Virus, Western Equine Encephalitis Virus (WEEV), Yellow Fever Virus, Adenovirus, Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Hepatitis B Virus (HBV), Herpes Simplex Virus 1 (HHV1), Herpes Simplex Virus 2
5 (HHV2), Molluscum contagiosum, Papilloma Virus (HPV), Smallpox Virus (Variola), Vaccinia Virus, Venezuelan Equine Encephalitis Virus (VEEV), Ebola Virus, West Nile Virus, Human Parvovirus B19 and Rotavirus.

19. The method according to claim 15, wherein said wild-type nucleic acid
10 sequence comprises the 16S ribosomal RNA gene coding sequence.

20. The method according to claim 15, wherein said wild-type nucleic acid sequence comprises the 16S ribosomal RNA gene coding sequence and a portion of the 23S ribosomal RNA gene coding sequence.

15

21. The method according to claim 15, wherein said wild-type nucleic acid sequence comprises the 16S ribosomal RNA gene coding sequence and a portion of the 23S ribosomal RNA gene coding sequence and the non-coding sequence therebetween.

22. The method according to claim 14, wherein said wild-type nucleic acid
20 sequence comprises the 18S ribosomal RNA gene coding sequence.

23. The method according to claim 14, wherein said wild-type nucleic acid sequence comprises the 18S ribosomal RNA gene coding sequence and the 5.8S ribosomal RNA gene coding sequence.

5 24. The method according to claim 14, wherein said wild-type nucleic acid sequence comprises the 18S ribosomal RNA gene coding sequence and the 5.8S ribosomal RNA gene coding sequence and the non-coding sequence therebetween.

10 25. The method according to claim 14, wherein said wild-type nucleic acid sequence comprises the 18S ribosomal RNA gene coding sequence and the 5.8S ribosomal RNA gene coding sequence and a portion of the 28S ribosomal RNA gene coding sequence.

15 26. The method according to claim 14, wherein said wild-type nucleic acid sequence comprises the 18S ribosomal RNA gene coding sequence and the 5.8S ribosomal RNA gene coding sequence and a portion of the 28S ribosomal RNA gene coding sequence and the non-coding sequences therebetween.

27. The method according to claim 1, wherein said polymerase is a thermostable polymerase.

20

28. The method according to claim 27, wherein said thermostable polymerase is a *Taq* polymerase.

29. The method according to claim 1, wherein said polymerase chain reaction thermally cycling said amplification mixture between at least one denaturation temperature, at least one annealing temperature and at least one elongation temperature for a period of
5 time sufficient to amplify said target nucleic acid sequence.

30. The method according to claim 7, wherein said process fragments said at least one wild-type nucleic acid sequence in said biological pathogen.

10 31. The method according to claim 7, wherein said process cross-links said at least one wild-type nucleic acid sequence in said biological pathogen.

32. The method according to claim 7, wherein said process covalently modifies said at least one wild-type nucleic acid sequence in said biological pathogen.

15

33. The method according to claim 1, wherein said biological material is selected from the group consisting of: cells; tissues; blood or blood components; proteins; enzymes; immunoglobulins; botanicals; and food.

20 34. The method according to claim 1, wherein said biological material is selected from the group consisting of: ligaments; tendons; nerves; bone; teeth; skin grafts; bone marrow; heart valves; cartilage; corneas; arteries and veins; organs; lipids; carbohydrates;

collagen; chitin and its derivatives; forensic samples, mummified material; human or animal remains; stem cells; islet of Langerhans cells; cells for transplantation; red blood cells; white blood cells; and platelets.

CI0043PCTseqlisting.ST25
SEQUENCE LISTING

<110> Clearant, Inc.
McKenney, Keith
Gillmeister, Lidja
Marlowe, Kristina
Armistead, David

<120> Pathogen Inactivation Assay

<130> CI-0043

<150> 10/361,002

<151> 2003-02-10

<160> 99

<170> PatentIn version 3.2

<210> 1

<211> 5594

<212> DNA

<213> B19 virus

<400> 1
ccaaatcaga tgccgccggt cgccgccggt aggcgggact tccggtacaa gatggcggac 60
aattacgtca tttcctgtga cgtcatttcc tgtgacgtca cttccggtgg gcgggacttc 120
cggaattagg gttggctctg ggccagcttg cttgggggttg cttgacact aagacaagcg 180
gcgcgccgct tgtcttagtg gcacgtcaac cccaagcgct ggcccagagc caaccctaat 240
tccggaagtc ccgcccaccg gaagtgacgt cacaggaaat gacgtcacag gaaatgacgt 300
aattgtccgc catcttgtag cggaagtccc gcctaccggc ggcgaccggc ggcattctgat 360
ttggtgtctt cttttaaatt ttagcgggct tttttcccgc cttatgcaaa tgggcagcca 420
ttttaagtgt ttactataa ttttattggt cagttttgta acggttaaaa tgggcggagc 480
gtaggcgggg actacagtat atatagcacg gcactgccgc agctctttct ttctgggctg 540
ctttttcctg gactttcttg ctgttttttg tgagctaact aacagggtatt tatactactt 600
gttaacatac taacatggag ctatttagag ggggtgcttca agtttcttct aatgttctgg 660
actgtgctaa cgataactgg tgggtgctctt tactggattt agacacttct gactgggaac 720
cactaactca tactaacaga ctaatggcaa tatacttaag cagtgtggct tctaagcttg 780
actttaccgg ggggccacta gcgggggtgct tgtacttttt tcaagtagaa tgtaacaaat 840
ttgaagaagg ctatcatatt catgtgggta ttggggggcc aggggttaaac ccagaaacc 900
tcacagtgtg tgtagagggg ttatttaata atgtacttta tcaccttgta actgaaaatg 960
taaagctaaa atttttgccg ggaatgacta caaaaggcaa atactttaga gatggagagc 1020
agtttataga aaactattta atgaaaaaaa tacctttaaa tgttgtagtg tgtgttacta 1080
atattgatgg atatatagat acctgtattt ctgctacttt tagaagggga gcttgccatg 1140
ccaagaaacc ccgcattacc acagccataa atgacactag tagtgatgct ggggagtcta 1200
gcggcacagg ggcagagggt gtgccaatta atgggaaggg aactaaggct agcataaagt 1260
ttcaaactat ggtaaactgg ttgtgtgaaa acagagtgtt tacagaggat aagtggaaac 1320

CI0043PCTseqlisting.ST25

tagttgactt taaccagtac actttactaa gcagtagtca cagtgggaagt tttcaaattc	1380
aaagtgcact aaaactagca atttataaag caactaatTT agtgcctaca agcacatttc	1440
tattgcatac agactttgag caggttatgt gtattaaaga caataaaatt gttaaattgt	1500
tactttgtca aaactatgac cccctattag tggggcagca tgtgttaaag tggattgata	1560
aaaaatgtgg caagaaaaat aactgtggt tttatgggcc gccaaagtaca ggaaaaacaa	1620
acttggcaat ggccattgct aaaagtgttc cagtatatgg catggttaac tgggaataatg	1680
aaaactttcc atttaatgat gtagcagggg aaagcttggg ggtctgggat gaagggtatta	1740
ttaagtctac aattgtagaa gctgcaaaag ccattttagg cgggcaacc accagggtag	1800
atcaaaaaat gcgtggaagt gtagctgtgc ctggagtacc tgtggttata accagcaatg	1860
gtgacattac ttttgttgta agcgggaaca ctacaacaac tgtacatgct aaagccttaa	1920
aagagcgaat ggtaaagtta aactttactg taagatgcag ccctgacatg gggttactaa	1980
cagaggctga tgtacaacag tggcttacat ggtgtaatgc acaaagctgg gaccactatg	2040
aaaactgggc aataaactac acttttgatt tccctggaat taatgcagat gccctccacc	2100
cagacctcca aaccaccca attgtcacag acaccagtat cagcagcagt ggtggtgaaa	2160
gctctgaaga actcagtga agcagctttt ttaacctcat cccccaggc gcctggaaca	2220
ctgaaacccc gcgctctagt acgcccattc cggggaccag ttcaggagaa tcatttgtcg	2280
gaagctcagt ttcctccgaa gttgtagctg catcgtggga agaagccttc tacacacctt	2340
tggcagacca gtttcgtgaa ctgttagttg gggttgatta tgtgtgggac ggtgtaaggg	2400
gtttacctgt gtgttgtgtg caacatatta acaatagtgg gggaggcttg ggactttgtc	2460
cccattgcat taatgtaggg gcttgggtata atggatggaa atttcgagaa ttacccccag	2520
atttgggtcg gtgtagctgc catgtgggag cttctaattc cttttctgtg ctaacctgca	2580
aaaaatgtgc ttacctgtct ggattgcaaa gctttgtaga ttatgagtaa agaaagtggc	2640
aatgggtggg aaagtgatga taaatttgct aaagctgtgt atcagcaatt tgtggaattt	2700
tatgaaaagg ttactggaac agacttagag cttattcaaa tattaaaaga tcactataat	2760
atttcttttag ataatcccct agaaaaccca tcctctctgt ttgacttagt tgctcgattt	2820
aaaaataacc ttaaaaactc tccagactta tatagtcatt attttcaaag tcatggacag	2880
ttatctgacc acccccatgc cttatcatcc agtagcagtc atgcagaacc tagaggagaa	2940
aatgcagtat tatctagtga agacttacac aagcctgggc aagttagcgt acaactaccc	3000
ggtactaact atgttggggc tggcaatgag ctacaagctg ggcccccgca aagtgtgtt	3060
gacagtgtg caaggattca tgactttagg tatagccaac tggctaagtt ggaataaat	3120
ccatatactc attggactgt agcagatgaa gagcttttaa aaaatataaa aaatgaaact	3180
gggtttcaag cacaagtagt aaaagactac tttactttaa aaggtgcagc tgcccctgtg	3240
gccattttc aaggaagttt gccggaagtt cccgcttaca acgcctcaga aaaataccca	3300
agcatgactt cagttaattc tgcagaagcc agcactggtg caggaggggg tggcagtaat	3360

CI0043PCTseqlisting.ST25

cctgtcaaaa gcatgtggag tgagggggcc acttttagtg ccaactctgt aacttgtaga	3420
ttttccagac agtttttaat tccttatgac ccagagcacc attataaggt gttttctccc	3480
gcagcaagca gctgccacaa tgccagtga aaggaggcaa aggtttgcac aattagtccc	3540
ataatgggat actcaacccc atggagatat ttagatttta atgctttaaa tttatttttt	3600
tcaccttag agtttcagca cttaattgaa aattatggaa gtatagctcc tgatgcttta	3660
actgtaacca tatcagaaat tgctgttaag gatgttacag acaaaactgg agggggggta	3720
caggttactg acagcactac agggcgcccta tccatgttag tagaccatga atacaagtac	3780
ccatatgtgt taggacaagg tcaggatact ttagccccag aacttcctat ttgggtatac	3840
tttccccctc aatatgctta cttaacagta ggagatgtta acacacaagg aatctctgga	3900
gacagcaaaa aattagcaag tgaagaatca gcattttatg ttttggaaca cagttctttt	3960
cagcttttag gtacaggagg tacagcaact atgtcttata agtttcctcc agtgccccca	4020
gaaaatttag agggctgcag tcaacacttt tatgaaatgt acaatccctt atacggatcc	4080
cgcttagggg ttcctgacac attaggaggt gacccaaaat ttagatcttt aacacatgaa	4140
gaccatgcaa ttcagcccca aaacttcatg ccagggccac tagtaaacctc agtgtctaca	4200
aaggagggag acagctctaa tactggagct ggaaaagcct taacaggcct tagcacaggc	4260
acctctcaaa aactagaat atccttacgc cctgggccag tgtcacagcc ataccaccac	4320
tgggacacag ataaatatgt tccaggaata aatgccattt ctcatggtca gaccacttat	4380
ggtaacgctg aagacaaaga gtatcagcaa ggagtgggta gatttccaaa tgaaaaagaa	4440
cagctaaaac agttacaggg tttaaacatg cacacctatt tccccataa aggaaccag	4500
caatatacag atcaaattga gcgcccccta atggtgggtt ctgtatggaa cagaagagcc	4560
cttcactatg aaagccagct gtggagtaaa attccaaatt tagatgacag ttttaaaact	4620
cagtttgtag ccttaggagg atgggggttg catcagccac ctctcaaat atttttaaaa	4680
atattaccac aaagtgggcc aattggaggt attaaatcaa tgggaattac taccttagtt	4740
cagtatgccg tgggaattat gacagtaact atgacattta aattggggcc ccgtaaagct	4800
acgggacggg ggaatcctca acctggagta tatccccgc acgcagcagg tcatttacca	4860
tatgtactat atgacccac agctacagat gcaaaacaac accacaggca tggatacgaa	4920
aagcctgaag aattgtggac agccaaaagc cgtgtgcacc cattgtaaac actccccacc	4980
gtgccctcag ccaggatgag taactaaacg cccaccagta ccaccagac tgtacctgcc	5040
ccctcctgta cctataagac agcctaacac aaaagatata gacaatgtag aatttaagta	5100
cttaaccaga tatgaacaac atgttattag aatgttaaga ttgtgtaata tgtatcaaaa	5160
tttagaaaaa taaacatttg ttgtgggtta aaaattatgt tgttgcgctt taaaaattta	5220
aaagaagaca ccaaatacaga tgccgccggg cgccgccggg aggcgggact tccggtacaa	5280
gatggcggac aattacgtca tttcctgtga cgtcatttcc tgtgacgtca cttccgggtg	5340
gcgggacttc cggaattagg gttggctctg ggccagcgct tgggggttgac gtgccactaa	5400

CI0043PCTseqlisting.ST25

gacaagcggc gcgccgcttg tcttagtgtc aaggcaaccc caagcaagct ggcccagagc 5460
 caaccctaatt tccggaagtc cgcgccaccg gaagtgcgacg cacaggaaat gacgtcacag 5520
 gaaatgacgt aattgtccgc catcttgtag cggaagtccc gcctaccggc ggcgaccggc 5580
 ggcatctgat ttgg 5594

<210> 2
 <211> 3221
 <212> DNA
 <213> Hepatitis B virus

<400> 2
 ttccactgcc ttccaccaag ctctgcaaga cccagagtc aggggtctgt attttcctgc 60
 tgggtggctcc agttcaggaa cagtaaacc tgctccgaat attgcctctc acatctcgtc 120
 aatctccgcg aggaccgggg accctgtgac gaacatggag aacatcacat caggattcct 180
 aggacccttg cccgtgttac aggcgggggt tttcttggtg acaagaatcc tcacaatacc 240
 gcagagtcta gactcgtggt ggacttctct caattttcta gggggatcac ccgtgtgtct 300
 tggccaaaat tcgcatccc caacctcaa tcaatcacca acctcctgtc ctccaatttg 360
 tcctgggttat cgctggatgt gtctgcggcg ttttatcata ttctcttca tcctgtgtct 420
 atgcctcatc ttcttatttg ttcttctgga ttatcaagg atgttgccc tttgtcctct 480
 aattctagga tcaacaacaa ccagtacggg accatgcaaa acctgcacga ctctgtctca 540
 aggcaactct atgtttccct catgttgctg tacaaaacct acggatggaa attgcacctg 600
 tattcccatc ccatcgtctt gggctttcgc aaaataccta tgggagtggt cctcagtcg 660
 tttctcttgg ctcatgttac tagtgccatt tggtcagtg ttcgtagggc tttccccac 720
 tgtttggtt tcagctatat ggatgatgtg gtattggggg ccaagtctgt acagcatcgt 780
 gagttccttt ataccgctgt taccaatttt cttttgtctc tgggtataca tttaaacct 840
 aaaaaacaa aaagatgggg ttattcccta aacttcattg gttatgtaat tggagttgg 900
 ggaacattgc cacaggatca tattgtacaa aaaatcaaac actgttttag aaaacttcct 960
 gttacaggc ctattgattg gaaagtatgt caaagaattg tgggtctttt gggctttgct 1020
 gctcctttta cacaatgtgg atatcctgcc ttaatgccct tgtagcatg tatacaagct 1080
 aaacaggctt tcaactttct gccaaactac aaggcctttc taagtaaaca gtacatgaac 1140
 ctttaccctg ttgctcggca acggcctggt ctgtgccaag tatttgctga tgcaaccccc 1200
 actggctggg gcttgcccat aggccatcag cgcatgcgcg gaacctttgt ggctcctctg 1260
 ccgatccata ctgcggaact ctagccgct tgttttgtc gcagccggtc tggagcgaac 1320
 ctcatcgga ctgacaattc tgcgtcctc tcgcggaaat atacctcgtt tccatggcta 1380
 ctaggctgtg ctgccaactg gatccttcgc gggacgtcct ttgtttacgt cccgtcggcg 1440
 ctgaatccc cgagcagacc ctctcggggc cgcttgggac tctctcgtcc ccttctccgt 1500
 ctgccgttcc agccgaccac ggggcgcacc tctctttacg cggctctccc gtctgtgcct 1560

CI0043PCTseqlisting.ST25

tctcatctgc cgggtccgtgt gcacttcgct tcacctctgc acgttgcagtg gagaccaccg 1620
 tgaacgcccc tcagatcctg cccaaggtct tacataagag gactccttga ctcccagcaa 1680
 tgtcaacgac cgaccttgag gcctacttca aagactgtgt gtttaaggac tgggaggagc 1740
 tgggggagga gattaggtta aaggtctttg tattaggagg ctgtaggcat aaattggtct 1800
 gcgcaccagc accatgcaac tttttcacct ctgcctaatac atctccttga catgtccac 1860
 tgttcaagcc tccaagctgt gccttgggtg gctttggggc atggacattg acccttataa 1920
 agaatttga gctactgtgg agttactctc gtttttgcct tctgacttct ttccttcctg 1980
 cagagatctc ctagacaccg cctcggctct gtatcgggaa gccttagagt ctcttgagca 2040
 ttgtcacct caccataccg cactcaggca agccattctc tgctgggggg aattgatgac 2100
 tctagctacc tgggtgggta ataatttga agatccagca tccagggatc tagtagtcaa 2160
 ttatgttaat actaacatgg gattaaagat caggcaactc ttgtggtttc atatctcttg 2220
 ccttactttt ggaagagaaa ctgtacttga atatttggct tctttcggag tgtggattcg 2280
 cactcctcca gcctatagac caccaaagc ccctatctta tcaacacttc cggaaactac 2340
 tgttgttaga cgacgggacc gaggcaggtc ccctagaaga agaactccct cgcctcgcag 2400
 acgcagatct caatcgccgc gtcgcagaag atctcaatct cgggaatctc aatgttagta 2460
 ttccttgga tcataagggtg ggaaacttca ctgggcttta ttcctctaca gcacctatct 2520
 ttaatcctga atggcaaact ctttccttcc ctaaaattca tttacaagag gacattatta 2580
 atagggtgtca acaatttgtg ggccctctca ctgtaaatga aaagagaaga ttgaaattaa 2640
 ttatgcctgc tagattctat cctaccaca ctaaatat t gcccttagac aaaggaatta 2700
 aaccttatta tccagatcag gtagttaatc attacttcca aaccagacat tatttacata 2760
 ctctttgga ggcggtatt ctatataaga gagaaccac acgtagcgca tcattttgcg 2820
 ggtcaccata ttcttgggaa caagagctac agcatgggag gttggtcatc aaaacctcgc 2880
 aaaggcatgg ggacgaatct ttctgttccc aaccctctgg gattctttcc cgatcatcag 2940
 ttggaccctg tattcggagc caactcaaac aatccagatt gggacttcaa ccccatcaag 3000
 gaccactggc cagcagccaa ccaggtagga gtgggagcat tcgggccagg gttcaccct 3060
 ccacacggcg gtgttttggg gtggagccct caggctcagg gcatgttgac cccagtgtca 3120
 acaattcctc ctctgcctc cgccaatcgg cagtcaggaa ggcagcctac tcccatctct 3180
 ccacctctaa gagacagtca tcctcaggcc atgcagtga a 3221

<210> 3
 <211> 5075
 <212> DNA
 <213> Porcine parvovirus

<400> 3
 aatctttaaa ctgaccaact gtctttgcgt atggtgacgt gatgacgcgc gctacgcgcg 60
 ctgccttcgg cagtcacacg tcaccatcag caaagacagt tggtcagttt aaagattaat 120
 aagacattcc attggctgaa aagaggcggg aaattcaaaa aaagaggcgg gaaaaaaga 180

CI0043PCTseqlisting.ST25

ggtggagcct aacactataa atacagttgc ttacttcagt tagttccttt ctgcttcaga	240
ctgcacttcg ctccagagac acagctacaa actactctca gctactgcag catggcagcg	300
ggaaacactt actcgggaaga ggtactaaaa gctaccaact ggcttcaaga taatgctcaa	360
aaagaagcat tctcttatgt atttaaaaca caaaaagtca atctaaatgg aaaagaaatt	420
gcttgggaata actacaacaa agatacaaca gatgcggaaa tgataaacct acaaagagga	480
gcagaaacat catgggacca ggcaacagac atggaatggg aatcagaaat cgacagcctc	540
acaaaacggc aagtactgat ttttgactct cttgttaaaa aatgtctctt tgaagggtata	600
ttgcaaaaga acctaagtcc aagtgactgc tactgggttca tacagcatga acatgggtcaa	660
gatactggct atcactgccca tgtactacta ggtggaaaag gcttacaaca agcaatggga	720
aaatgggttca gaaaacaatt aaacaattta tggagtagat ggtaataat gcaatgcaaa	780
gtacctctaa caccagttga aagaataaaa ttaaggggaat tagcagagga tgggtgagtgg	840
gtatcgctac taacctacac tcacaaacaa actaaaaaac aatatacaaa aatgactcat	900
tttggaataa tgattgctta ctacttccta aataaaaaaa gaaagacaac tgaaagagag	960
catggatatt atctcagctc agattctggc ttcattgacaa atttcttaaa agaaggcgag	1020
agacacttag tcagtcacct atttactgaa gcaaataaac ctgaaactgt ggaaacaacg	1080
gttactacag ctcaggaagc caaaagaggc agaatacaaa caaaaaaga agtaagcata	1140
aatgcacaa taagagactt ggtaataaaa agatgtacta gcatagaaga ctggatgatg	1200
acagatccag acagttatat agaatgatg gctcaaaccg gaggagaaaa tttaatcaaa	1260
aatacactag aaataacaac tcttactcta gcaagaacaa aaacagcata tgacttaata	1320
cttgaaaagg caaaaccaag catgctacca acatttaata ttagcaatac aagaacatgt	1380
aaaatattca gcatgcacaa ttggaactac attaaagtct gccatgctat aacttggtga	1440
ctaaacagac aaggaggaaa aagaaataca attctatttc atgggccagc atcaacagga	1500
aaaagtataa ttgctcaaca cattgcaaac ttagttggta atgttggttg ctacaatgca	1560
gccaatgtga actttccatt taatgactgt acaaataaaa acttaatatg gattgaagaa	1620
gcaggaaaact tctctaacca agtaaaccac ttcaaagcca tatgttcagg tcaacaatt	1680
agaattgacc aaaaaggtaa aggaagcaaa caaattgaac caactcctgt aataatgact	1740
acaaatgaag acataactaa agttagaata ggatgcgagg aaagaccaga acatacacia	1800
ccaataagag acagaatgtt aaacataaac ctaaccagaa aactgccagg tgattttgga	1860
cttttagaag aaactgaatg gccactaata tgtgcttggt tggtaaagaa aggttaccac	1920
gcaacaatgg ctacttatat gcatcattgg ggaaatgtac ctgattggtc agaaaaatgg	1980
gaggagccaa aatgcaaac cccaataaat acaccaacag actctcagat ttccacatca	2040
gtgaaaactt cgccagcgga caacaactac gcagcaactc caatacagga ggacctggat	2100
ttagcttttag ccttgagagc gtggagcgag ccaacaacac caactttcac caacctgcac	2160
ttaactccaa caccgccaga ttcagcaata cggacaccaa gtccaacttg gtcggaaata	2220

CI0043PCTseqlisting.ST25

gaaaccgaca taagagcctg ctttggtgaa aactgtgcac ccacaacaaa ctttgaataa 2280
 ggtaggatgg cgcctcctgc aaaaagagca agaggtaagg gtagttttaa gggggtggtg 2340
 ggcatacata taaaactaac tgcaataat tttttatat attacaggac taactctacc 2400
 aggatacaaa taccttggtc caggaaactc actagaccaa ggagaaccaa ctaatccatc 2460
 agacgccgca gcaaaagaac acgacgaagc ctacgacaaa tacataaaat ctggaaaaaa 2520
 tccatacttc tacttctcag cagctgatga aaaattcata aaagaaactg aacacgcaaa 2580
 agactacgga ggtaaaattg gacattactt cttcagagca aagcgtgcct ttgctccaaa 2640
 actctcagaa acagactcac caactacatc tcaacaacca gaggtaagaa gatcgccgag 2700
 aaaacaccca gggcttaaac caccaggaaa aagacctgct ccaagacata tttttataaa 2760
 cttagctaaa aaaaaagcta aaggacatc taatacaaac tctaactcaa tgagtgaaaa 2820
 tgtggaacaa cacaacccta ttaatgcagg cactgaattg tctgcaacag gaaatgaatc 2880
 tgggggtggg ggcggcgggtg gcgggggtag ggggtgctggg ggggttggtg tgtctacagg 2940
 tactttcaat aatcaaacag aatttcaata cttgggggag ggcttggtta gaatcactgc 3000
 acacgcatca agactcatac atctaaatat gccagaacac gaaacataca aaagaatata 3060
 tgtactaaat tcagaatcag ggggtggcggg acaaatggta caagacgatg cacacacaca 3120
 aatggtaaca ctttggtcac taatagatgc taacgcatgg ggagtgtggt tcaatccagc 3180
 ggactggcag ttaatatcca acaacatgac agaaataaac ttagttagtt ttgaacaaga 3240
 aatattcaat gtagtactta aaacaattac agaatcagca acctcaccac caacaaaat 3300
 atataataat gatctaactg caagcttaat ggtcgcacta gacaccaata acacacttcc 3360
 atacacacca gcagcaccta gaagtgaac acttggtttt tatccatggt tacctacaaa 3420
 accaactcaa tacagatatt acctatcatg catcagaaac ctaaattcac caacatacac 3480
 tggacaatca caacaaataa cagactcaat acaaacagga ctacacagtg acattatggt 3540
 ctacacaata gaaaatgcag taccaattca tcttctaaga acaggagatg aattctccac 3600
 aggaatatat cactttgaca caaaaccact aaaattaact cactcatggc aaacaacag 3660
 atctctagga ctgcctccaa aactactaac tgaacctacc acagaaggag accaacaccc 3720
 aggaacacta ccagcagcta acacaagaaa aggttatcac caacaatta ataatagcta 3780
 cacagaagca acagcaatta ggccagctca ggtaggatat aatacaccat acatgaattt 3840
 tgaatactcc aatggtggac catttctaac tcctatagta ccaacagcag acacacaata 3900
 taatgatgat gaaccaaatg gtgctataag atttacaatg gattaccaac atggacactt 3960
 aaccacatct tcacaagagc tagaaagata cacattcaat ccacaaagta aatgtggaag 4020
 agctccaaag caacaattta atcaacaggc accactaaac ctagaaaata caaataatgg 4080
 aacactttta ctttcagatc caataggagg gaaatctaac atgcatttca tgaatacact 4140
 caatacatat ggaccattaa cagcactaaa caatactgca cctgtatttc caaatggtca 4200
 aatatgggat aaagaacttg atacagatct aaaacctaga ctacatgtta cagctccatt 4260

CI0043PCTseqlisting.ST25

tgtttgtaaa aacaatccac caggacaact atttgtaaaa atagcaccaa acctaacaga	4320
tgatttcaat gctgactctc ctcaacaacc tagaataata acttattcaa acttttggtg	4380
gaaaggaaca ctaacattca cagcaaaaat gagatccagt aatatgtgga accctattca	4440
acaacacaca acaacagcag aaaacattgg taactatatt cctacaaata ttggtggcat	4500
aagaatgttt ccagaatatt cacaacttat accaagaaaa ttatactaga aataactctg	4560
taaataaaaa ctgagttact tggttaatca tgtactacta tcattgtata cttcaataaa	4620
aataaattgt aaaatcaata aaactaagtt acttagtttc tgtataccta tactagaaat	4680
aactctgtaa ataaaaactc agttacttgg ttaatcatgt actactatca ttgtatactt	4740
caataaaaat aaattgtaaa atcaataaaa ctaagttact tagtttctgt ataccaatta	4800
tccccaaaaa acaataaaat tttaaaaga aacaagctct catgtgttta ctattaacta	4860
aaccaaccac acttatatga ccttatgtct ttaggggtggg tgggtgggaa ttactatgta	4920
ttcctttgag ttagttggtc gcctttgggc gactaaccaa gcggctctgc cgcttggtta	4980
gtcgcacggc gaccaactaa ctcaaaggaa tacatagtaa tccccacca cccaccctaa	5040
agacataagg tcatataagt gtggttggtt tagtt	5075

<210> 4
 <211> 11703
 <212> DNA
 <213> Sindbis virus

<400> 4	
attgacggcg tagtacacac tattgaatca aacagccgac caattgcact accatcacaa	60
tggagaagcc agtagtaaac gtagacgtag acccccagag tccgtttgtc gtgcaactgc	120
aaaaagctt cccgcaattt gaggtagtag cacagcaggt cactccaaat gaccatgcta	180
atgccagagc attttcgcat ctggccagta aactaatcga gctggagggt cctaccacag	240
cgacgatctt ggacataggc agcgcaccgg ctctgtagaat gttttccgag caccagtatc	300
attgtgtctg ccccatgctg agtccagaag acccggaccg catgatgaaa tacgccagta	360
aactggcggg aaaagcgtgc aagattacaa acaagaactt gcatgagaag attaaggatc	420
tccggaccgt acttgatacg ccggatgctg aaacaccatc gctctgcttt cacaacgatg	480
ttacctgcaa catgcgtgcc gaatattccg tcatgcagga cgtgtatatc aacgctcccg	540
gaactatcta tcatcaggct atgaaaggcg tgcggaccct gtactggatt ggcttcgaca	600
ccaccagtt catgttctcg gctatggcag gttcgtaccc tgcgtacaac accaactggg	660
ccgacgagaa agtccttgaa gcgcgtaaca tcggactttg cagcacaaag ctgagtgaag	720
gtaggacagg aaaattgtcg ataattgagga agaaggagtt gaagcccggg tcgcggtttt	780
atttctccgt aggatcgaca ctttatccag aacacagagc cagcttgacg agctggcatc	840
ttccatcggg gttccacttg aatggaaagc agtcgtacac ttgccgctgt gatacagtgg	900
tgagttgcga aggctacgta gtgaagaaaa tcaccatcag tcccgggatc acgggagaaa	960

CI0043PCTseqlisting.ST25

ccgtgggata	cgcggttaca	cacaatagcg	agggcttctt	gctatgcaaa	gttactgaca	1020
cagtaaaagg	agaacgggta	tcgttccttg	tgtgcacgta	catcccggcc	accatatgcg	1080
atcagatgac	tgggtataatg	gccacggata	tatcacctga	cgatgcacaa	aaacttcttg	1140
ttgggctcaa	ccagcgaatt	gtcattaacg	gtaggactaa	caggaacacc	aacaccatgc	1200
aaaattacct	tctgccgatc	atagcacaa	gggttcagcaa	atgggctaag	gagcgcaagg	1260
atgatcttga	taacgagaaa	atgctgggta	ctagagaacg	caagcttacg	tatggctgct	1320
tgtgggcggt	tcgcactaag	aaagtacatt	cgttttatcg	cccacctgga	acgcagacct	1380
gcgtaaaagt	cccagcctct	tttagcgctt	ttcccatgtc	gtccgtatgg	acgacctctt	1440
tgcccatgtc	gctgaggcag	aaattgaaac	tggcattgca	accaaagaag	gaggaaaaac	1500
tgctgcaggt	ctcggaggaa	ttagtcatgg	aggccaaggc	tgcttttgag	gatgctcagg	1560
aggaagccag	agcggagaag	ctccgagaag	cacttccacc	attagtggca	gacaaaggca	1620
tcgaggcagc	cgcagaagtt	gtctgcgaag	tggaggggct	ccaggcggac	atcggagcag	1680
cattagttga	aacccgcgc	ggtcacgtaa	ggataatacc	tcaagcaa	gaccgtatga	1740
tcggacagta	tatcgtttgc	tcgccaaact	ctgtgctgaa	gaatgccaaa	ctcgaccag	1800
cgcacccgct	agcagatcag	gttaagatca	taacacactc	cggaagatca	ggaaggtagc	1860
cggtcgaacc	atacgacgct	aaagtactga	tgccagcagg	aggtgccgta	ccatggccag	1920
aattcctagc	actgagttag	agcgccacgt	tagtgtacaa	cgaaagagag	tttgtgaacc	1980
gcaaactata	ccacattgcc	atgcatggcc	ccgccaagaa	tacagaagag	gagcagtaca	2040
aggttacaaa	ggcagagctt	gcagaaacag	agtacgtggt	tgacgtggac	aagaagcggt	2100
gcgttaagaa	ggaagaagcc	tcaggtctgg	tcctctcggg	agaactgacc	aaccctccct	2160
atcatgagct	agctctggag	ggactgaaga	cccgacctgc	ggtcccgtac	aaggctgaaa	2220
caataggagt	gataggcaca	ccggggctcg	gcaagtcagc	tattatcaag	tcaactgtca	2280
cggcacgaga	tcttgttacc	agcggaaaga	aagaaaattg	tcgcgaaatt	gaggccgacg	2340
tgctaagact	gaggggtatg	cagattacgt	cgaagacagt	agattcgggt	atgctcaacg	2400
gatgccacaa	agccgtagaa	gtgctgtacg	ttgacgaagc	gttcgctgac	cacgcaggag	2460
cactacttgc	cttgattgct	atcgtcaggc	cccgaagaa	ggtagtacta	tgcggagacc	2520
ccatgcaatg	cggattcttc	aacatgatgc	aactaaaggt	acatttcaat	caccctgaaa	2580
aagacatatg	caccaagaca	ttctacaagt	atatctcccg	gcgttgca	cagccagtta	2640
cagctattgt	atcgacactg	cattacgatg	gaaagatgaa	aaccacgaac	ccgtgcaaga	2700
agaacattga	aatcgatatt	acaggggcca	caaagccgaa	gccaggggat	atcatcctga	2760
catgtttccg	cgggtgggtt	aagcaattgc	aaatcgacta	tcccggacat	gaagtaatga	2820
cagccgcggc	ctcacaaggg	ctaaccagaa	aaggagtgtg	tgccgtccgg	caaaaagtca	2880
atgaaaacc	actgtacg	atcacatcag	agcatgtgaa	cggtgtgctc	acccgactg	2940
aggacaggct	agtgtggaaa	accttgagg	gcgacccatg	gattaagcag	cccactaaca	3000

CI0043PCTseqlisting.ST25

tacctaaagg aaactttcag gctactatag aggactggga agctgaacac aagggaataa	3060
ttgctgcaat aaacagcccc actccccgtg ccaatccgtt cagctgcaag accaacgttt	3120
gctgggcgaa agcattggaa ccgatactag ccacggccgg tatcgtactt accggttgcc	3180
agtggagcga actgttccca cagtttgccg atgacaaacc acattcggcc atttacgcct	3240
tagacgtaat ttgcattaag tttttcggca tggacttgac aagcggactg ttttctaaac	3300
agagcatccc actaacgtac catcccgcg attcagcgag gccggtagct cattgggaca	3360
acagcccagg aaccgcgaag tatgggtacg atcacgccat tgccgccgaa ctctcccgt	3420
gatttccggt gttccagcta gctgggaagg gcacacaact tgatttgag acggggagaa	3480
ccagagttat ctctgcacag cataacctgg tcccggtgaa ccgcaatctt cctcacgcct	3540
tagtccccga gtacaaggag aagcaaccg gcccggtcaa aaaattcttg aaccagttca	3600
aacaccactc agtacttggt gtatcagagg aaaaaattga agctccccgt aagagaatcg	3660
aatggatcgc cccgattggc atagccggtg cagataagaa ctacaacctg gctttcgggt	3720
ttccgccgca ggcacggtac gacctggtgt tcatcaacat tggaaactaaa tacagaaacc	3780
accactttca gcagtgcgaa gaccatgcg cgaccttaaa aaccctttcg cgttcgcccc	3840
tgaattgcct taaccagga ggcaccctcg tgggtgaagtc ctatggctac gccgaccgca	3900
acagtgagga cgtagtcacc gctcttgcca gaaagtttgt cagggtgtct gcagcgagac	3960
cagattgtgt ctcaagcaat acagaaatgt acctgatttt ccgacaacta gacaacagcc	4020
gtacacggca attcaccctg caccatctga attgcgtgat ttcgtccgtg tatgagggta	4080
caagagatgg agttggagcc gcgccgtcat accgcaccaa aagggagaat attgctgact	4140
gtcaagagga agcagttgtc aacgcagcca atccgctggg tagaccaggc gaaggagtct	4200
gccgtgccat ctataaacgt tggccgacca gttttaccga ttcagccacg gagacaggca	4260
ccgcaagaat gactgtgtgc ctaggaaaga aagtgatcca cgcggtcggc cctgatttcc	4320
ggaagcacc agaagcagaa gccttgaaat tgctacaaa cgcctaccat gcagtggcag	4380
acttagtaaa tgaacataac atcaagtctg tcgccattcc actgctatct acaggcattt	4440
acgcagccgg aaaagaccgc cttgaagtat cacttaactg cttgacaacc gcgctagaca	4500
gaactgacgc ggacgtaacc atctattgcc tggataagaa gtggaaggaa agaatcgacg	4560
cggcactcca acttaaggag tctgtaacag agctgaagga tgaagatatg gagatcgacg	4620
atgagttagt atggatccat ccagacagtt gcttgaaggg aagaaaggga ttcagtacta	4680
caaaaggaaa attgtattcg tacttcgaag gcaccaaatt ccatcaagca gcaaaagaca	4740
tggcggagat aaaggtcctg ttccctaatt accaggaaag taatgaacaa ctgtgtgcct	4800
acatattggg tgagaccatg gaagcaatcc gcgaaaagt cccggtcgac cataaccctg	4860
cgtctagccc gcccaaacg ttgccgtgcc tttgcatgta tgccatgacg ccagaaaggg	4920
tccacagact tagaagcaat aacgtcaaag aagttacagt atgctcctcc accccccttc	4980
ctaagcacia aattaagaat gttcagaagg ttcagtgcac gaaagtagtc ctgtttaatc	5040

CI0043PCTseqlisting.ST25

cgcacactcc	cgcatctggt	cccgcccgtg	agtagataga	agtgccagaa	cagcctaccg	5100
ctcctcctgc	acaggccgag	gaggccccc	aagttgtagc	gacaccgtca	ccatctacag	5160
ctgataaacac	ctcgcttgat	gtcacagaca	tctcactgga	tatggatgac	agtagcgaag	5220
gctcactttt	ttcgagcttt	agcggatcgg	acaactctat	tactagtatg	gacagttggt	5280
cgtcaggacc	tagttcacta	gagatagtag	accgaaggca	ggtggtggtg	gctgacgttc	5340
atgccgtcca	agagcctgcc	cctattccac	cgccaaggct	aaagaagatg	gcccgcctgg	5400
cagcggcaag	aaaagagccc	actccaccgg	caagcaatag	ctctgagtcc	ctccacctct	5460
cttttggtgg	ggtatccatg	tccctcggat	caattttcga	cggagagacg	gcccgccagg	5520
cagcgggtaca	acccctggca	acaggcccca	cggatgtgcc	tatgtctttc	ggatcgtttt	5580
ccgacggaga	gattgatgag	ctgagccgca	gagtaactga	gtccgaaccc	gtcctgtttg	5640
gatcatttga	accgggcgaa	gtgaactcaa	ttatatcgtc	ccgatcagcc	gtatcttttc	5700
cactacgcaa	gcagagacgt	agacgcagga	gcaggaggac	tgaatactga	ctaaccgggg	5760
taggtgggta	catattttcg	acggacacag	gccctgggca	cttgcaaaag	aagtcggttc	5820
tgcagaacca	gcttacagaa	ccgaccttgg	agcgcaatgt	cctggaaaga	attcatgccc	5880
cgggtgctga	cacgtcgaaa	gaggaacaac	tcaaactcag	gtaccagatg	atgcccaccg	5940
aagccaacaa	aagtaggtac	cagtctcgta	aagtagaaaa	tcagaaagcc	ataaccactg	6000
agcgactact	gtcaggacta	cgactgtata	actctgccac	agatcagcca	gaatgctata	6060
agatcaccta	tccgaaacca	ttgtactcca	gtagcgtacc	ggcgaactac	tccgatccac	6120
agttcgctgt	agctgtctgt	aacaactatc	tgcatgagaa	ctatccgaca	gtagcatctt	6180
atcagattac	tgacgagtac	gatgcttact	tggatatggt	agacgggaca	gtcgcctgcc	6240
tggatactgc	aaccttctgc	cccgctaagc	ttagaagtta	cccgaaaaaa	catgagtata	6300
gagccccgaa	tatccgcagt	gcggttccat	cagcgatgca	gaacacgcta	caaaatgtgc	6360
tcattgccgc	aactaaaaga	aattgcaacg	tcacgcagat	gcgtgaactg	ccaacactgg	6420
actcagcgac	attcaatgtc	gaatgctttc	gaaaatatgc	atgtaatgac	gagtattggg	6480
aggagttcgc	tcggaagcca	attaggatta	ccactgagtt	tgtaaccgca	tatgtagcta	6540
gactgaaagg	ccctaaggcc	gccgcactat	ttgcaaagac	gtataatttg	gtcccattgc	6600
aagaagtgcc	tatggataga	ttcgtcatgg	acatgaaaag	agacgtgaaa	gttacaccag	6660
gcacgaaaca	cacagaagaa	agaccgaaag	tacaagtgat	acaagccgca	gaacccttgg	6720
cgactgctta	cttatgcggg	attcaccggg	aattagtgcg	taggcttacg	gccgtcttgc	6780
ttccaaacat	tcacacgctt	tttgacatgt	cggcggagga	ttttgatgca	atcatagcag	6840
aacacttcaa	gcaaggcgac	ccggtactgg	agacggatat	cgcatcattc	gacaaaagcc	6900
aagacgacgc	tatggcggtta	accggtctga	tgatcttggg	ggacctgggt	gtggatcaac	6960
cactactcga	cttgatcgag	tgcgcctttg	gagaaatatc	atccacccat	ctacctacgg	7020
gtactcgttt	taaattcggg	gcgatgatga	aatccggaat	gttcctcaca	ctttttgtca	7080

CI0043PCTseqlisting.ST25

acacagtttt gaatgtcgtt atcgccagca gagtactaga agagcggctt aaaacgtcca	7140
gatgtgcagc gttcattggc gacgacaaca tcatacatgg agtagtatct gacaaagaaa	7200
tggctgagag gtgcgccacc tggctcaaca tggaggttaa gatcatcgac gcagtcacg	7260
gtgagagacc accttacttc tgcggcggat ttatcttgca agattcgggtt acttccacag	7320
cgtgccgcgt ggcggatccc ctgaaaaggc tgtttaagtt gggtaaaccg ctcccagccg	7380
acgacgagca agacgaagac agaagacgcg ctctgctaga tgaacaaaag gcgtgggtta	7440
gagtaggtat aacaggcact ttagcagtgg ccgtgacgac ccggtatgag gtagacaata	7500
ttacacctgt cctactggca ttgagaactt ttgcccagag caaaagagca ttccaagcca	7560
tcagagggga aataaagcat ctctacgggtg gtcctaaata gtcagcatag tacatttcac	7620
ctgactaata ctacaacacc accaccatga atagaggatt ctttaacatg ctcggccgcc	7680
gccccctccc ggcgccact gccatgtgga ggccgcggag aaggaggcag gcggcccgga	7740
tgcttcccc caacgggctg gcttctcaa tccagcaact gaccacagcc gtcagtgtccc	7800
tagtcattgg acaggcaact agacctcaac ccccacgtcc acgcccgcga ccgcgccaga	7860
agaagcaggc gcccaagcaa ccaccgaagc cgaagaaacc aaaaacgcag gagaagaaga	7920
agaagcaacc tgcaaaacc aaaccggaa agagacagcg catggcactt aagttggagg	7980
ccgacagatt gttcgacgtc aagaacgagg acggagatgt catcgggcac gcactggcca	8040
tggaaggaaa ggtaatgaaa cctctgcacg tgaaaggaac catcgaccac cctgtgctat	8100
caaagctcaa atttaccag tcgtcagcat acgacatgga gttcgcacag ttgccagtca	8160
acatgagaag tgaggcattc acctacacca gtgaacaccc cgaaggattc tataactggc	8220
accacggagc ggtgcagtat agtggaggta gatttaccat ccctcgcgga gtaggaggca	8280
gaggagacag cggtcgtccg atcatggata actccggtcg ggttgctcgc atagtcctcg	8340
gtggcgctga tgaaggaaca cgaactgcc tttcggctgt cacctggaat agtaaagga	8400
agacaattaa gacgaccccg gaaggacag aagagtggtc cgagcacca ctggtcacgg	8460
caatgtgttt gctcggaaat gtgagcttcc catgacgacg cccgcccaca tgctataccc	8520
gcgaaccttc cagagccctc gacatcctt aagagaacgt gaacctagag gcctacgata	8580
ccctgtcaa tgccatattg cgggtcggat cgtctggcag aagcaaaaga agcgtcattg	8640
acgactttac cctgaccagc ccctacttgg gcacatgctc gtactgccac catactgtac	8700
cgtgcttcag ccctgttaag atcgagcagg tctgggacga agcggacgat aacaccatac	8760
gcatacagac ttccgcccag tttggatacg accaaagcgg agcagcaagc gcaaacaagt	8820
accgctacat gtcgcttaag caggatcaca ccgttaaaga aggcaccatg gatgacatca	8880
agattagcac ctgaggaccg tgtagaaggc ttagctaaa aggatacttt ctctcgcaa	8940
aatgccctcc aggggacagc gtaacggtta gcatagttag tagcaactca gcaacgtcat	9000
gtacactggc ccgcaagata aaacaaaaat tcgtgggacg ggaaaaatat gatctacctc	9060
ccgttcacgg taaaaaatt cttgcacag tgtacgaccg tctgaaagaa acaactgcag	9120

CI0043PCTseqlisting.ST25

gctacatcac tatgcacagg ccgagaccgc acgcttatac atcctacctg gaagaatcat	9180
cagggaaagt ttacgcaaag ccgccatctg ggaagaacat tacgtatgag tgcaagtgcg	9240
gcgactacaa gaccggaacc gtttcgaccc gcaccgaaat cactggttgc accgccatca	9300
agcagtgcgt cgcctataag agcgacaaa cgaagtgggt cttcaactca ccggacttga	9360
tcagacatga cgaccacacg gcccaggga aattgcattt gcctttcaag ttgatcccga	9420
gtacctgcat ggtccctgtt gcccacgcgc cgaatgtaat acatggcttt aaacacatca	9480
gcctccaatt agatacagac cacttgacat tgctcaccac caggagacta ggggcaaacc	9540
cggaaaccaac cactgaatgg atcgtcggaa agacggtcag aaacttcacc gtcgaccgag	9600
atggcctgga atacatatgg ggaaatcatg agccagttag ggtctatgcc caagagtcag	9660
caccaggaga ccctcacgga tggccacacg aaatagtaca gcattactac catcgccatc	9720
ctgtgtacac catcttagcc gtcgcatcag ctaccgtggc gatgatgatt ggcgtaactg	9780
ttgcagtgtt atgtgcctgt aaagcgcgcc gtgagtgcct gacgccatac gccctggccc	9840
caaacgccgt aatcccaact tcgctggcac tcttgtgctg cgttaggctg gccaatgctg	9900
aaacgttcac cgagaccatg agttacttgt ggtcgaacag tcagccgttc ttctgggtcc	9960
agttgtgcat acctttggcc gctttcatcg ttctaatacg ctgctgtctc tgctgcctgc	10020
cttttttagt ggttgccggc gcctacctgg cgaaggtaga cgctacgaa catgcgacca	10080
ctgttccaaa tgtgccacag ataccgtata aggcacttgt tgaaagggca gggtatgccc	10140
cgctcaattt ggagatcact gtcattgtcct cggaggtttt gccttcacc aaccaagagt	10200
acattacctg caaattcacc actgtggtcc cctcccaaaa aatcaaagtc tgcggtcctt	10260
tggaaatgtca gccggccgct catgcagact atacctgcaa ggtcttcgga ggggtctacc	10320
cctttatgtg gggaggagcg caatgttttt gcgacagtga gaacagccag atgagtgagg	10380
cgtacgtcga attgtcagca gattgcgcgt ctgaccacgc gcaggcgatt aagggtgcaca	10440
ctgccgcgat gaaagtagga ctgctgattg tgtacgggaa cactaccagt ttcctagatg	10500
tgtacgtgaa cggagtcaca ccaggaaact ctaaagactt gaaagtcata gctggaccaa	10560
tttcagcatc gtttacgcca ttcgatcata aggtcgttat ccatcgcgcc ctggtgtaca	10620
actatgactt cccggaatat ggagcgatga aaccaggagc gtttgagac attcaagcta	10680
cctccttgac tagcaaggat ctcatcgcca gcacagacat taggctactc aagccttccg	10740
ccaagaactg gcatgtcccg tacacgcagg cctcatcagg atttgagatg tggaaaaaca	10800
actcaggccg cccactgcag gaaaccgcac ctttcgggtg taagattgca gtaaattccgc	10860
tccgagcggg ggactgttca tacgggaaca ttccatttc tattgacatc ccgaacgctg	10920
cctttatcag gacatcagat gcaccactgg tctcaacagt caaatgtgaa gtcagttagt	10980
gcacttattc agcagacttc ggcgggatgg ccaccctgca gtatgtatcc gaccgcgaag	11040
gtcaatgccc cgtacattcg cattcgagca cagcaactct ccaagagtcg acagtacatg	11100
tcctggagaa aggagcgggt acagtacact ttagcaccgc gagtccacag gcgaacttta	11160

CI0043PCTseqlisting.ST25

tcgtatcgct gtgtgggaag aagacaacat gcaatgcaga atgtaaacca ccagctgacc 11220
 atatcgtgag caccgccac aaaaatgacc aagaatttca agccgccatc tcaaaaacat 11280
 catggagttg gctgtttgcc cttttcggcg ggcctcgtc gctattaatt ataggactta 11340
 tgatttttgc ttgcagcatg atgctgacta gcacacgaag atgaccgcta cgccccaatg 11400
 atccgaccag caaaactcga tgtacttccg aggaactgat gtgcataatg catcaggctg 11460
 gtacattaga tccccgctta ccgcgggcaa tatagcaaca ctaaaaactc gatgtacttc 11520
 cgaggaagcg cagtgcataa tgctgcgcag tgttgccaca taaccactat attaaccatt 11580
 tatctagcgg acgcaaaaaa ctcaatgtat ttctgaggaa gcgtggtgca taatgccacg 11640
 cagcgtctgc ataactttta ttatttcttt tattaatcaa caaaattttg tttttaacat 11700
 ttc 11703

<210> 5
 <211> 10945
 <212> DNA
 <213> West Nile virus

<400> 5
 gaggattaac aacaattaac acagtgcgag ctgtttctta gcacgaagat ctcgatgtct 60
 aagaaaccag gagggcccgg caagagccgg gctgtcaata tgctaaaacg cggaatgccc 120
 cgcgtgttgt ccttgattgg actgaagagg gctatgttga gcctgacga cggaagggg 180
 ccaatacgat ttgtgttggc tctcttggcg ttcttcaggt tcacagcaat tgctccgacc 240
 cgagcagtgc tggatcgatg gagagggtgtg aacaacaaa cagcgatgaa acaccttctg 300
 agttttaaga aggaactagg gaccttgacc agtgctatca atcggcggag ctcaaaacaa 360
 aagaaaagag gaggaagac cggaattgca gtcattgattg gcctgacgc cagcgtagga 420
 gcagttaccc tctctaactt ccaagggaag gtgatgatga cggtaaatgc tactgacgtc 480
 acagatgtca tcacgattcc aacagctgct ggaaagaacc tatgcattgt cagagcaatg 540
 gatgtgggat acatgtgcga tgatactatc acctatgaat gccagtgct gtcggctggt 600
 aatgatccag aagacatcga ctgttggtgc acaaagtcag cagtctacgt caggtatgga 660
 agatgcacca agacacgcca ctcaagacgc agtcggaggt cactgacagt gcagacacac 720
 ggagaaagca ctctagcgaa caagaagggg gcttggtatg acagcaccaa ggccacaagg 780
 tatttggtaa aaacagaatc atggatcttg aggaaccctg gatatgccct ggtggcagcc 840
 gtcattggtt ggatgcttgg gagcaacacc atgcagagag ttgtgtttgt cgtgctattg 900
 cttttggtgg cccagctta cagcttcaac tgccttgga tgagcaacag agacttcttg 960
 gaaggagtgt ctggagcaac atgggtggat ttggttctcg aaggcgatag ctgcgtgact 1020
 atcatgtcta aggacaagcc taccatcgat gtgaagatga tgaatatgga ggcgccaac 1080
 ctggcagagg tccgcagtta ttgctatttg gctaccgtca gcgatctctc caccaaagct 1140
 gcgtgcccga ccatggggga agccacaat gacaaacgtg ctgaccgagc ttttgtgtgc 1200
 agacaaggag tgggtggacag gggctggggc aacggctgcg gactatttgg caaaggaagc 1260

CI0043PCTseqlisting.ST25

attgacacat ggcgcaaatt tgcctgctct accaaggcaa taggaagaac catcttgaaa	1320
gagaatatca agtacgaagt ggccattttt gtccatggac caactactgt ggagtgcgac	1380
ggaaactact ccacacaggt tggagccact caggcaggga gattcagcat cactcctgcg	1440
gcgcccttcat acacactaaa gcttgagaa tatggagagg tgacagtga ctgtgaacca	1500
cggtcagggg ttgacaccaa tgcatactac gtgatgactg ttggaacaaa gacgttcttg	1560
gtccatcgtg agtggttcat ggacctcaac ctcccttga gcagtgttg aagtactgtg	1620
tggaggaaca gagagacgtt aatggagttt gaggaaccac acgccacgaa gcagtctgtg	1680
atagcattgg gctcacaaga gggagctctg catcaagctt tggctggagc cattcctgtg	1740
gaattttcaa gcaacactgt caagttgacg tcgggtcatt tgaagtgtag agtgaagatg	1800
gaaaaattgc agttgaaggg aacaacctat ggcgtctgtt caaaggcttt caagtttctt	1860
gggactcccg cagacacagg tcacggcact gtggtgttg aattgcagta cactggcacg	1920
gatggacctt gcaaagttcc tatctcgtca gtggcttcat tgaacgacct aacgccagtg	1980
ggcagattgg tcaactgtcaa ccttttgtt tcagtggcca cggccaacgc taaggctctg	2040
attgaattgg aaccaccctt tggagactca tacatagtgg tgggcagagg agaacaacag	2100
atcaatcacc attggcacia gtctggaagc agcattggca aagcctttac aaccaccctc	2160
aaaggagcgc agagactagc cgctctagga gacacagctt gggacttttg atcagttgga	2220
ggggtgttca cctcagtttg gaaggctgtc catcaagtgt tcggaggagc attccgctca	2280
ctgttcggag gcatgtcctg gataacgcaa ggattgctgg gggctctcct gttgtggatg	2340
ggcatcaatg ctctgatag gtccatagct ctacgtttc tcgcagtttg aggagtctg	2400
ctcttcctct ccgtgaacgt gcacgctgac actgggtgtg ccataaacat caccgcgcaa	2460
gagctgagat gtggaagtgg agtgttcata cacaatgatg tggaggcttg gatggaccgg	2520
tacaagtatt accctgaaac gccacaaggc ctagccaaga tcattcagaa agctcataag	2580
gaaggagtgt gcggtctacg atcagtttcc agactggagc atcaaatgtg ggaagcagtg	2640
aaggacgagc tgaacactcc tttgaaggag aatgggtgtg accttagtgt cgtggttgag	2700
aaacaggagg gaatgtacaa gtcagcacct aaacgcctca ccgccaccac ggaaaaattg	2760
gaaattggct ggaaggcctg gggaaagagt atttatttg caccagaact cgccaacaac	2820
acctttgttg ttgatggtcc ggagaccaag gaatgtccga ctcagaatcg cgcttggaat	2880
agcttagaag tggaggattt tggatttggc ctaccagca ctcggtgtt cctgaaggctc	2940
agagaaggca acacaactga atgtgactcg aagatcattg gaacggctgt caagaacaac	3000
ttggcgatcc acagtgacct gtcctatttg attgaaagca ggctcaatga tacgtggaag	3060
cttgaaaggg cagttctggg tgaagtcaaa tcatgtacgt ggcctgagac gcataccttg	3120
tggggcgatg gaatccttga gagtgacttg ataataccag tcacactggc gggaccacga	3180
agcaatcaca atcggagacc tgggtacaag acacaaaacc agggcccatg ggacgaaggc	3240
cgggtagaga ttgacttcga ttactgcca ggaactacgg tcaccctgag tgagagctgc	3300

CI0043PCTseqlisting.ST25

ggacaccgtg	gacctgccac	tcgcaccacc	acagagagcg	gaaagttgat	aacagattgg	3360
tgctgcagga	gctgcacctt	accaccactg	cgctaccaa	ctgacagcg	ctgttggtat	3420
ggtatggaga	tcagaccaca	gagacatgat	gaaaagaccc	tcgtgcagtc	acaagtgaat	3480
gcttataatg	ctgatatgat	tgacctttt	cagttggg	ttctggtcgt	gttcttgcc	3540
accaggagg	tccttcgca	gaggtggaca	gccaagatca	gcatgccagc	tatactgatt	3600
gctctgctag	tcctggtgtt	tgggggcatt	acttacactg	atgtgttacg	ctatgtcatc	3660
ttggtggggg	cagctttcgc	agaatcta	tcgggaggag	acgtggtaca	cttggcgctc	3720
atggcgacct	tcaagataca	accagtgttt	atggtggcat	cgtttctcaa	agcgagatgg	3780
accaaccagg	agaacatfff	gttgatgttg	gcggctgttt	tctttcaa	ggcttatcac	3840
gatgcccgcc	aaattctgct	ctgggagatc	cctgatgtgt	tgaattcact	ggcggtagct	3900
tggtatgatac	tgagagccat	aacattcaca	acgacatcaa	acgtggttgt	tccgctgcta	3960
gccctgctaa	cacccgggct	gagatgcttg	aatctggatg	tgtacaggat	actgctgttg	4020
atggtcggaa	taggcagctt	gatcaggag	aagaggagtg	cagctgcaa	aaagaaagga	4080
gcaagtctgc	tatgcttggc	tctagcctca	acaggacttt	tcaaccccat	gatccttgct	4140
gctggactga	ttgcatgtga	tcccaaccgt	aaacgcggat	ggcccgaac	tgaagtgatg	4200
acagctgtcg	gcctaattgt	tgccatcgtc	ggagggctgg	cagagcttga	cattgactcc	4260
atggccattc	caatgactat	cgcggggctc	atgtttgctg	ctttcgat	ttctgggaaa	4320
tcaacagata	tgtggattga	gagaacggcg	gacatttcct	gggaaagtga	tgcagaaatt	4380
acaggctcga	gcgaaagagt	tgatgtgcgg	cttgatgatg	atggaaactt	ccagctcatg	4440
aatgatccag	gagcaccttg	gaagatatgg	atgctcagaa	tggtctgtct	cgcgattagt	4500
gcgtacaccc	cctgggcaat	cttgccctca	gtagttggat	tttgataac	tctccaatac	4560
acaaagagag	gaggcgtgtt	gtgggacact	ccctcaccaa	aggagtacaa	aaagggggac	4620
accaccaccg	gcgtttacag	gatcatgact	cgtagggctgc	tcggcagtta	tcaagcagga	4680
gcgggcgtga	tggttgaagg	tgttttccac	accctttggc	atacaacaaa	aggagccgct	4740
ttgatgagcg	gagagggccg	cctggaccca	tactggggca	gtgtcaagga	ggatcgactt	4800
tgttacggag	gaccctggaa	attgcagcac	aagtggaacg	ggcaggatga	ggtgcagatg	4860
attgtggtgg	aacctggcaa	gaacgttaag	aacgtccaga	cgaaaccagg	ggtgttcaaa	4920
acacctgaag	gagaaatcgg	ggccgtgact	ttggacttcc	ccactggaac	atcaggctca	4980
ccaatagtgg	acaaaaacgg	tgatgtgatt	gggctttatg	gcaatggagt	cataatgccc	5040
aacggctcat	acataagcgc	gatagtgcag	ggtgaaagga	tggtgagcc	aatcccagcc	5100
ggattcgaac	ctgagatgct	gaggaaaaaa	cagatcactg	tactggatct	ccatcccggc	5160
gccggtaaaa	caaggaggat	tctgccacag	atcatcaaag	aggccataaa	cagaagactg	5220
agaacagccg	tgctagcacc	aaccagggtt	gtggctgctg	agatggctga	agcactgaga	5280
ggactgccc	tccggtacca	gacatccgca	gtgcccagag	aacataatgg	aatgagatt	5340

CI0043PCTseqlisting.ST25

gttgatgtca	tgtgtcatgc	taccctcacc	cacaggctga	tgtctcctca	cagggtgccg	5400
aactacaacc	tgttcgtgat	ggatgaggct	catttcaccg	accagctag	cattgcagca	5460
agaggttaca	tttccacaaa	ggtcgagcta	ggggaggcgg	cggcaatatt	catgacagcc	5520
accccaccag	gcacttcaga	tccattccca	gagtccaatt	caccaatttc	cgacttacag	5580
actgagatcc	cggatcgagc	ttggaactct	ggatacgaat	ggatcacaga	atacaccggg	5640
aagacggttt	ggtttgtgcc	tagtgtcaag	atggggaatg	agattgccct	ttgcctacaa	5700
cgtgctggaa	agaaagtagt	ccaattgaac	agaaagtcgt	acgagacgga	gtacccaaaa	5760
tgtaagaacg	atgattggga	ctttgttatc	acaacagaca	tatctgaaat	gggggctaac	5820
ttcaaggcga	gcaggtgat	tgacagccgg	aagagtgtga	aaccaaccat	cataacagaa	5880
ggagaaggga	gagtgtcct	gggagaacca	tctgcagtga	cagcagctag	tgccgcccag	5940
agacgtggac	gtatcggtag	aaatccgtcg	caagttggtg	atgagtactg	ttatgggggg	6000
cacacgaatg	aagacgactc	gaacttcgcc	cattggactg	aggcacgaat	catgctggac	6060
aacatcaaca	tgccaaacgg	actgatcgct	caattctacc	aaccagagcg	tgagaaggta	6120
tataccatgg	atggggaata	ccggctcaga	ggagaagaga	gaaaaaactt	tctggaactg	6180
ttgaggactg	cagatctgcc	agtttggtcg	gcttacaagg	ttgcagcggc	tggagtgtca	6240
taccacgacc	ggaggtggtg	ctttgatggt	cctaggacaa	acacaatttt	agaagacaac	6300
aacgaagtgg	aagtcacac	gaagcttggg	gaaaggaaga	ttctgaggcc	gcgctggatt	6360
gacgccaggg	tgtactcgga	tcaccaggca	ctaaaggcgt	tcaaggactt	cgccctggga	6420
aaacgttctc	agatagggct	cattgaggtt	ctgggaaaga	tgcttgagca	cttcatgggg	6480
aagacatggg	aagcacttga	caccatgtac	gttgtggcca	ctgcagagaa	aggaggaaga	6540
gctcacagaa	tggccctgga	ggaactgcca	gatgctcttc	agacaattgc	cttgattgcc	6600
ttattgagtg	tgatgaccat	gggagtattc	ttcctcctca	tgacgcggaa	gggcattgga	6660
aagatagggt	tgggaggcgc	tgtcttggga	gtagcgacct	tttctgttg	gatggctgaa	6720
gttcaggaa	cgaagatcgc	cggaatgttg	ctgctctccc	ttctcttgat	gattgtgcta	6780
attcctgagc	cagagaagca	acgttcgcag	acagacaacc	agctagccgt	gttcctgatt	6840
tgtgtcatga	cccttgtgag	cgcagtgga	gccaacgaga	tgggttggt	agataagacc	6900
aagagtga	taagcagttt	gtttgggcaa	agaattgagg	tcaaggagaa	tttcagcatg	6960
ggagagtttc	ttctggactt	gaggccggca	acagcctggt	cactgtacgc	tgtgacaaca	7020
gcggtcctca	ctccactgct	aaagcatttg	atcacgtcag	attacatcaa	cacctcattg	7080
acctcaataa	acgttcaggc	aagtgcacta	ttcacactcg	cgcgaggctt	ccccttcgtc	7140
gatgttgagg	tgctcggtct	cctgctagca	gccggatgct	ggggacaagt	caccctcacc	7200
gttacggtaa	cagcggcaac	actccttttt	tgccactatg	cctacatggt	tcccggttgg	7260
caagctgagg	caatgcgctc	agcccagcgg	cggacagcgg	ccggaatcat	gaagaacgct	7320
gtagtgga	gcatcgggc	cacggacgtc	ccagaattag	agcgcaccac	acccatcatg	7380

CI0043PCTseqlisting.ST25

cagaagaaag	ttggacagat	catgctgatc	ttggtgtctc	tagctgcagt	agtagtgaac	7440
ccgtctgtga	agacagtacg	agaagccgga	attttgatca	cggccgcagc	ggtgacgctt	7500
tgggagaatg	gagcaagctc	tgtttggaac	gcaacaactg	ccatcggact	ctgccacatc	7560
atgcgtgggg	gttggttgtc	atgtctatcc	ataacatgga	cactcataaa	gaacatggaa	7620
aaaccagggc	taaaaagagg	tggggcaaaa	ggacgcacct	tgggagaggt	ttggaaagaa	7680
agactcaacc	agatgacaaa	agaagagttc	actaggtacc	gcaaagaggc	catcatcgaa	7740
gtcgatcgct	cagcggcaaa	acacgccagg	aaagaaggca	atgtcactgg	agggcatcca	7800
gtctctaggg	gcacagcaaa	actgagatgg	ctggtcgaac	ggaggtttct	cgaaccggtc	7860
ggaaaagtga	ttgaccttgg	atgtggaaga	ggcggttggg	gttactatat	ggcaacccaa	7920
aaaagagtcc	aagaagtcag	agggtacaca	aagggcggtc	ccggacatga	agagccccaa	7980
ctagtgcaaa	gttatggatg	gaacattgtc	accatgaaga	gtggagtggg	tgtgttctac	8040
agaccttctg	agtgttgtga	caccctcctt	tgtgacatcg	gagagtcctc	gtcaagtgtc	8100
gaggttgaag	agcataggac	gattcgggtc	cttgaaatgg	ttgaggactg	gctgcaccga	8160
gggccaaggg	aattttgcgt	gaagggtgtc	tgcccctaca	tgccgaaagt	catagagaag	8220
atggagctgc	tccaacgccg	gtatgggggg	ggactgggtc	gaaaccact	ctcacggaat	8280
tccacgcacg	agatgtattg	ggtgagtcga	gcttcaggca	atgtggtaca	ttcagtgaat	8340
atgaccagcc	agggtgtcct	aggaagaatg	gaaaaaagga	cctggaaggg	accccaatac	8400
gaggaagatg	taaacttggg	aagtggaacc	agggcggtgg	gaaaaccct	gctcaactca	8460
gacaccagta	aaatcaagaa	caggattgaa	cgactcaggc	gtgagtacag	ttcgacgtgg	8520
caccacgatg	agaaccaccc	atatagaacc	tggaactacc	acggcagtta	tgatgtgaag	8580
cccacaggct	ccgccagttc	gctggtcaat	ggagtgggtc	ggctcctctc	aaaaccatgg	8640
gacaccatca	cgaatgttac	caccatggcc	atgactgaca	ctactccctt	cgggcagcag	8700
cgagtgttca	aagagaaggt	ggacacgaaa	gctcctgaac	cgccagaagg	agtgaagtac	8760
gtgctcaacg	agaccaccaa	ctggttgtgg	gcgtttttgg	ccagagaaaa	acgtcccaga	8820
atgtgtcttc	gagaggaatt	cataagaaag	gtcaacagca	atgcagcttt	gggtgccatg	8880
tttgaagagc	agaatcaatg	gaggagcgcc	agagaagcag	ttgaagatcc	aaaattttgg	8940
gagatggtgg	atgaggagcg	cgaggcacat	ctgcgggggg	aatgtcacac	ttgcatttac	9000
aacatgatgg	gaaagagaga	gaaaaaacc	ggagagtctg	gaaaggccaa	gggaagcaga	9060
gccatttggt	tcatgtggct	cggagctcgc	tttctggagt	tcgaggctct	gggttttctc	9120
aatgaagacc	actggcttgg	aagaaagaac	tcaggaggag	gtgtcgaggg	cttgggcctc	9180
caaaaactgg	gttacatcct	gcgtgaagtt	ggcaccgggc	ctgggggcaa	gatctatgct	9240
gatgacacag	ctggctggga	caccgcacac	acgagagctg	acttggaaaa	tgaagctaag	9300
gtgcttgagc	tgcttgatgg	ggaacatcgg	cgtcttgcca	gggccatcat	tgagctcacc	9360
tatcgtcaca	aagttgtgaa	agtgatgcgc	ccggctgctg	atggaagaac	cgatcatggat	9420

CI0043PCTseqlisting.ST25

```

gttatctcca gagaagatca gagggggagt ggacaagttg tcacctacgc cctaaacact 9480
ttcaccaacc tggccgtcca gctggtgagg atgatggaag gggaggaggt gattggccca 9540
gatgatgtgg agaaactcac aaaagggaaa ggacccaaag tcaggacctg gctgtttgag 9600
aatggggaag aaagactcag ccgcatggct gtcagtggag atgactgtgt ggtaaagccc 9660
ctggacgatc gctttgccac ctcgctccac ttcctcaatg ctatgtcaaa ggttcgcaaa 9720
gacatccaag agtggaacc gtcaactgga tggatgatt ggcagcaggt tccattttgc 9780
tcaaaccatt tactgaatt gatcatgaaa gatggaagaa cactggtggt tccatgccga 9840
ggacaggatg aattggtagg cagagctcgc atatctccag gggccggatg gaacgtccgc 9900
gacactgctt gtctggctaa gtcttatgcc cagatgtggc tgcttctgta cttccacaga 9960
agagacctgc ggctcatggc caacgccatt tgctccgctg tccctgtgaa ttgggtccct 10020
accggaagaa ccacgtggtc catccatgca ggaggagagt ggatgacaac agaggacatg 10080
ttggaggctt ggaaccgtgt ttggatagag gagaatgaat ggatggaaga caaaacccca 10140
gtggagaaat ggagtgcgt cccatattca ggaaaacgag aggacatctg gtgtggcagc 10200
ctgattggca caagagccc agccacgtgg gcagaaaaca tccagggtggc tatcaaccaa 10260
gtcagagcaa tcatcggaga tgagaagtat gtggattaca tgagttcact aaagagatat 10320
gaagacacaa ctttggttga ggacacagta ctgtagatat ttaatcaatt gtaaatagac 10380
aatataagta tgcataaaag tgtagtttta tagtagtatt tagtggtgtt agtgtaaata 10440
gttaagaaaa ttttgaggag aaagtcaggc cggaagtgc ccgccaccg aagttgagta 10500
gacggtgctg cctgcgactc aacccaggga ggactgggtg aacaaagccg cgaagtgatc 10560
catgtaagcc ctcaaacg tctcggaagg aggacccac atgttgtaac ttcaaagccc 10620
aatgtcagac cacgctacgg cgtgctactc tgcggagagt gcagtctgcg atagtgcgcc 10680
aggaggactg ggttaacaaa ggcaaacca cgccccacgc ggcctagcc ccggaatgg 10740
tgtaaccag ggcgaaagga ctagaggta gaggagacc cgcggtttaa agtgcacggc 10800
ccagcctggc tgaagctgta ggtcagggga aggactagag gttagtggag acccctgccc 10860
acaaaacacc acaaaaaac agcatattga cacctgggat agactaggag atcttctgct 10920
ctgcacaacc agccacacgg cacag 10945

```

```

<210> 6
<211> 1542
<212> DNA
<213> Escherichia coli 16S Ribosomal RNA

```

```

<220>
<221> misc_feature
<222> (896)..(896)
<223> n is a, c, g, or t

```

```

<400> 6
aaattgaaga gtttgatcat ggctcagatt gaacgtggc ggcaggccta acacatgcaa 60

```

CI0043PCTseqlisting.ST25

gtcgaacggt aacaggaakc agcttgctga tttgctgacg agtggcggac gggtagtaaa 120
 tgtctgggaa actgcctgat ggagggggat aactactgga aacggtagct aataccgcat 180
 aacgtcgcaa gaccaaagag ggggaccttc gggcctcttg ccatcggatg tgcccagatg 240
 ggattagcta gtaggtgggg taaaggctca cctaggcgac gatccctagc tggcttgaga 300
 ggatgaccag ccacactgga actgagacac ggtccagact cctacgggag gcagcagtgg 360
 ggaatattgc acaatgggag caagcctgat gcagccatgc cgcgtgtatg aagaaggcct 420
 tcgggttgta aagtactttc agcggggagg aaggagtaaa agttaatacc tttgctcatt 480
 gacgttaccg gcagaagaag caccggctaa ctccgtgcca gcagccgcgg taatacggag 540
 ggtgcaagcg ttaatcgga ttactgggag taaagcgac gcagggcggt ttgtaagtca 600
 gatgtgaaat ccccggttc aacctgggaa ctgcatctga tactggcaag cttgagtctc 660
 gtagaggggg gtagaattcc aggtgtagcg gtgaaatgag tagagatctg gaggaatacc 720
 ggtggcgaag gcggccccct ggacgaagac tgacgctcag gtgcgaaagc gtggggagca 780
 aacaggatta gataccctgg tagtccacgc cgtaaagcat gtcgacttgg aggttgtgcc 840
 cttgaggcgt ggcttccgga gctaacgcgt taagtckacc gcctggggag tacggncgca 900
 aggttaaaac tcaaatgaat tgacgggggc ccgcacaagc ggtggagcat gtggtttaat 960
 tcgatgcaac gcgaagaacc ttacctggtc ttgacatcca cagaactttc cagagatgga 1020
 ttggtgcctt cgggaactgt gagacaggtg ctgcatggct gtcgtcagct cgtgttgtga 1080
 aatgttgggt taagtcccg c aacgagcgca acccttatcc tttgttgcca gcggtccggc 1140
 cgggaactca aaggagactg ccagtataaa actggaggaa ggtggggatg acgtcaagtc 1200
 atcatggccc ttacgaccag ggctacacac gtgctacaat ggcgcataca aagagaagcg 1260
 ayctcgag agcaagcgga cctcataaag tgcgtcgtag tccggattgg agtctgcaac 1320
 tcgactccat gaagtcggaa tcgctagtaa tcgtggatca gaatgccacg gtgaatacgt 1380
 tccccggcct tgtacacacc gcccgtcaca ccatgggagt gggttgcaaa agaagtaggt 1440
 agcttaacct tcgggagggc gcttaccact ttgtgattca tgactggggt gaagtcgtaa 1500
 caaggtaacc gtaggggaac ctgcggttgg atcacctcct ta 1542

<210> 7

<211> 2905

<212> DNA

<213> Escherichia coli 23 S Ribosomal RNA

<400> 7

ggttaagcga ctaagcgtac acggtggatg ccctggcagt cagaggcgat gaaggacgtg 60
 ctaatctgag ataagcgtcg gtaaggatg atgaaccgtt ataaccggcg atttccgaat 120
 ggggaaaccc agtgtgtttc gacacactat cattaactga atccataggt taatgaggcg 180
 aaccggggga actgaaacat ctaagtaccc cgaggaaaag aaatcaaccg agattcccc 240
 agtagcggcg agcgaacggg gagcagccca gagcctgaat cagtgtgtgt gttagtggaa 300
 gcgtctggaa aggcgcgcga tacagggtga cagccccgta cacaaaaatg cacatgctgt 360

CI0043PCTseqlisting.ST25

gagctcgatg agtagggcgg gacacgtggt atcctgtctg aatatggggg gaccatcctc	420
caaggctaaa tactcctgac tgaccgatag tgaaccagta ccgtgagggg aaggcgaaaa	480
gaaccccggc gaggggagtg aaaaagaacc tgaaaccgtg tacgtacaag cagtgggagc	540
acgcttaggc gtgtgactgc gtaccttttg tataatgggt cagcgactta tattctgtag	600
caaggttaac cgaatagggg agccgaaggg aaaccgagtc ttaactgggc gttaagttgc	660
agggtataga cccgaaaccc ggtgatctag ccatgggcag gttgaagggt gggtaacact	720
aactggagga ccgaaccgac taatgttgaa aaattagcgg atgacttggt gctgggggtg	780
aaaggccaat caaacggga gatagctggt tctccccgaa agctatttag gtagcgctc	840
gtgaattcat ctccgggggt agagcactgt ttcggcaagg gggcatccc gacttaccaa	900
cccgatgcaa actgcgaata ccggagaatg ttatcacggg agacacacgg cgggtgctaa	960
cgtccgtcgt gaagagggaa acaaccaga ccgccagcta aggtcccaa gtcatggta	1020
agtgggaaac gatgtgggaa ggcccagaca gccaggatgt tggcttagaa gcagccatca	1080
tttaagaaa gcgtaatagc tactggctg agtcggcctg cgcggaagat gtaacggggc	1140
taaaccatgc accgaagctg cggcagcgac gcttatgctg tgttgggtag gggagcgttc	1200
tgaagcctg cgaagggtg ctgtgaggca tgctggaggt atcagaagtg cgaatgctga	1260
cataagtaac gataaagcgg gtgaaaagcc cgctcgccgg aagaccaagg gttcctgtcc	1320
aacgttaatc ggggcagggt gagtcgaccc ctaaggcgag gccgaaaggc gtagtcgatg	1380
ggaaacaggt taatattcct gtacttggtg ttactgcgaa ggggggacgg agaaggctat	1440
gttggccggg cgacggttgt cccggtttaa gcgtgtaggc tggttttcca ggcaaaccg	1500
gaaaatcaag gctgaggcgt gatgacgagg cactacggtg ctgaagcaac aaatgccctg	1560
cttcaggaa aagcctctaa gcatcaggta acatcaaatc gtaccccaaa ccgacacagg	1620
tggtcaggta gagaatacca aggcgcttga gagaactcgg gtgaaggaa taggcaaat	1680
ggtgccgtaa cttcgggaga aggcacgctg atatgtaggt gaagcgactt gctcgtggag	1740
ctgaaatcag tcgaagatac cagctggctg caactgttta ttaaaaacac agcactgtgc	1800
aaacacgaaa gtggacgtat acggtgtgac gcctgcccgg tgccggaagg ttaattgatg	1860
gggttagcgg taacgcgaag ctcttgatcg aagccccggt aaacggcggc cgtaactata	1920
acggtcctaa ggtagcgaat ttccttgctg ggtaagttcc gacctgcacg aatggcgtaa	1980
tgatggccag gctgtctcca cccgagactc agtgaaattg aactcgtgt gaagatgcag	2040
tgtaccgcg gcaagacgga aagaccccggt gaacctttac tatagcttga cactgaacat	2100
tgagccttga tgtgtaggat aggtgggagg ctttgaagtg tggacgccag tctgcatgga	2160
gccgaccttg aaataaccac ctttaatggt tgatgttcta acgttggccc gtaatccggg	2220
ttgcccagag tgtctggtg gtagtttgac tggggcggtc tcctcctaaa gagtaacgga	2280
ggagcacgaa ggttggctaa tcctggtcgg acatcaggag gttagtgcaa tggcataagc	2340
cagcttgact gcgagcgtga cggcgcgagc aggtgcgaaa gcaggtcata gtgatccggt	2400

CI0043PCTseqlisting.ST25

ggttctgaat ggaagggcca tcgctcaacg gataaaaggt actccgggga taacaggctg 2460
 ataccgcccc agagttcata tcgacggcgg tgtttggcac ctcatgtcg gctcatcaca 2520
 tcctggggct gaagtaggtc ccaagggat ggctgttcgc catttaaagt ggtacgcgag 2580
 ctgggttttag aacgtcgtga gacagttcgg tccctatctg ccgtgggccc tggagaactg 2640
 aggggggctg ctctagtac gagaggaccg gagtggacgc atcactggtg ttcgggttgt 2700
 catgccaatg cactgcccgg tagctaaatg cggaagagat aagtgtgaa agcatctaag 2760
 cacgaaactt gcccgcagat gagttctccc tgaccctta agggctcctga aggaacgttg 2820
 aagacgacga cgttgatagg ccgggtgtgt aagcgacgc atgcgttgag ctaaccggta 2880
 ctaatgaacc gtgaggctta acctt 2905

<210> 8
 <211> 1798
 <212> DNA
 <213> Yeast (*S. cerevisiae*)

<400> 8
 tatctggttg atcctgccag tagtcatatg cttgtctcaa agattaagcc atgcatgtct 60
 aagtataagc aatttataca gtgaaactgc gaatggctca tttaatcagt tatcgtttat 120
 ttgatagttc ctttactaca tgggtataacc gtggtaattc tagagctaata acatgcttaa 180
 aatctcgacc ctttgaaga gatgtattta ttagataaaa aatcaatgtc ttcggactct 240
 ttgatgattc ataataactt ttcgaatcgc atggccttgt gctggcgatg gttcattcaa 300
 atttctgccc tatcaacttt cgatggtagg atagtggcct accatggttt caacgggtaa 360
 cggggaataa gggttcgatt ccggagaggg agcctgagaa acggctacca catccaagga 420
 aggcagcagg cgcgcaaatt acccaatcct aattcaggga ggtagtgaca ataaataacg 480
 atacagggcc cattcgggtc ttgtaattgg aatgagtaca atgtaaatac cttaacgagg 540
 aacaattgga gggcaagtct ggtgccagca gccgcggtaa ttccagctcc aatagcgtat 600
 attaaagttg ttgcagttaa aaagctcgta gttgaacttt gggcccgggt ggccgggtccg 660
 attttttcgt gtactggatt tccaacgggg cttttccttc tggctaacct tgagtccttg 720
 tggctcttg cgaaccagga cttttacttt gaaaaatta gagtgttcaa agcaggcgta 780
 ttgctcgaat atattagcat ggaataatag aataggacgt ttggttctat tttgttggtt 840
 tctaggacca tcgtaatgat taatagggac ggtcgggggc atcggatttc aattgtcgag 900
 gtgaaattct tggatttatt gaagactaac tactgcgaaa gcatttgcca aggacgtttt 960
 cattaatcaa gaacgaaagt taggggatcg aagatgatct ggtaccgtcg tagtcttaac 1020
 cataaactat gccgactaga tcgggtggtg tttttttaat gaccactcg gtaccttacg 1080
 agaaatcaaa gtctttgggt tctgggggga gtatggtcgc aaggctgaaa cttaaaggaa 1140
 ttgacggaag ggcaccacta ggagtggagc ctgcggctaa tttgactcaa cacggggaaa 1200
 ctaccagggt ccagacacaa taaggattga cagattgaga gctctttctt gatattgtgg 1260

CI0043PCTseqlisting.ST25

gtggtggtgc atggccggtt ctcagttggt ggagtgattt gtctgcttaa ttgcgataac 1320
 gaacgagacc ttaacctact aaatagtggg gctagcattt gctggttatc cacttccttag 1380
 agggactatc ggtttcaagc cgatggaagt ttgaggcaat aacaggctctg tgatgccctt 1440
 agaacgttct gggccgcacg cgcgctacac tgacggagcc agcgagtcta accttggccg 1500
 agaggctctt gtaatcttgt gaaactccgt cgtgctgggg atagagcatt gtaattattg 1560
 ctcttcaacg aggaattcct agtaagcgca agtcacacag ttgcgttgat tacgtccctg 1620
 cctttgtac acaccgcccg tcgctagtac cgattgaatg gcttagtgag gcctcaggat 1680
 ctgcttagag aagggggcaa ctccatctca gagcggagaa tttggacaaa cttggtcatt 1740
 tagaggaact aaaagtcgta acaaggtttc cgtaggtgaa cctgcggaag gatcatta 1798

<210> 9
 <211> 3911
 <212> DNA
 <213> Yeast 25S Ribosomal RNA

<400> 9
 aattccgtga tgggccttta ggttttacca actgcggcta atcttttttt atactgagcg 60
 tattggaacg ttatcgataa gaagagagcg tctaggcgaa caatgttctt aaagtttgac 120
 ctcaaatcag gtaggagtac ccgctgaact taagcatatc aataagcggg ggaaaagaaa 180
 ccaaccggat tgccttagta acggcgagtg aagcggcaaa agctcaaatt tgaaatctgg 240
 taccttcggt gcccagattg taatttgag agggcaactt tggggccggt ccttgtctat 300
 gttccttggg acaggacgtc atagaggggtg agcatcccgt gtggcgagga gtgcggttct 360
 ttgtaaagtg ctttcgaaga gtcgagttgt ttgggaatgc agctctaagt ggggtggtaaa 420
 ttccatctaa agctaaatat tggcgagaga ccgatagcga acaagtacag tgatggaaaag 480
 atgaaaagaa ctttgaaaag agagtgaaaa agtacgtgaa attgttgaaa gggaagggca 540
 tttgatcaga catggtgttt tgtgccctct gtccttgtg ggtaggggaa tctcgcattt 600
 cactgggcca gcatcagttt tgggtggcagg ataaatccat aggaatgtag cttgcctcgg 660
 taagtattat agcctgtggg aatactgccg gctgggactg aggactgcga cgtaagtcaa 720
 ggatgctggc ataattggtta tatgccgccc gtcttgaaac acggaccaag gagtctaacg 780
 tctatgcgag tgtttggtg taaaacccat acgcgtaatg aaagtgaacg taggttgggg 840
 cctcgaaga ggtgcacaat cgaccgatcc tgatgtcttc ggatggattt gagtaagagc 900
 atagctgttg ggacccgaaa gatggtgaac tatgcctgaa tagggtgaag ccagaggaaa 960
 ctctggtgga ggctcgtagc ggttctgacg tgcaaatcga tcgtcgaatt tgggtatagg 1020
 ggcgaaagac taatcgaacc atctagtagc tggttcctgc cgaagtttcc ctccaggatag 1080
 cagaagctcg tatcagtttt atgaggtaaa gcgaatgatt agagggttccg gggtcgaaat 1140
 gaccttgacc tattctcaaa ctttaaatat gtaagaagtc cttgttactt aattgaacgt 1200
 ggacatttga atgaagagct tttagtgggc catTTTTTggt aagcagaact ggcatgacg 1260
 gatgaaccga acgtagagtt aaggtgccgg aatacacgct catcagacac cacaaaagg 1320

CI0043PCTseqlisting.ST25

gttagttcat	ctagacagcc	ggacggtggc	catggaagtc	ggaatccgct	aaggagtgtg	1380
taacaactca	ccggccgaat	gaactagccc	tgaaaatgga	tggcgctcaa	gcgtgttacc	1440
tatactctac	cgtcaggggt	gatatgatgc	cctgacgagt	aggcaggcgt	ggagggtcagt	1500
gacgaagcct	agaccgtaag	gtcgggtcga	acggcctcta	gtgcagatct	tggtggtagt	1560
agcaaatatt	caaataagaa	ctttgaagac	tgaagtgggg	aaagggttcca	cgtcaacagc	1620
agttggacgt	gggttagtcg	atcctaagag	atggggaagc	tccgtttcaa	aggcctgatt	1680
ttatgcaggc	caccatcgaa	agggaatccg	gtaagattcc	ggaacttgga	tatggattct	1740
tcacggtaac	gtaactgaat	gtggagacgt	cggcgcgagc	cctgggagga	gttatctttt	1800
cttcttaaca	gcttatcacc	ccggaattgg	tttatccgga	gatggggctt	tatggctgga	1860
agaggccagc	acctttgctg	gctccggtgc	gcttgtgacg	gcccgtgaaa	atccacagga	1920
aggaatagtt	ttcatgctag	gtcgtactga	taaccgcagc	aggctctcaa	ggtgaacagc	1980
ctctagttga	tagaataatg	tagataaggg	aagtcggcaa	aatagatccg	taacttcggg	2040
ataaggattg	gctctaaggg	tcgggtagtg	agggccttgg	tcagacgcag	cgggcgtgct	2100
tgtggactgc	ttggtggggc	ttgctctgct	aggcggacta	cttgcggtcc	ttgttgtaga	2160
cggccttggg	aggctctctg	tagaccgtcg	cttgctacaa	ttaacagatc	aacttagaac	2220
tggtagcgac	aaggggaatc	tgactgtcta	attaaaacat	agcattgcga	tggtcagaaa	2280
gtgatgttga	cgcaatgtga	tttctgccca	gtgctctgaa	tgtcaaagtg	aagaaattca	2340
accaagcgcg	agtaaacggc	gggagtaact	atgactctct	taaggtagcc	aatgcctcg	2400
tcataaatt	agtacgcgc	atgaatggat	taacgagatt	cccactgtcc	ctatctacta	2460
tctagcga	ccacagccaa	gggaacgggc	ttggcagaat	cagcggggaa	agaagaccct	2520
gttagagctt	actctagttt	gacattgtga	agagacatag	aggggtgtaga	ataagtggga	2580
gcttcggcgc	cagtgaata	ccactacctt	tatagtttct	ttacttattc	aatgaagcgg	2640
agctggaatt	cattttccac	gttctagcat	tcaaggctcc	attcggggct	gatccgggtt	2700
gaagacattg	tcagggtggg	agtttggtcg	gggcggcaca	tctgttaaac	gataacgcag	2760
atgtcctaag	gggggtcat	ggagaacaga	aatctccagt	agaacaaaag	ggtaaagccc	2820
cttagtttga	tttcagtgtg	aatacaaacc	attgaaagtg	tggcctatcg	atcctttagt	2880
ccctcggaat	ttgaggctag	aggtgccaga	aaagttacca	cagggataac	tggttgtggt	2940
cagtcaagcg	ttcatagcga	cattgctttt	tgattcttcg	atgtcggctc	ttcctatcat	3000
accgaagcag	aattcggtaa	gcgttggtat	gttcacccac	taatagggaa	catgagctgg	3060
gtttagaccg	tcgtgagaca	ggtagttttt	accctactga	tgaatgttac	cagcaatagt	3120
aattgaactt	agtagagag	gaacagttca	ttcggataat	tggtttttgc	ggctgtctga	3180
tcaggcattg	ccgcgaagca	ccatccgctg	gattatggct	gaacgcctct	aagtcagaat	3240
ccatgctaga	acgcggtgat	ttctttgctc	cacacaatat	agatggatac	gaataaggcg	3300
tccttgtggc	gtcgtgaac	catagcaggc	tagcaacggg	gcacttggcg	gaaaggcctt	3360

CI0043PCTseqlisting.ST25

gggTgcttgc tggcgaattg caatgtcatt ttgcgtgggg ataaatcatt tgtatacgac 3420
 ttagatgtac aacgggggtat tgtaagcggg agagtagcct tgttgttacg atctgctgag 3480
 attaagcctt tgttgtctga tttgtttttt atttctttct aagtgggtac tggcaggagc 3540
 cggggcctag tttagagaga agtagactca acaagtctct ataaatttta tttgtcttaa 3600
 gaattctatg atccgggtaa aaacatgtat tgtatatatc tattataata tacgatgagg 3660
 atgatagtgt gtaagagtgt accatttact aatgtatgta agttactatt tactatttgg 3720
 tctttttatt ttttattttt tttttttttt tcgttgcaaa gatggggtga aagagaaggg 3780
 ctttcacaaa gcttcccag cgtgaaagga tttgccgga cagtttgctt catggagcag 3840
 tttttccgc accatcagag cggcaaacat gagtgcttgt ataagtttag agaattgaga 3900
 aaagctcatt t 3911

<210> 10
 <211> 16569
 <212> DNA
 <213> Human mitochondrial DNA

<400> 10
 gatcacaggc ctatcacctt attaacctt cagggagct ctccatgcat ttggtatttt 60
 cgtctggggg gtatgcacgc gatagcattg cgagacgctg gagccggagc accctatgtc 120
 gcagtatctg tctttgattc ctgcctcatc ctattattta tcgcacctac gttcaatatt 180
 acaggcgaac atacttacta aagtgtgtta attaatatt gcttgttaga cataataata 240
 acaattgaat gtctgcacag ccactttcca cacagacatc ataacaaaaa atttccacca 300
 aacccccctt cccccgttc tggccacagc acttaaacac atctctgcca aacccccaaa 360
 acaaagaacc ctaacaccag cctaaccaga tttcaattt tatcttttgg cggtatgcac 420
 ttttaacagt cccccccaa ctaacacatt attttccct cccactcca tactactaat 480
 ctcatcaata caacccccgc ccctctacc cagcacacac acaccgctgc taaccccata 540
 ccccgaacca accaaacccc aaagacaccc cccacagttt atgtagctta cctcctcaaa 600
 gcaatacact gaaaatgttt agacgggctc acatcacccc ataaacaaat aggtttgggtc 660
 ctagcctttc tattagctct tagtaagatt acacatgcaa gcatccccgt tccagttagt 720
 tcacctcta aatcaccacg atcaaaagg acaagcatca agcacgcagc aatgcagctc 780
 aaaacgctta gcctagccac acccccacgg gaaacagcag tgattaacct ttagcaataa 840
 acgaaagttt aactaagcta tactaacccc aggggttggtc aatttcgtgc cagccaccgc 900
 ggtcacacga ttaacccaag tcaatagaag ccggcgtaaa gagtgtttta gatcaccccc 960
 tccccataa agctaaaact cacctgagtt gtaaaaaact ccagttgaca caaaatagac 1020
 tacgaaagtg gctttaacat atctgaacac acaatagcta agaccacaaac tgggattaga 1080
 taccacctta tgcttagccc taaacctcaa cagttaaata aacaaaactg ctcgccagaa 1140
 cactacgagc cacagcttaa aactcaaagg acctggcggg gcttcatatc cctctagagg 1200

CI0043PCTseqlisting.ST25

agcctgttct gtaatcgata aaccccgatc aacctcacca cctcttgctc agcctatata	1260
ccgccatctt cagcaaacc tgatgaaggc tacaaagtaa gcgcaagtac ccacgtaaag	1320
acgttaggtc aaggtgtagc ccatgagggt gcaagaaatg ggctacattt tctacccag	1380
aaaactacga tagcccttat gaaacttaag ggtcgaagggt ggatttagca gtaaaactaag	1440
agtagagtgc ttagttgaac agggccctga agcgcgtaga caccgcccgt caccctcctc	1500
aagtatactt caaaggacat ttaactaaaa cccctacgca tttatataga ggagacaagt	1560
cgtaacatgg taagtgtact ggaaagtga cttggacgaa ccagagtgtg gcttaacaca	1620
aagcacccaa cttacactta ggagatttca acttaacttg accgctctga gctaaaccta	1680
gccccaaacc cactccacct tactaccaga caaccttagc caaaccattt acccaaataa	1740
agtataggcg atagaaattg aaacctggcg caatagatat agtaccgcaa gggaaagatg	1800
aaaaattata accaagcata atatagcaag gactaaccct tataccttct gcataatgaa	1860
ttaactagaa ataactttgc aaggagagcc aaagctaaga cccccgaaac cagacgagct	1920
acctaagaac agctaaaaga gcacaccctg ctatgtagca aaatagtggg aagatttata	1980
ggtagaggcg acaaacctac cgagcctggt gatagctggt tgtccaagat agaactcttag	2040
ttcaacttta aatttgccca cagaaccctc taaatcccct tgtaaattta actgttagtc	2100
caaagaggaa cagctctttg gacactagga aaaaacctg tagagagagt aaaaaattta	2160
acacccatag taggcctaaa agcagccacc aattaagaaa gcgttcaagc tcaacaccca	2220
ctacctaaaa aatcccaaac atataactga actcctcaca cccaattgga ccaatctatc	2280
accctataga agaactaatg ttagtataag taacatgaaa acattctcct ccgcataagc	2340
ctgcgtcaga ttaaaacact gaactgacaa ttaacagccc aatatctaca atcaaccaac	2400
aagtcattat taccctcact gtcaacccaa cacaggcatg ctcataagga aagggttaaaa	2460
aaagtaaaag gaactcggca aatcttacct cgctgttta ccaaaaacat cacctctagc	2520
atcaccagta ttagaggcac cgctgcccc gtgacacatg tttaacggcc gcggtacctt	2580
aaccgtgcaa aggtagcata atcacttggt ccttaaatag ggacctgtat gaatggctcc	2640
acgaggggtc agctgtctct tacttttaac cagtgaatg gacctgcccg tgaagaggcg	2700
ggcataacac agcaagacga gaagacccta tggagcttta atttattaat gcaaacagta	2760
cctaacaaac ccacagggtc taaactacca aacctgcatt aaaaatttcg gttggggcga	2820
cctcggagca gaacccaacc tccgagcagt acatgctaag acttcaccag tcaaagcgaa	2880
ctactatact caattgatcc aataacttga ccaacggaac aagttaccct agggataaca	2940
gcgcaatcct attctagagt ccatatcaac aatagggttt acgacctcga tgttgatca	3000
ggacatcccg atggtgcagc cgctattaaa ggttcgtttg ttcaacgatt aaagtcctac	3060
gtgatctgag ttcagaccgg agtaatccag gtcggtttct atctacctc aaattcctcc	3120
ctgtacgaaa ggacaagaga aataaggcct acttcacaaa gcgccttccc ccgtaaatga	3180
tatcatctca acttagtatt ataccacac ccaccaaga acagggtttg ttaagatggc	3240

CI0043PCTseqlisting.ST25

agagcccggg	aatcgcataa	aacttaaaac	tttacagtca	gaggttcaat	tcctcttctt	3300
aacaacatac	ccatggccaa	cctcctactc	ctcattgtac	ccatttcta	cgcaatggca	3360
ttcctaatac	ttaccgaacg	aaaaattcta	ggctatatac	aactacgcaa	aggccccaac	3420
gttgtagggc	cctacgggct	actacaaccc	ttcgctgacg	ccataaaaact	cttcacaaaa	3480
gagcccctaa	aaccgcccac	atctaccatc	accctctaca	tcaccgcccc	gaccttagct	3540
ctcaccatcg	ctcttctact	atgaaccccc	ctccccatac	ccaacccccct	ggtcaacctc	3600
aacctaggcc	tcctatttat	tctagccacc	tctagcctag	ccgtttactc	aatcctctga	3660
tcagggtgag	catcaaactc	aaactacgcc	ctgatcggcg	cactgcgagc	agtagcccaa	3720
acaatctcat	atgaagtcac	cctagccatc	attctactat	caacattact	aataagtggc	3780
tcctttaacc	tctccaccct	tatcacaaca	caagaacacc	tctgattact	cctgccatca	3840
tgacccttg	ccataatatg	atttatctcc	acactagcag	agaccaaccg	aacccccctc	3900
gaccttgccg	aaggggagtc	cgaactagtc	tcaggcttca	acatcgaata	cgccgcaggc	3960
cccttcgccc	tattcttcat	agccgaatac	acaacatta	ttataataaa	caccctcacc	4020
actacaatct	tcctaggaac	aacatatgac	gcactctccc	ctgaactcta	cacaacatat	4080
tttgtcacca	agaccctact	tctaacctcc	ctgttcttat	gaattcgaac	agcatacccc	4140
cgattccgct	acgaccaact	catacacctc	ctatgaaaaa	acttcctacc	actcacctta	4200
gcattactta	tatgatatgt	ctccataccc	attacaatct	ccagcattcc	ccctcaaacc	4260
taagaaatat	gtctgataaa	agagttactt	tgatagagta	aataatagga	gcttaaacc	4320
ccttatttct	aggactatga	gaatcgaacc	catccctgag	aatccaaaat	tctccgtgcc	4380
acctatcaca	ccccatccta	aagtaaggtc	agctaaataa	gctatcgggc	ccataccccg	4440
aaaatgttg	ttataaccctt	ccgtactaa	ttaatccctt	ggcccaaccc	gtcatctact	4500
ctaccatctt	tgagggcaca	ctcatcacag	cgctaagctc	gcactgattt	tttacctgag	4560
taggcctaga	aataaacatg	ctagctttta	ttccagttct	aacaaaaaaa	ataaaccttc	4620
gttccacaga	agctgccatc	aagtatttcc	tcacgcaagc	aaccgcatcc	ataatccttc	4680
taatagctat	cctcttcaac	aatatactct	ccggacaatg	aaccataacc	aatactacca	4740
atcaatactc	atcattaata	atcataatag	ctatagcaat	aaaactagga	atagccccct	4800
ttcacttctg	agtcccagag	gttacccaag	gcaccctctt	gacatccggc	ctgcttcttc	4860
tcacatgaca	aaaactagcc	cccatctcaa	tcataataca	aatctctccc	tcactaaacg	4920
taagccttct	cctcactctc	tcaatcttat	ccatcatagc	aggcagttga	ggtggattaa	4980
accagacca	gctacgcaaa	atcttagcat	actcctcaat	taccacata	ggatgaataa	5040
tagcagttct	accgtacaac	cctaacataa	ccattcttaa	tttaactatt	tatattatcc	5100
taactactac	cgcattccta	ctactcaact	taaactccag	caccacgacc	ctactactat	5160
ctcgcacctg	aaacaagcta	acatgactaa	cacccttaat	tccatccacc	ctcctctccc	5220
taggaggcct	gccccgcta	accggctttt	tgcccaaatg	ggccattatc	gaagaattca	5280

CI0043PCTseqlisting.ST25

caaaaaacaa tagcctcatc atccccacca tcatagccac catcacccctc cttaacctct	5340
acttttacct acgcctaatac tactccacct caatcacact actccccata tctaacaacg	5400
taaaaaataaa atgacagttt gaacatacaa aaccaccccc attcctcccc acactcatcg	5460
cccttaccac gctactccta cctatctccc cttttatact aataatctta tagaaattta	5520
ggttaaatac agaccaagag ctttcaaagc cctcagtaag ttgcaatact taattttctgt	5580
aacagctaag gactgcaaaa cccactctg catcaactga acgcaaatca gccactttta	5640
ttaagctaag cccttactag accaatggga cttaaaccga caaacactta gttaacagct	5700
aagcaccta atcaactggc ttcaatctac ttctcccgcc gccgggaaaa aaggcgggag	5760
aagccccggc aggtttgaag ctgcttcttc gaatttgcaa ttcaatatga aaatcacctc	5820
ggagctggtg aaaagaggcc taaccctgt ctttagattt acagtccaat gcttcaactca	5880
gccattttac ctacccccca ctgatgttcg ccgaccgttg actattctct acaaaccaca	5940
aagacattgg aacactatac ctattattcg gcgcatgagc tggagtccta ggcacagctc	6000
taagctcct tattcgagcc gagctgggcc agccaggcaa cttcttaggt aacgaccaca	6060
tctacaacgt tatcgtcaca gcccatgcat ttgtaataat cttcttcata gtaataccca	6120
tcataatcgg aggccttggc aactgactag ttcccctaataaatcggtgcc cccgatatgg	6180
cgtttccccg cataaacaac ataagcttct gactcttacc tccctctctc ctactcctgc	6240
tcgcatctgc tatagtggag gccggagcag gaacagggtg aacagtctac cctcccttag	6300
cagggaaacta ctccccacct ggagcctccg tagacctaac catcttctcc ttacacctag	6360
cagggtgtctc ctctatctta ggggccatca atttcatcac aacaattatc aatataaaac	6420
cccctgccat aaccaatac caaacgcccc tcttcgtctg atccgtccta atcacagcag	6480
tcctacttct cctatctctc ccagtcctag ctgctggcat cactatacta ctaacagacc	6540
gcaacctcaa caccaccttc ttcgaccccg ccggaggagg agacccatt ctataccaac	6600
acctattctg atttttcggt caccctgaag tttatattct tatcctacca ggcttcggaa	6660
taatctccca tattgtaact tactactccg gaaaaaaga accatttgga tacataggta	6720
tggctctgagc tatgatatac attggcttcc taggggttat cgtgtgagca caccatata	6780
ttacagtagg aatagacgta gacacacgag catatttcac ctccgtacc ataatcatcg	6840
ctatccccac cggcgtcaaa gtatttagct gactcgccac actccacgga agcaatatga	6900
aatgatctgc tgcagtgtc tgagccctag gattcatctt tcttttcacc gtaggtggcc	6960
tgactggcat tgtattagca aactcatcac tagacatcgt actacacgac acgtactacg	7020
ttgtagccca cttccactat gtcctatcaa taggagctgt atttgccatc ataggaggct	7080
tcattcactg atttccccta ttctcaggct acaccctaga ccaaacctac gccaaaatcc	7140
atttcactat catattcatc ggcgtaaatc taactttctt cccacaacac tttctcgcc	7200
tatccggaat gccccgacgt tactcggact accccgatgc atacaccaca tgaaacatcc	7260
tatcatctgt aggcctattc atttctctaa cagcagtaat attaataatt ttcatgattt	7320

CI0043PCTseq1isting.ST25

gagaagcctt cgcttcgaag cgaaaagtcc taatagtaga agaaccctcc ataaacctgg	7380
agtgactata tggatgcccc ccaccctacc acacattcga agaaccgta tacataaaat	7440
ctagacaaaa aaggaaggaa tcgaaccccc caaagctggt ttcaagcaa ccccatggcc	7500
tccatgactt tttcaaaaag gtattagaaa aaccatttca taactttgtc aaagttaa	7560
tataggctaa atcctatata tcttaatggc acatgcagcg caagtaggtc tacaagacgc	7620
tacttcccc atcatagaag agcttatcac ctttcatgat cagccctca taatcatttt	7680
ccttatctgc ttcctagtcc tgtatgccct tttcctaaca ctcaacaac aactaactaa	7740
tactaacatc tcagacgctc aggaaataga aaccgtctga actatcctgc ccgccatcat	7800
cctagtctc atcgccctcc catccctacg catcctttac ataacagacg aggtcaacga	7860
tccctccctt accatcaa	7920
ctacggcgga ctaatttca actcctacat acttccccca ttattcctag aaccaggcga	7980
cctgcgactc cttgacgttg acaatcgagt agtactcccg attgaagccc ccattcgtat	8040
aataattaca tcacaagacg tcttgactc atgagctgtc cccacattag gcttaaaaac	8100
agatgcaatt cccggacgtc taaaccaaac cactttcacc gctacacgac cgggggtata	8160
ctacggtcaa tgctctgaaa tctgtggagc aaaccacagt ttcatgcca tcgtcctaga	8220
attaattccc ctaaaaatct ttgaaatagg gcccgattt accctatagc acccctcta	8280
ccccctctag agccactgt aaagctaact tagcattaac cttttaagtt aaagattaag	8340
agaaccaaca cctctttaca gtgaaatgcc ccaactaat actaccgtat ggcccaccat	8400
aattaccccc atactcctta cactattcct catcaccaa ctaaaaat	8460
ctaccaccta cctccctcac caaagcccat aaaaataaaa aattataaca aaccctgaga	8520
acaaaaatga acgaaaatct gttcgcttca ttcattgccc ccacaatcct aggcctaccc	8580
gccgcagtac tgatcattct atttccccct ctattgatcc ccacctcaa atatctcatc	8640
aacaaccgac taatcaccac ccaacaatga ctaatcaaac taacctcaa acaaatgata	8700
accatacaca aactaaagg acgaacctga tctcttatac tagtatcctt aatcattttt	8760
attgccacaa ctaacctcct cggactcctg cctcactcat ttacaccaac caccaccta	8820
tctataaacc tagccatggc catccccctta tgagcgggca cagtgattat aggccttcgc	8880
tctaagatta aaaatgccct agccacttc ttaccacaag gcacacctac acccctatc	8940
cccatactag ttattatcga aaccatcagc ctactcattc aaccaatagc cctggccgta	9000
cgcctaaccg ctaacattac tgcaggccac ctactcatgc acctaattgg aagcgccacc	9060
ctagcaatat caaccattaa ccttccctct acacttatca tcttcacaat tctaattcta	9120
ctgactatcc tagaaatcgc tgtgcctta atccaagcct acgttttcac acttctagta	9180
agcctctacc tgcacgacaa cacataatga cccaccaatc acatgcctat catatagtaa	9240
aaccagccc atgacccta acaggggccc tctcagccct cctaataacc tccggcctag	9300
ccatgtgatt tcacttcac tccataacgc tctcatact aggcctacta accaacacac	9360

CI0043PCTseqlisting.ST25

taaccatata ccaatgatgg cgcgatgtaa cagagaaaag cacataccaa ggccaccaca	9420
caccacctgt ccaaaaaggc cttcgatacg ggataatcct atttattacc tcagaagttt	9480
ttttcttcgc aggatttttc tgagcctttt accactccag cctagcccct accccccaat	9540
taggagggca ctggcccca acaggcatca ccccgctaaa tcccctagaa gtccactcc	9600
taaacacatc cgtattactc gcatcaggag tatcaatcac ctgagctcac catagtctaa	9660
tagaaaacaa ccgaaaccaa ataattcaag cactgcttat tacaatttta ctgggtctct	9720
attttaccct cctacaagcc tcagagtact tcgagtctcc cttcaccatt tccgacggca	9780
tctacggctc aacatttttt gtagccacag gcttcacgg acttcacgtc attattggct	9840
caactttcct cactatctgc ttcacccgcc aactaatatt tcactttaca tccaaacatc	9900
actttggctt cgaagccgcc gcctgatact ggcattttgt agatgtgggt tgactatttc	9960
tgatgtctc catctattga tgagggtctt actcttttag tataaatagt accgttaact	10020
tccaattaac tagttttgac aacattcaaa aaagagtaat aaacttcgcc ttaatttta	10080
taatcaacac cctcctagcc ttactactaa taattattac attttgacta ccacaactca	10140
acggctacat agaaaaatcc accccttacg agtgccggtt cgaccctata tccccgcc	10200
gcgtcccttt ctccataaaa ttcttcttag tagctattac cttcttatta tttgatctag	10260
aaattgccct ctttttacc ctaccatgag ccctacaaac aactaacctg ccactaatag	10320
ttatgtcatc cctcttatta atcatcatcc tagccctaag tctggcctat gagtgactac	10380
aaaaaggatt agactgaacc gaattggtat atagtttaaa caaacgaat gatttcgact	10440
cattaaatta tgataatcat atttaccaa tgcccctcat ttacataaat attatactag	10500
catttaccat ctcaattcta ggaatactag tatatcgctc acacctcata tcctccctac	10560
tatgcctaga aggaataata ctatcgctgt tcattatagc tactctcata accctcaaca	10620
cccactccct cttagccaat attgtgccta ttgccatact agtctttgcc gcctgcgaag	10680
cagcggtgagg ctagcccta ctagtctcaa tctccaacac atatggccta gactacgtac	10740
ataacctaaa cctactcaa tgctaaaact aatcgccca acaattatat tactaccact	10800
gacatgactt tccaaaaaac acataatttg aatcaacaca accaccaca gcctaattat	10860
tagcatcatc cctctactat tttttaacca aatcaacaac aacctattta gctgttcccc	10920
aaccttttcc tccgaccccc taacaacccc cctcctaata ctaactacct gactcctacc	10980
cctcacaatc atggcaagcc aacgccactt atccagtga ccactatcac gaaaaaaact	11040
ctacctctct atactaatct ccctacaaat ctccttaatt ataacattca cagccacaga	11100
actaatcata ttttatatct tcttcgaaac cacacttatc cccaccttgg ctatcatcac	11160
ccgatgaggc aaccagccag aacgcctgaa cgagggcaca tacttcctat tctacaccct	11220
agtaggctcc cttcccctac tcacgcact aatttacact cacaacaccc taggctcact	11280
aaacattcta ctactactc tctgcccc agaactatca aactcctgag ccaataactt	11340
aatatgacta gcttacacaa tagcttttat agtaaagata cctctttacg gactccactt	11400

CI0043PCTseqlisting.ST25

atgactccct aaagcccatg tcgaagcccc catcgctggg tcaatagtagc ttgccgcagt 11460
 actcttaaaa ctaggcggct atggtataat acgcctcaca ctcatctca accccctgac 11520
 aaaacacata gcctaccctt tccttgtagt atccctatga ggcataatta taacaagctc 11580
 catctgccta cgacaaacag acctaaaatc gctcattgca tactcttcaa tcagccacat 11640
 agccctcgta gtaacagcca ttctcatcca aacccttgta agcttcaccg gcgcagtcac 11700
 tctcataatc gccacgggc ttacatctc attactattc tgccctagcaa actcaaacta 11760
 cgaacgcact cacagtcgca tcataatcct ctctcaagga cttcaaactc tactcccact 11820
 aatagctttt tgatgacttc tagcaagcct cgctaacctc gccttaccac ccactattaa 11880
 cctactggga gaactctctg tgctagtaac caggttctcc tgatcaaata tcactctcct 11940
 acttacagga ctcaacatac tagtcacagc cctatactcc ctctacatat ttaccacaac 12000
 acaatggggc tcactcacc accacattaa caacataaaa ccctcattca cagagaaaaa 12060
 caccctcatg ttcatacacc tatcccccat tctctccta tccctcaacc ccgacatcat 12120
 taccgggttt tctcttgta aatatagttt aaccaaaca tcagattgtg aatctgacaa 12180
 cagaggctta cgaccctta tttaccgaga aagctcaca gaactgctaa ctcatgcccc 12240
 catgtctaac aacatggctt tctcaacttt taaaggataa cagctatcca ttggtcttag 12300
 gccccaaaaa ttttggtgca actccaaata aaagtaataa ccatgcacac tactataacc 12360
 accctaacc tgacttcctt aattcccccc atccttacca ccctcgtaa ccctaacaaa 12420
 aaaaactcat accccatta tgtaaaatcc attgtcgcac ccaccttat tatcagtctc 12480
 ttccccacaa caatattcat gtgcctagac caagaagtta ttatctcgaa ctgacactga 12540
 gccacaacc aaacaacca gctctcccta agcttcaaac tagactactt ctccataata 12600
 ttcatccctg tagcattggt cgttacatgg tccatcatag aattctcact gtgatata 12660
 aactcagacc caaacattaa tcagttcttc aaatatctac tcattctcct aattaccata 12720
 ctaatcttag ttaccgctaa caacctatc caactgttca tcggctgaga gggcgtagga 12780
 attatatcct tcttgctcat cagttgatga tacgccgag cagatgcaa cacagcagcc 12840
 attcaagcaa tcctatacaa ccgtatcggc gatatcgggt tcattctcgc cttagcatga 12900
 tttatcctac actccaactc atgagacca caacaaatag cccttctaaa cgctaatacca 12960
 agcctcacc cactactagg cctcctccta gcagcagcag gcaaatcagc ccaattaggt 13020
 ctccaccct gactccctc agccatagaa ggccccacc cagctcagc cctactccac 13080
 tcaagcacta tagttgtagc aggaatcttc ttactcatcc gcttccacc cctagcagaa 13140
 aatagcccac taatccaaac tctaacta tgcttaggcg ctatcaccac tctgttcgca 13200
 gcagtctgcg cccttacaca aaatgacatc aaaaaatcg tagccttctc cacttcaagt 13260
 caactaggac tcataatagt tacaatcggc atcaaccaac cacacctagc attcctgcac 13320
 atctgtacc acgccttctt caaagccata ctatttatgt gctccgggtc catcatccac 13380
 aaccttaaca atgaacaaga tttcgaaaa ataggaggac tactcaaac catacctctc 13440

CI0043PCTseqlisting.ST25

acttcaacct ccctcacat tggcagccta gcattagcag gaataccttt cctcacaggt 13500
 ttctactcca aagaccacat catcgaaacc gcaaacatat catacacaaa cgcctgagcc 13560
 ctatctatta ctctcatcgc tacctccctg acaagcgcct atagcactcg aataattctt 13620
 ctcaccctaa cagggtcaacc tcgcttcccc acccttacta acattaacga aaataacccc 13680
 accctactaa accccattaa acgcctggca gccggaagcc tattcgcagg atttctcatt 13740
 actaacaaca tttccccgc atcccccttc caaacaacaa tccccctcta cctaaaactc 13800
 acagccctcg ctgtcacttt cctaggactt ctaacagccc tagacctcaa ctacctaac 13860
 aacaaactta aaataaaatc cccactatgc acattttatt tctccaacat actcggattc 13920
 taccctagca tcacacaccg cacaatcccc tatctaggcc ttcttacgag ccaaaacctg 13980
 cccctactcc tcctagacct aacctgacta gaaaagctat tacctaaaac aatttcacag 14040
 caccaaactc ccacctccat catcacctca acccaaaaag gcataattaa actttacttc 14100
 ctctctttct tcttcccact catcctaacc ctactcctaa tcacataacc tattcccccg 14160
 agcaatctca attacaatat atacaccaac aaacaatggt caaccagtaa ctactactaa 14220
 tcaacgcca taatcatata aagccccgc accaatagga tcctcccgaa tcaacctga 14280
 cccctctcct tcataaatta tttagcttcc tacactatta aagtttacca caaccaccac 14340
 cccatcatat tctttcacc acagcaccaa tcctacctcc atcgctaacc cactaaaac 14400
 actcaccaag acctcaaccc ctgaccccca tgctcagga tactcctcaa tagccatcgc 14460
 tgtagtatat ccaaagacaa ccatcattcc ccctaaataa attaaaaaaa ctattaaacc 14520
 catataacct cccccaaaat tcagaataat aacacaccg accacaccgc taacaatcaa 14580
 tactaaaccc ccataaatag gagaaggctt agaagaaaac cccacaaacc ccattactaa 14640
 acccacactc aacagaaaca aagcatatc cattattctc gcacggacta caaccacgac 14700
 caatgatatg aaaaaccatc gttgtatttc aactacaaga acaccaatga cccaatacg 14760
 caaaattaac cccctaataa aattaattaa ccatcattc atcgacctcc ccaccccatc 14820
 caacatctcc gcatgatgaa acttcggctc actccttggc gcctgcctga tcctccaaat 14880
 caccacagga ctattcctag ccatgcacta ctcaccagac gcctcaaccg ccttttcatc 14940
 aatcgccac atcactcgag acgtaaatta tggctgaatc atccgctacc ttcacgcaa 15000
 tggcgctca atattcttta tctgcctctt cctacacatc gggcgaggcc tatattacgg 15060
 atcatttctc tactcagaaa cctgaaacat cggcattatc ctctgcttg caactatagc 15120
 aacagccttc ataggctatg tcctcccgtg aggccaaata tcattctgag gggccacagt 15180
 aattacaaac ttactatccg ccatcccata cattgggaca gacctagttc aatgaatctg 15240
 aggaggctac tcagtagaca gtcccaccct cacacgattc tttacctttc acttcatctt 15300
 gcccttcatt attgcagccc tagcaacact ccacctccta ttcttgacg aaacgggatc 15360
 aaacaacccc ctaggaatca cctccattc cgataaaatc accttccacc cttactacac 15420
 aatcaaagac gccctcggct tacttctctt ctttctctcc ttaatgacat taacactatt 15480

CI0043PCTseqlisting.ST25

ctcaccagac ctcctaggcg acccagacaa ttatacccta gccaacccct taaacacccc 15540
 tccccacatc aagcccgaat gatatttcct attcgctac acaattctcc gatccgtccc 15600
 taacaaacta ggaggcgtcc ttgccctatt actatccatc ctcctcctag caataatccc 15660
 catcctccat atatccaaac aacaaagcat aatatttcgc ccactaagcc aatcacttta 15720
 ttgactccta gccgcagacc tcctcattct aacctgaatc ggaggacaac cagtaagcta 15780
 cccttttacc atcattggac aagtagcatc cgtactatac ttcacaacaa tcctaatacct 15840
 aataccaact atctccctaa ttgaaaacaa aataactcaa tgggcctgtc cttgtagtat 15900
 aaactaatac accagtcttg taaaccggag atgaaaacct ttttccaagg acaaatacaga 15960
 gaaaaagtct ttaactccac cattagcacc caaagctaag attctaattt aaactattct 16020
 ctgttctttc atggggaagc agatttgggt accaccaag tattgactca cccatcaaca 16080
 accgctatgt atttcgtaca ttactgccag ccaccatgaa tattgtacgg taccataaat 16140
 acttgaccac ctgtagtaca taaaaaccca atccacatca aaacccccct cccatgctta 16200
 caagcaagta cagcaatcaa ccctcaacta tcacacatca actgcaactc caaagccacc 16260
 cctcaccac taggatacca acaaacctac ccacccttaa cagtacatag tacataaagc 16320
 catttaccgt acatagcaca ttacagtcaa atcccttctc gtcccatgg atgaccccc 16380
 tcagataggg gtcccttgac caccatcctc cgtgaaatca atatcccgca caagagtgt 16440
 actctcctcg ctccgggccc ataacacttg ggggtagcta aagtgaactg tatccgacat 16500
 ctggttccta cttcagggtc ataaagccta aatagcccac acgttcccct taaataagac 16560
 atcacgatg 16569

<210> 11
 <211> 17
 <212> DNA
 <213> B19 Virus

<400> 11
 tgggtctggga tgaaggt 17

<210> 12
 <211> 23
 <212> DNA
 <213> B19 virus

<400> 12
 ccattttagg cgggcaacc acc 23

<210> 13
 <211> 21
 <212> DNA
 <213> B19 virus

<400> 13
 tggaagtgt gctgtgcctg g 21

<210> 14
 <211> 23

CI0043PCTseqlisting.ST25

<212> DNA
 <213> B19 virus
 <400> 14
 agaatcattt gtcggaagct cag 23

<210> 15
 <211> 20
 <212> DNA
 <213> B19 virus
 <400> 15
 acaagcctgg gcaagtttagc 20

<210> 16
 <211> 21
 <212> DNA
 <213> B19 virus
 <400> 16
 acaatgccag tggaaaggag g 21

<210> 17
 <211> 23
 <212> DNA
 <213> B19 virus
 <400> 17
 cttaacaca tgaagaccat gca 23

<210> 18
 <211> 28
 <212> DNA
 <213> B19 virus
 <400> 18
 cctctcaaaa cactagaata tccttacg 28

<210> 19
 <211> 27
 <212> DNA
 <213> B19 virus
 <400> 19
 cagccatacc accactggga cacagat 27

<210> 20
 <211> 23
 <212> DNA
 <213> B19 virus
 <400> 20
 aatgccattt ctcattgtca gac 23

<210> 21
 <211> 20
 <212> DNA
 <213> B19 virus
 <400> 21
 gcaaaacaac accacaggca 20

CI0043PCTseqlisting.ST25

<210> 22
 <211> 22
 <212> DNA
 <213> Hepatitis B virus
 <400> 22
 caacctccaa tcactcacca ac 22

<210> 23
 <211> 24
 <212> DNA
 <213> Hepatitis B virus
 <400> 23
 cctccaattt gtcctgggta tcgc 24

<210> 24
 <211> 23
 <212> DNA
 <213> Hepatitis B virus
 <400> 24
 gtgtctgcgg cgttttatca tat 23

<210> 25
 <211> 23
 <212> DNA
 <213> Hepatitis B virus
 <400> 25
 tgtttggcct tcagctatat gga 23

<210> 26
 <211> 22
 <212> DNA
 <213> Hepatitis B virus
 <400> 26
 aattgtgggt cttttgggct tt 22

<210> 27
 <211> 18
 <212> DNA
 <213> Hepatitis B virus
 <400> 27
 ttctccgtct gccgttcc 18

<210> 28
 <211> 21
 <212> DNA
 <213> Hepatitis B virus
 <400> 28
 accagcacca tgcaactttt t 21

<210> 29
 <211> 25
 <212> DNA

CI0043PCTseqlisting.ST25

<213> Hepatitis B virus
 <400> 29
 tttttcacct ctgcctaatac atctc 25

 <210> 30
 <211> 16
 <212> DNA
 <213> Hepatitis B virus
 <400> 30
 tcccactggt caagcc 16

 <210> 31
 <211> 21
 <212> DNA
 <213> Hepatitis B virus
 <400> 31
 acctcaccat accgcactca g 21

 <210> 32
 <211> 25
 <212> DNA
 <213> Hepatitis B virus
 <400> 32
 gggaattgat gactctagct acctg 25

 <210> 33
 <211> 22
 <212> DNA
 <213> Hepatitis B virus
 <400> 33
 atcctgaatg gcaaactcct tc 22

 <210> 34
 <211> 20
 <212> DNA
 <213> Hepatitis B virus
 <400> 34
 gagaaaccac acgtagcgca 20

 <210> 35
 <211> 16
 <212> DNA
 <213> Hepatitis B virus
 <400> 35
 caccctcca cacggc 16

 <210> 36
 <211> 27
 <212> DNA
 <213> Hepatitis B virus
 <400> 36
 atctctccac ctctaagaga cagtcac 27

CI0043PCTseqlisting.ST25

<210> 37
 <211> 22
 <212> DNA
 <213> Porcine parvovirus

 <400> 37
 cctcacaaaa cggcaagtac tg 22

 <210> 38
 <211> 36
 <212> DNA
 <213> Porcine parvovirus

 <400> 38
 acctaagtcc aagtgactgc tactggttca tacagc 36

 <210> 39
 <211> 29
 <212> DNA
 <213> Porcine parvovirus

 <400> 39
 gttaataatg caatgcaaag tacctctaa 29

 <210> 40
 <211> 25
 <212> DNA
 <213> Porcine parvovirus

 <400> 40
 aaagacaact gaaagagagc atgga 25

 <210> 41
 <211> 30
 <212> DNA
 <213> Porcine parvovirus

 <400> 41
 ttcagctca gattctggct tcatgacaaa 30

 <210> 42
 <211> 22
 <212> DNA
 <213> Porcine parvovirus

 <400> 42
 caattctatt tcatgggcca gc 22

 <210> 43
 <211> 17
 <212> DNA
 <213> Porcine parvovirus

 <400> 43
 cgtggagcga gccaaca 17

 <210> 44
 <211> 28
 <212> DNA
 <213> Porcine parvovirus

CI0043PCTseqlisting.ST25

<400> 44		
ctgcacttaa ctccaacacc gccagatt		28
<210> 45		
<211> 24		
<212> DNA		
<213> Porcine parvovirus		
<400> 45		
gcaatacggg caccaagtcc aact		24
<210> 46		
<211> 23		
<212> DNA		
<213> Porcine parvovirus		
<400> 46		
gaggttaagaa gatcgccgag aaa		23
<210> 47		
<211> 28		
<212> DNA		
<213> Porcine parvovirus		
<400> 47		
aacctcacca ccaacaaaa tatataat		28
<210> 48		
<211> 29		
<212> DNA		
<213> Porcine parvovirus		
<400> 48		
actactaact gaacctacca cagaaggag		29
<210> 49		
<211> 26		
<212> DNA		
<213> Porcine parvovirus		
<400> 49		
cttttacctt cagatccaat aggagg		26
<210> 50		
<211> 18		
<212> DNA		
<213> Sindbis virus		
<400> 50		
gcgtgcggac cctgtact		18
<210> 51		
<211> 25		
<212> DNA		
<213> Sindbis virus		
<400> 51		
attggcttcg acaccaccca gttca		25

CI0043PCTseqlisting.ST25

<210> 52
 <211> 20
 <212> DNA
 <213> Sindbis virus

 <400> 52
 ttctcggcta tggcagggtc 20

 <210> 53
 <211> 25
 <212> DNA
 <213> Sindbis virus

 <400> 53
 gtttatttct ccgtaggatc gacac 25

 <210> 54
 <211> 20
 <212> DNA
 <213> Sindbis virus

 <400> 54
 aaaactgctg caggtctcgg 20

 <210> 55
 <211> 22
 <212> DNA
 <213> Sindbis virus

 <400> 55
 gaaatcgata ttacaggggc ca 22

 <210> 56
 <211> 21
 <212> DNA
 <213> Sindbis virus

 <400> 56
 gcattaagtt tttcggcatg g 21

 <210> 57
 <211> 18
 <212> DNA
 <213> Sindbis virus

 <400> 57
 cgattggcat agccggtg 18

 <210> 58
 <211> 21
 <212> DNA
 <213> West Nile virus

 <400> 58
 tcagcgatct ctccaccaa g 21

 <210> 59
 <211> 22
 <212> DNA
 <213> West Nile virus

CI0043PCTseqlisting.ST25

<400> 59
 tgcccgacca tgggggaagc cc 22

<210> 60
 <211> 21
 <212> DNA
 <213> West Nile virus

<400> 60
 caatgacaaa cgtgctgacc c 21

<210> 61
 <211> 20
 <212> DNA
 <213> West Nile virus

<400> 61
 gctagtccctg gtgtttgggg 20

<210> 62
 <211> 24
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA

<400> 62
 agagtttgat catggctcag attg 24

<210> 63
 <211> 24
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA

<400> 63
 ctggcggcag gcctaacaca tgca 24

<210> 64
 <211> 21
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA

<400> 64
 aataccgcat aacgtcgcaa g 21

<210> 65
 <211> 20
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA

<400> 65
 gatgcaacgc gaagaacctt 20

<210> 66
 <211> 23
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA

<400> 66
 gactgggggtg aagtcgtaac aag 23

<210> 67

CI0043PCTseqlisting.ST25

<211> 24
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA
 <400> 67
 gtaacaaggt aaccgtaggg gaac 24

<210> 68
 <211> 19
 <212> DNA
 <213> Escherichia coli 16S Ribosomal RNA
 <400> 68
 gcggttgat cacctcctt 19

<210> 69
 <211> 22
 <212> DNA
 <213> Escherichia coli 23S Ribosomal RNA
 <400> 69
 ccgatagtga accagtaccg tg 22

<210> 70
 <211> 25
 <212> DNA
 <213> Escherichia coli 23S Ribosomal RNA
 <400> 70
 atgttgaaaa attagcggat gactt 25

<210> 71
 <211> 18
 <212> DNA
 <213> Escherichia coli 23S Ribosomal RNA
 <400> 71
 gcactgtttc ggcaaggg 18

<210> 72
 <211> 18
 <212> DNA
 <213> Escherichia coli 23S Ribosomal RNA
 <400> 72
 gccggaagac caagggtt 18

<210> 73
 <211> 24
 <212> DNA
 <213> Escherichia coli 23S Ribosomal RNA
 <400> 73
 ggccgtaact ataacggtcc taag 24

<210> 74
 <211> 26
 <212> DNA
 <213> Escherichia coli 23S Ribosomal RNA
 <400> 74

CI0043PCTseqlisting.ST25	
gataagtgc t gaaagcatct aagcac	26
<210> 75	
<211> 25	
<212> DNA	
<213> Yeast (<i>S. cerevisiae</i>)	
<400> 75	
ctgccagtag tcatatgctt gtctc	25
<210> 76	
<211> 36	
<212> DNA	
<213> Yeast (<i>S. cerevisiae</i>)	
<400> 76	
tacagtgaatg ctgcgaatgg ctcattaaat cagtta	36
<210> 77	
<211> 27	
<212> DNA	
<213> Yeast (<i>S. cerevisiae</i>)	
<400> 77	
taatacatgc ttaaaatctc gaccctt	27
<210> 78	
<211> 24	
<212> DNA	
<213> Yeast (<i>S. cerevisiae</i>)	
<400> 78	
gtcttcggac tctttgatga ttca	24
<210> 79	
<211> 17	
<212> DNA	
<213> Yeast (<i>S. cerevisiae</i>)	
<400> 79	
gcagccgcgg taattcc	17
<210> 80	
<211> 24	
<212> DNA	
<213> Yeast (<i>S. cerevisiae</i>)	
<400> 80	
gctgaaactt aaaggaattg acgg	24
<210> 81	
<211> 23	
<212> DNA	
<213> Yeast (<i>S. cerevisiae</i>)	
<400> 81	
tggaagtttg aggcaataac agg	23
<210> 82	
<211> 19	

CI0043PCTseqlisting.ST25

<212> DNA
 <213> Yeast (*S. cerevisiae*)
 <400> 82
 tgaacctgcg gaaggatca 19

<210> 83
 <211> 24
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 83
 aagcatatca ataagcggag gaaa 24

<210> 84
 <211> 20
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 84
 ctctggtgga ggctcgtagc 20

<210> 85
 <211> 18
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 85
 aatggatggc gctcaagc 18

<210> 86
 <211> 25
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 86
 tgaaaatcca caggaaggaa tagtt 25

<210> 87
 <211> 21
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 87
 ctaagggtcg ggtagtgagg g 21

<210> 88
 <211> 20
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 88
 agaaattcaa ccaagcgcca 20

<210> 89
 <211> 19
 <212> DNA
 <213> Yeast 25S Ribosomal RNA
 <400> 89
 atgtcatttt gcgtgggga 19

CI0043PCTseqlisting.ST25

<210> 90
<211> 23
<212> DNA
<213> Human mitochondrial DNA

<400> 90
gttcaccctc taaatcacca cga 23

<210> 91
<211> 23
<212> DNA
<213> Human mitochondrial DNA

<400> 91
caagcacgca gcaatgcagc tca 23

<210> 92
<211> 26
<212> DNA
<213> Human mitochondrial DNA

<400> 92
ggaaacagca gtgattaacc tttagc 26

<210> 93
<211> 28
<212> DNA
<213> Human mitochondrial DNA

<400> 93
gactacgaaa gtggctttaa catatctg 28

<210> 94
<211> 24
<212> DNA
<213> Human mitochondrial DNA

<400> 94
tagagtgctt agttgaacag ggcc 24

<210> 95
<211> 24
<212> DNA
<213> Human mitochondrial DNA

<400> 95
taggcgatag aaattgaaac ctgg 24

<210> 96
<211> 21
<212> DNA
<213> Human mitochondrial DNA

<400> 96
tttgtaaga tggcagagcc c 21

<210> 97
<211> 20
<212> DNA

CI0043PCTseqlisting.ST25

<213> Human mitochondrial DNA

<400> 97

agaatcgaac ccatccctga

20

<210> 98

<211> 19

<212> DNA

<213> Human mitochondrial DNA

<400> 98

tttcaccgta ggtggcctg

19

<210> 99

<211> 20

<212> DNA

<213> Human mitochondrial DNA

<400> 99

aatcgctgtc gccttaatcc

20